Characterization of dCDK12, hCDK12, and hCDK13 in the Context of RNA Polymerase II CTD Phosphorylation and Transcription-Associated Events by Bartkowiak, Bartlomiej
 i
v 
 
Characterization of dCDK12, hCDK12, and hCDK13 in the Context of RNA Polymerase 
II CTD Phosphorylation and Transcription-Associated Events  
by 
Bartlomiej Bartkowiak 
Department of Biochemistry 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
Arno Greenleaf, Supervisor 
 
___________________________ 
Mariano Garcia-Blanco 
 
___________________________ 
Kenneth Kreuzer 
 
___________________________ 
Paul Modrich 
 
___________________________ 
Pei Zhou 
 
Dissertation submitted in partial fulfillment of 
the requirements for the degree of Doctor 
of Philosophy in the Department of 
Biochemistry in the Graduate School 
of Duke University 
 
2014 
 
 
 i
v 
 
ABSTRACT 
Characterization of dCDK12, hCDK12, and hCDK13 in the Context of RNA Polymerase 
II CTD Phosphorylation and Transcription-Associated Events 
by 
Bartlomiej Bartkowiak 
Department of Biochemistry 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
Arno Greenleaf, Supervisor 
 
___________________________ 
Mariano Garcia-Blanco 
 
___________________________ 
Kenneth Kreuzer 
 
___________________________ 
Paul Modrich 
 
___________________________ 
Pei Zhou 
 
An abstract of a dissertation submitted in partial 
fulfillment of the requirements for the degree 
of Doctor of Philosophy in the Department of 
Biochemistry in the Graduate School of 
Duke University 
 
2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Bartlomiej Bartkowiak 
2014 
 
  
iv 
Abstract 
Eukaryotic RNA polymerase II (RNAPII) not only synthesizes mRNA, but also 
coordinates transcription-related processes through the post-translational modification 
of its unique C-terminal repeat domain (CTD). The CTD is an RNAPII specific extension 
of the enzyme’s largest subunit and consists of multiple repeating heptads with the 
consensus sequence Y1S2P3T4S5P6S7. In Saccharomyces cerevisiae (Sc), RNAPII committed to 
productive elongation is phosphorylated at the S2 positions of the CTD, primarily by 
CTDK-I (composed of the CDK-like Ctk1, the cyclin-like Ctk2, and Ctk3) the principal 
elongation-phase CTD kinase in Sc.  Although responsible for the bulk of S2 
phosphorylation in vivo, Ctk1 coexists with the essential kinase Bur1 which also 
contributes to S2 phosphorylation during elongation.  In higher eukaryotes there appears 
to be only one CTD S2 kinase:  P-TEFb, which had been suggested to reconstitute the 
activity of both of the Sc S2 CTD kinases.  Based on comparative genomics, we 
hypothesized that the previously-unstudied Drosophila CDK12 (dCDK12) and little-
studied human CDK12 and CDK13 (hCDK12 and hCDK13) proteins are CTD 
elongation-phase kinases, the metazoan orthologs of yeast Ctk1.  Using fluorescence 
microscopy we show that the distribution of dCDK12 on formaldehyde-fixed polytene 
chromosomes is virtually identical to that of hyperphosphorylated RNAPII, but is 
distinct from that of P-TEFb. Chromatin immunoprecipitation experiments confirm that 
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dCDK12 is present on the transcribed regions of active Drosophila genes in a pattern 
reminiscent of a S2 CTD kinase.  Appropriately, we show that dCDK12, hCDK12, and 
hCDK13 purified from nuclear extracts manifest CTD kinase activity in vitro and 
associate with CyclinK, implicating it as the cyclin subunit of the kinase.  Most 
importantly we demonstrate that RNAi knockdown of dCDK12 in Drosophila cell culture 
and hCDK12 in human cell lines alters the phosphorylation state of the CTD.  In an 
effort to further characterize the transcriptional roles of human CDK12/CyclinK we 
overexpress, purify to near homogeneity, and characterize, full-length hCDK12/CyclinK. 
Additionally, we also identify hCDK12 associated proteins via mass spectrometry, 
revealing interactions with multiple RNA processing factors, and attempt to engineer an 
analog sensitive CDK12 human cell line.   Overall, these results demonstrate that CDK12 
is a major elongation-associated CTD kinase, the ortholog of yCtk1.  Our findings clarify 
the relationships between two yeast CDKs, Ctk1 and Bur1, and their metazoan 
homologues and draw attention to major metazoan CTD kinase activities that have gone 
unrecognized and unstudied until now.  Furthermore, the results suggest that hCDK12 
affects RNA processing events in two distinct ways:  Indirectly through generating 
factor-binding phospho-epitopes on the CTD of elongating RNAPII and directly through 
binding to specific factors.
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Figure 5.6:  hCDK12 expression in the putative CDK12 analog sensitive cell line.  (a.) 
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1. Introduction
1
  
1.1 The C-terminal Domain of RNA Polymerase II 
Eukaryotic transcription and the concomitant pre-mRNA processing that 
accompanies it require the precise coordination between, and recruitment of, specific 
sets of factors at specific stages of the transcription cycle.  This coupling of transcription 
and associated processes has been shown to be dependent on a particular feature of 
RNA Polymerase II (RNAPII), the C-terminal repeat domain or CTD (Bartkowiak et al., 
2011; Corden, 2013; Phatnani and Greenleaf, 2006).  Distinguishing RNAPII from its 
prokaryotic and eukaryotic (RNAPIII and RNAPI) counterparts, the CTD is an 
unstructured extension of the enzyme’s largest subunit, Rpb1, and is composed of a 
tandem array of seven amino acid repeats with the consensus sequence Y1S2P3T4S5P6S7.  
The number of these heptad repeats varies from organism to organism and appears to 
correlate with genomic complexity; there are 26 repeats in yeast, 44-46 in Drosophila, and 
52 in humans (Allison et al., 1988; Corden, 1990).  Despite being dispensable for the 
catalytic activity of RNAPII, the CTD is conserved throughout evolution and is essential 
to life; no animal, plant, or fungal Rpb1 sequence found to date lacks a CTD (Stiller and 
Hall, 2002).  Additionally, the total number of heptad repeats is also important; as an 
example, yeast cells or fruit files that have two thirds of the CTD repeats removed are 
                                                     
1 Adapted from Bartkowiak, B., Mackellar, A. L., Greenleaf, A. L., 2011. Updating the CTD Story: From Tail 
to Epic. Genet Res Int. 2011, 623718. 
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not viable (Nonet et al., 1987; Zehring et al., 1988).  Somewhat surprisingly, despite the 
overall conservation of the CTD the range of deviation from the consensus sequence can 
be highly variable (Chapman et al., 2008).  The amount of variation depends on the 
organism in question; for a large group of eukaryotes called the “CTD-clade,” the 
consensus sequence is strongly stabilized (Stiller and Hall, 2002).  But even within this 
clade some organisms stand out as exceptions, an example of particular interest being 
Drosophila melanogaster which contains only two canonical CTD consensus repeats.  
Despite the nonconformance of Drosophila at the heptad level, the overall repetitive 
structure of the CTD is still conserved as 75% of the sequence still lies in the tandemly 
repeated register (Stiller and Hall, 2002) (Fig. 1.1). 
The conservation and expansion of the CTD throughout evolution suggest that it 
plays a fundamental, but unknown role in RNAPII transcription.  Initial models for CTD 
function were varied and included the CTD interacting with initiation factors and/or 
DNA, removing DNA bound proteins, restricting RNA secondary structure, and even 
localizing RNAPII to specific locations in the nucleus (Corden, 1990).  Many of these 
models, especially the ones postulating protein-protein interactions, recognized the 
potential of CTD post-translational modification, especially phosphorylation, as a 
regulatory mechanism for CTD function. 
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Figure 1.1:  Amino acid sequence of human, Drosophila melanogaster, and Saccharomyces cerevisiae 
Rpb1 C-terminal domains.  Residues that conform to the consensus sequence are shown in black (or if 
the entire heptad contains canonical sequence, highlighted in green); residues that deviate from the 
consensus are in red; and terminal/upstream residues that do not conform to the consensus are shown in 
blue.  Sequences were obtained from the UCSC Genome Browser (Kent et al., 2002). 
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The idea that phosphorylation plays a regulatory role in transcription was first 
proposed in the 1970s.  Early research on RNAPII revealed that the polymerase 
underwent phosphorylation in vivo (Bell et al., 1976), a modification that resulted in the 
manifestation of Rpb1 as several distinct ,by apparent molecular weight, species on SDS 
PAGE gels:  A nonphosphorylated IIa form (215kD), a phosphorylated IIo form (240kD), 
and a proteolyzed IIb form which lacked the CTD (180kD) (Dahmus, 1994; Kedinger et 
al., 1974; Schwartz and Roeder, 1975).   It was also noted that the IIa, but not the IIb form 
could be further phosphorylated by incubation with casein kinase (Dahmus, 1981); this 
insight, coupled with molecular cloning techniques, resulted in both the discovery of the 
CTD and the realization that it is the vector of RNAPII phosphorylation (Allison et al., 
1985; Corden et al., 1985; Dahmus, 1994).  Although exposed in terms of its sequence and 
potential modification, the CTD’s true function would continue to be a mystery for 
almost another ten years. 
The discovery of mRNA processing CTD binding proteins in the mid-1990s 
(Corden and Patturajan, 1997; Yuryev et al., 1996), coupled with the fact that newly 
synthesized mRNA crosslinked exclusively to the hyperphosphorylated form of the 
CTD (Bartholomew et al., 1986; Cadena and Dahmus, 1987; Dahmus, 1994), supported 
the proposal that the CTD linked transcription to transcription associated processes 
(Greenleaf, 1993).  This proposal has been experimentally verified over the last three 
decades and we now know that the CTD functions as a selective binding scaffold for 
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nuclear factors, allowing it to coordinate transcription with varied nuclear processes in a 
temporal fashion (Phatnani and Greenleaf, 2006). 
1.2 The “phospho-CTD cycle” and the “CTD code” 
1.2.1 Phosphorylation of the CTD 
The binding specificity of the CTD, and therefore the recruitment of particular 
factors, is mainly determined by the CTD’s phosphorylation state, which undergoes a 
series of changes throughout the transcription cycle.  The primary structure of the CTD 
heptad repeat lends itself as a fantastic target for this particular post translational 
modification as five out of seven of its residues can be phosphorylated.  Serine 2, Serine 
5, and Serine 7 of the heptad repeat have been identified as the key players in this 
transcriptionally regulated phosphorylation; however, recent studies have also 
demonstrated the phosphorylation and involvement of Threonine 4 and Tyrosine 1 
(Hintermair et al., 2012; Hsin et al., 2014; Hsin et al., 2011; Mayer et al., 2012).   
In a highly generalized model of the “phospho-CTD cycle,” RNAPII is recruited 
for assembly at the promoter with an unphosphorylated CTD; CTD phosphorylation 
prior to preinitiation complex (PIC) formation has an inhibitory effect on transcription 
initiation (Hengartner et al., 1998).  Upon PIC formation, the CTD is phosphorylated at 
the Ser5 and Ser7 positions; this is followed by an increase in Ser2 phosphorylation 
during elongation (Komarnitsky et al., 2000), yielding a CTD that contains a mix of 
doubly (and when considering Ser7, perhaps triply) phosphorylated repeats at Ser2 and 
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Ser5 in the center of the gene (reviewed in (Bartkowiak et al., 2011; Eick and Geyer, 2013; 
Phatnani and Greenleaf, 2006) and (Buratowski, 2009)).  As the polymerase elongates 
towards the 3’ end of the gene, the activity of Ser5-specific phosphatases decrease the 
Ser5 phosphorylation levels, leaving CTDs phosphorylated at Ser2 to terminate 
transcription.  However the CTD of terminating RNAPII may also be phosphorylated at 
Ser7 positions, as the Ser7 mark has been reported to be retained at high levels 
throughout the entire transcription unit on many protein-coding genes (Tietjen et al., 
2010).  In the first of many complications to this simplified model, we must note the 
phosphorylation of Tyr1 (Baskaran et al., 1993) and Thr4 (Zhang and Corden, 1991), 
which having been recently characterized as functionally significant (Hintermair et al., 
2012; Hsin et al., 2014; Hsin et al., 2011; Mayer et al., 2012), are now being incorporated 
into the general model (Fig. 1.2).  
Despite being highly intuitive, and very useful, this segmented (Ser5P to Ser2/5P 
to Ser2P with Ser7P throughout) description of the “phospho-CTD cycle” is 
oversimplified for several reasons.  First, although this model accounts for variations in  
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Figure 1.2:  Simplified schematics of the “phospho-CTD cycle” and CTD modifications as determined by 
Chromatin Immunoprecipiatation (ChIP) experiments in Saccharomyces cerevisiae.  Unphosphorylated 
RNAPII (IIa) is recruited to promoters, where upon PIC formation the CTD (grey squiggles) is 
phosphorylated at the Ser5 (blue) and Ser7 (black) positions.  During elongation there is an increase in 
Ser2 (red) phosphorylation with a concomitant decrease of Ser5 phosphorylation; at the 3’ end of the 
transcription unit Ser2 phosphorylation predominates.  The ChIP visualization of the CTD modifications 
also displays the enrichment pattern of the more recently characterized phosphorylation of Tyr1 and 
Thr4.  ChIP signals are not normalized to RNAPII levels.  The ChIP enrichment view is adapted from 
(Eick and Geyer, 2013). 
the general phosphorylation pattern of the CTD, it fails to fully capture the highly 
dynamic nature of the process.  The phosphorylation state of the CTD is likely to be in 
continuous flux throughout the entire transcription cycle, with multiple kinases and 
phosphatases working together to maintain specific phosphorylation patterns on a 
particular subsets of heptads.  For example, it has been shown that the Ser7 phosphates 
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at the 3’ end of the gene are actually placed anew, after being removed by a phosphatase 
(Tietjen et al., 2010).   Another important set of complications to the simple gradient 
model is the existence of specific patterns of phosphorylated repeats within the CTD.  It 
is worth noting that the repetitive nature of the CTD makes it impossible to determine 
exactly which of the 52 heptad positions (in mammals) are phosphorylated.  In addition 
the particular pattern of phosphorylated residues within each heptad and within 
sequential heptad units is also unknown; therefore the Ser2, 5, and 7 phosphorylated 
CTD of elongating RNAPII is likely to be composed of heptads phosphorylated at one, 
both, all, and none of the relevant positions.  The general model of the “phospho-CTD 
cycle” also fails to account for exceptions to the canonical patterns of phosphorylation, 
the differences among the modifications of the CTD as RNAPII transcribes specific 
genes, and is further complicated by the existence of other CTD modifications. 
1.2.2 Other CTD modifications 
It has not escaped notice that the modification of the CTD is not theoretically 
limited to phosphorylation.  Many other post translational modifications have been 
observed, including glycosylation (Kelly et al., 1993; Ranuncolo et al., 2012) , acetylation 
(Schroder et al., 2013), and methylation (Sims et al., 2011).  Non-canonical modifications, 
once fully characterized as functionally significant, have the potential to expand the 
CTD code further and redefine aspects of the general model.   
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One important CTD modification, which until recently had not been directly 
observed to play a direct role in factor binding, is the enzymatic isomerization of the 
peptidyl-proline bonds in the heptad repeats.  Although multiple studies have 
suggested a role for the CTD interacting peptidyl-prolyl cis/trans isomerases (Ess1 in 
yeast and Pin1 in humans) in transcription and CTD phosphorylation (Krishnamurthy et 
al., 2009; Wilcox et al., 2004; Xu and Manley, 2007), all of the structures of CTD-
substrates/CTD-binding protein complexes revealed the CTD proline residues to be 
exclusively in the more energetically stable, and therefore predominant, trans state.  This 
changed when two structural studies found that the Ser5 specific CTD phosphatase 
Ssu72 bound to the cis conformation of a Ser5-Pro6 motif within the heptad repeat 
(Werner-Allen et al., 2011; Xiang et al., 2010).   Concordantly, the activity of the proline 
isomerase Ess1 was found to facilitate the rapid dephosphorylation of the CTD by Ssu72 
in vitro, suggesting that this cis/trans interconversion plays a role in the fine-tuning of 
the phosphorylation state of the CTD (Werner-Allen et al., 2011).  These findings have 
broad implications for CTD biology, both in increasing the number of distinct CTD 
states and serving as a regulatory mechanism for CTD phosphorylation.  However, it 
still remains to be determined whether proline isomerization is a general property of 
RNAPII transcription or is gene specific (Werner-Allen et al., 2011), this distinction may 
apply to other types of modifications as well.   
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As previously mentioned, the general “phospho-CTD cycle” fails to account for 
gene specific patterns and modifications.  Two good examples of non-canonical CTD 
modifications which affect a specific transcript class are the methylation of an arginine 
(R1810) in heptad 31 (Sims et al., 2011) and the acetylation of the eight lysines in the 
human CTD (see Fig. 1.1).  Mediated by the methyltransferase CARM1 and inhibited by 
Ser5 and Ser2 phosphorylation, methylation of the CTD appears to repress the 
expression of snRNAs and snoRNAs in a general manner (Sims et al., 2011).  The 
acetylation of the lysines is mediated by p300/KAT3B, and despite the fact that it does 
not affect the expression of housekeeping genes, mutation of the lysines or inhibition of 
p300 results in the loss of epidermal growth factor induced expression of some 
immediate-early genes such as c-Fos and Egr2 (Schroder et al., 2013).  These and other 
modifications of the non-canonical heptads may serve as a discriminatory mark for 
RNAPII recruited to particular genes or transcript classes.  It should also be noted that 
Ser7P is thought to be transcript class specific CTD modification as Ser7 to alanine 
mutations in the CTD cause a defect in snRNA transcription while having little effect on 
protein coding genes (Egloff et al., 2007).  However, the ubiquitous nature of Ser7P on 
protein coding genes, along with the finding that Ser7 is enriched on RNAPII within 
introns (Kim et al., 2010) argues for some, perhaps more subtle, functional role for Ser7P 
on most transcription units.   
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Thus the general phospho-CTD cycle has given way to a “CTD code” of 
staggering complexity; one that we are just beginning to explore in detail.  This 
complexity reflects the vast number of different genes, processing events, and 
transcriptional programs that RNAPII must coordinate.   
1.3 Functions of the CTD 
The CTD has been implicated in a broad spectrum of transcription associated 
functions and its collection of binding partners has continued to expand over the last 
few years.  Important associated processes include mRNA (and snRNA) capping, 
splicing, 3’end processing, termination, and more recently nuclear export.  In terms of 
non-RNA processing associated events, the CTD has been shown to play roles in 
transcriptional activation, cotranscriptional chromatin modification, chromatin 
remodeling, and genome stability2.  Of course the analysis of the CTD’s role in each 
specific function is very challenging, as many of the CTD-mediated transcriptional 
processes are interlinked.   For example, capping has been shown to influence both the 
splicing of the first intron and 3’ end processing (Cooke and Alwine, 1996; Flaherty et al., 
1997; Hart et al., 1985; Inoue et al., 1989; Lewis et al., 1996); splicing of the last intron 
affects 3’ end processing, and vice versa (Bauren et al., 1998; Niwa and Berget, 1991; 
Vagner et al., 2000); and alternative splice site choices are affected by the co-
                                                     
2 See below and (Bartkowiak et al., 2011; Corden, 2013; MacKellar and Greenleaf, 2011; Winsor et al., 2013) 
for details. 
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transcriptional histone modifications at splice site junctions (Allo et al., 2009; Luco et al., 
2010; Schor et al., 2009).  While these interactions demonstrate the high degree of 
coordination involved in mRNA synthesis, they unfortunately complicate the 
interpretation of functional studies.  In a broad sense, it is fair to state that exactly how 
Ser2, Ser5, and Ser7 phosphorylation affect initiation, elongation, and termination 
remains poorly understood.  Despite the lack of a universal synthesis, particular aspects 
of CTD function have been characterized to an impressive level of detail and many of 
the more enigmatic functions are slowly giving way to continued investigation.  I will go 
over a few of the CTD’s most prominent functions in the following subsections, taking 
the opportunity to also survey some of the key factors which bind to the phospho-CTD. 
1.3.1 5’ Capping 
One of the most clearly recognized functions of the CTD is its involvement in the 
5’ end capping of mRNA through the recruitment of the capping machinery.  The 
modification of the 5’ end of the RNA with the 5’ 7-methyl guanosine cap is unique to 
RNAPII transcripts, and occurs just after the transcript clears the polymerase’s exit 
channel (Jove and Manley, 1984; Rasmussen and Lis, 1993).  Transcripts made by a CTD-
less RNAPII were found to be inefficiently capped, leading to the characterization of the 
physical interaction between the capping enzymes and the phospho-CTD (Cho et al., 
1997; McCracken et al., 1997a; Yue et al., 1997).  Subsequent studies showed that the 
capping enzyme associates with the 5’ end of genes in vivo, and that this association is 
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dependent on the phosphorylation of the CTD (Komarnitsky et al., 2000; Schroeder et al., 
2000).  This localization correlates nicely with the enzyme’s function and is dependent 
on the phosphorylation of Ser5 (Kanin et al., 2007; Schroeder et al., 2000).  In addition to 
raising the local concentration of the capping enzyme near the exit channel, the CTD has 
also been shown to stimulate its activity:  An example of a phosphorylation state specific 
function, mammalian guanylyltransferase was found to bind to both Ser2P and Ser5P 
synthetic heptad repeats, but was allosterically activated only by Ser5P (Ho and 
Shuman, 1999).   The interaction between the 5’ capping machinery and the CTD has 
also been investigated structurally and these studies resulted in some interesting 
insights.  The crystal structure of the C. albicans guanylyltransferase Cgt1 and a synthetic 
Ser5P four heptad repeat revealed that the CTD peptide binds to an extended docking 
site on the enzyme surface using two non-adjacent heptads, which  leaves a full heptad 
repeat looped out away from the interaction site (Fabrega et al., 2003).   This looping not 
only demonstrates the inherent flexibility of the CTD, it also suggests that by binding 
two remote heptads, CTD binding factors may be able to loop out large portions of the 
CTD.  The loop could potentially result in the formation of novel structural motifs, 
which could in turn serve as binding sites for other CTD binding factors, leading to an 
organized, sequential binding (Meinhart et al., 2005).  Whether this actually occurs is still 
on open question; however, recent studies have shown that the binding of some well-
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known 3’ end processing factors to the CTD appears to be cooperative in nature (Lunde 
et al., 2010). 
1.3.2 3’ End processing 
Another well recognized function of the CTD is its role in 3’ end processing and 
termination3.  Analogous to capping, transcription by a CTD less RNAPII was shown to 
affect both processes, and cleavage and polyadenylation factors were found to bind to 
the phospho-CTD (Barilla et al., 2001; Hirose and Manley, 1998; Kyburz et al., 2003; 
Licatalosi et al., 2002; Maniatis and Reed, 2002; McCracken et al., 1997b; Proudfoot et al., 
2002).  Accordingly, the deletion of Ctk1 (a Ser2 CTD kinase) in yeast has been shown to 
decrease the efficiency of cleavage at poly(A) sites (Skaar and Greenleaf, 2002) and result 
in the disruption of polyadenylation factor recruitment to the 3’ end of the gene (Ahn et 
al., 2004).  Genome wide analysis has also shown that depletion of Ctk1 using a 
tetracycline-repressible degron mutant, causes a “pileup” of polymerases at the poly(A) 
site in a subset of genes with good consensus poly(A) sequences (Kim et al., 2010).  This 
increase in RNAPII occupancy suggests that improper CTD phosphorylation at these 
sites can result in a strong transcriptional pause; perhaps due to the rate limiting 
recruitment of a specific factor.  Strongly linked to polyadenylation, termination has also 
been reported to be affected by the CTD (McCracken et al., 1997b); in addition Rtt103, a 
component of the termination complex has been shown to bind Ser2P CTD (Kim et al., 
                                                     
3 See (Proudfoot, 2004) and (Buratowski, 2005) for more information. 
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2004).  However the role of CTD modification in termination is not yet well understood4.  
Intriguingly, it has been observed that the recruitment of one well-recognized CTD 
binding 3’ end processing factor, Pcf11 (which preferentially binds to Ser2 
phophorylated CTD) does not directly correlate with the level of Ser2 CTD 
phosphorylation (Ahn et al., 2004; Licatalosi et al., 2002; Mayer et al., 2010); analysis by 
chromatin immunoprecipitation (ChIP) indicates that Pcf11 is recruited mainly at the 
poly(A) site, while Ser2P levels rise throughout the coding region.  Potential 
explanations for this phenomenon highlight some of the interesting complications 
surrounding phospho-CTD factor recruitment.  Perhaps Pcf11 requires a certain 
threshold of Ser2P or both Ser2P and an external signal, such as the presence of the 
newly synthesized polyadenylation site, the unmasking of particular CTD epitopes, or 
the presence of additional factors (Pcf11 CTD binding was recently shown to be 
cooperative (Lunde et al., 2010)).  Other considerations include the remodeling of the 
CTD via a pattern specific change, such as the formation of Ser2P only heptads, or 
modifications undetectable to ChIP.  With regards to the latter and the previous 
discussion on proline isomerization, Pcf11 is reported to specifically recognize three 
neighboring trans prolines within a mixed population of cis-trans isomers (Noble et al., 
2005).  It is likely that the recruitment of many other CTD binding factors is also 
                                                     
4 See (Buratowski, 2005), (Buratowski, 2009), and (Kuehner et al., 2011) for further discussion. 
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mediated through multiple mechanisms and dependent on the satisfaction of particular 
sets of conditions. 
1.3.3 snRNA Processing 
One of the more recently discovered functions of the CTD is its role in snRNA 
transcription and 3’ end processing (Jacobs et al., 2004; Medlin et al., 2003).  Even though 
they are transcribed by RNAPII, snRNAs are unlike most coding genes; they do not 
undergo splicing or polyadenylation, instead relying on a conserved 3’ box RNA 
processing element downstream of the coding region for proper 3’ end processing and 
termination (Egloff et al., 2008).  The 3’ end processing of snRNAs has received a lot of 
attention as it is currently the only specific function attributed to the phosphorylation of 
the Ser7 position of the heptad repeat (Egloff et al., 2007).  Seemingly dispensable for 
viability and the expression of protein coding genes, Ser7 has been found to be essential 
for endogenous snRNA gene expression.  This requirement for Ser7 phosphorylation 
was subsequently linked to the Integrator complex (Egloff et al., 2007); a large CTD 
associated multiprotein complex involved in snRNA 3’ end processing (Baillat et al., 
2005).  Further characterization of the CTD-Integrator interaction not only revealed that 
both Ser2P and Ser7P were required, but that efficient binding required a specific 
arrangement of the modifications (Egloff et al., 2010).  Screening of synthetic diheptad 
repeats revealed that although maximal binding was achieved with both Ser2 and Ser7 
repeats phosphorylated, the minimal interaction domain consisted of a Ser7P on the first 
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heptad followed by a Ser2P on the second heptad; any other combination of two 
phosphates was insufficient for Integrator binding (Egloff et al., 2010).  These findings 
lend further support for the pattern specific binding of CTD associated factors and, 
coupled with the fact that Integrator is specific to snRNA genes, also suggest that the 
appropriate Ser2P/Ser7P patterns may be snRNA gene specific (although many other 
discriminatory mechanisms could be at play, an example might be the previously 
discussed methylation of R1810). 
1.3.4 Histone modification 
Tying together two important aspects of gene expression and transcriptional 
coordination, the CTD has also been shown to be involved in the cotranscriptional 
modification and remodeling of histones.  Providing the first clear link between the CTD 
and histone modification, the Set1 and Set2 histone methyltransferases were found to be 
recruited to actively transcribed genes at specific stages of the transcription cycle (5’ end 
vs interior of the gene respectively) through an interaction with the Ser5P and Ser2/5P 
CTD (Kizer et al., 2005; Krogan et al., 2003a; Krogan et al., 2003b).  Thus Set1 activity, the 
methylation of histone H3 at the K4 position, peaks near the promoter, while Set2 
activity, methylation of H3 at K36, occurs downstream in the coding region.  The H3K36 
trimethylation mark can be used to identify transcriptionally active genes and has been 
shown to suppress inappropriate transcription from cryptic promoters through what 
appeared to be the recruitment of the histone deacetylase Rpd3S (Joshi and Struhl, 2005; 
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Keogh et al., 2005).  Surprisingly, more recent studies have found that Rpd3S is actually 
recruited via direct binding to the phospho-CTD; although H3K36 trimethylation is 
dispensable for Rpd3S recruitment, it appears to be required for activation of its 
deacetylation activity (Drouin et al., 2010; Govind et al., 2010).  Intriguingly Set2 is 
capable of H3K36 dimethylation independent of its CTD interacting SRI domain or Ctk1 
(Youdell et al., 2008), implying that only one specific aspect (H3K36 trimethylation) of 
Set2’s activity is regulated by interaction with the phospho-CTD.  Another interesting 
chromatin related CTD binding factor is the histone H3 chaperone and transcription 
elongation factor Spt6 (Yoh et al., 2007).  Spt6 is a nucleosome remodeler and has been 
shown to bind the Ser2P CTD through a tandem SH2 domain (Burugula et al., 2014; Sun 
et al., 2010).  Spt6 has been found to be required for the optimal loading of the 
mammalian Set2 (HYPB/SETD2) on the coding regions of several genes (Yoh et al., 2008), 
thus linking nucleosome reassembly with elongation coupled H3K36 trimethylation in 
vivo.  Several other chromatin related CTD interactions include the recruitment of the 
chromatin remodeling factor CHD8 (Rodriguez-Paredes et al., 2009) and the FACT 
histone chaperone via HP1 (Kwon et al., 2010).  
1.3.5 Splicing 
One of the more intriguing, but relatively poorly characterized, functions of the 
CTD is its involvement in cotranscriptional splicing (Goldstrohm et al., 2001; Munoz et 
al., 2010).  Although neither active transcription nor the CTD are absolutely required for 
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splicing (presynthesized mRNAs can be spliced by injection into Xenopus oocytes or by 
incubation with nuclear extracts (Bird et al., 2004)), experimental evidence accumulated 
over the last three decades implicates the CTD as a key player in the coupling between 
the two processes.  The link between the CTD and splicing was first noted in the mid to 
late 90s with the observation that the hyperphophorylated RNAPII associates with the 
SR (Serine/Arginine rich) family of splicing factors and with components of the splicing 
machinery (Kim et al., 1997; Mortillaro et al., 1996; Yuryev et al., 1996).  Concordantly 
transcription by a CTD less RNAPII was shown to result in low splicing efficiency in vivo 
(McCracken et al., 1997b) and the addition of anti-CTD antibody or exogenous 
expression of CTD peptides resulted in the accumulation of unspliced transcripts 
(Yuryev et al., 1996) and the nuclear reorganization of splicing factors (Du and Warren, 
1997).  In what could be considered the reciprocal experiment, it was also shown that 
isolated CTD fragments and purified phosphorylated RNAPII were able to activate 
splicing reactions in vitro (Hirose et al., 1999; Zeng and Berget, 2000).    
In addition to the SR-like CTD associated factors (SCAFs) (Patturajan et al., 
1998b; Yuryev et al., 1996), several other CTD binding splicing factors have been 
identified, including the yeast U1 snRNP component Prp40 (Morris and Greenleaf, 2000) 
and the mammalian splicing factors CA150 (TCERG1)(Carty et al., 2000),  PSF, and 
p54/NRB (Emili et al., 2002).   A recent addition has been the splicing factor U2AF, which 
was shown to be recruited to the Ser2P CTD in complex with another splicesome 
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component, Prp19 (David et al., 2011; Gu et al., 2013).  Although alternative splicing has 
been directly demonstrated to be affected by the presence of the CTD (de la Mata and 
Kornblihtt, 2006), due to the fact that RNAPII elongation rate has also been shown to 
play a role in alternative splicing (de la Mata et al., 2003; Kadener et al., 2001) it is 
difficult to determine how much of the effect is due to the specific recruitment of 
splicing factors to the CTD and how much is due to changes in the elongation rate 
(kinetic coupling) or other processes.  With regards to kinetic coupling and the CTD, one 
study which merits specific mention is that of Batsche et al. who reported that the 
inclusion of a set of alternative exons in the middle of the CD44 gene was dependent on 
the accumulation of RNAPII induced by the catalytic subunit of the SWI/SNF chromatin 
remodeling complex (Batsche et al., 2006).  Surprisingly, this “stalled” RNAPII exhibited 
a SWI/SNF-dependent switch of the RNAPII phosphorylation state from the elongation 
characteristic Ser2P to the more promoter characteristic Ser5P, perhaps creating a barrier 
to further elongation.  In addition to its general role in the recruitment of splicing 
factors, it has also been suggested that the CTD may function as a molecular tether for 
distant splice sites within the mRNA.  This would be accomplished through the binding 
of the nascent 3’ splice site to a CTD associated splicing factor, thus effectively 
immobilizing it near the polymerases mRNA exit channel in anticipation of the cognate 
5’ splice site.  Enhancement of the local concentration of the splice sites would then 
dramatically increase the efficacy of the splicing reaction (Goldstrohm et al., 2001).  This 
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tethering model is especially attractive in higher eukaryotes in which the intron lengths 
of many genes exceed thousands of base pairs.  Although studies have demonstrated 
that mRNA tethering is likely (Dye et al., 2006), it has yet to be directly linked to the 
CTD and its phosphorylation. 
1.4 The CTD kinases 
The proper regulation of CTD associated processes is dependent on the 
appropriate modification of the CTD during the transcription cycle.  The specific 
phosphorylation events within the heptad repeat are mediated through the activity of a 
transcription-associated subset of cyclin-dependent kinases (CDKs) known as CTD 
kinases.  Unlike their cell cycle counterparts, the CTD kinases form complexes with 
members of the non-cycling “transcription cyclin” family and are active throughout the 
cell cycle.  Nevertheless, CTD kinase activity is tightly regulated by a variety of 
mechanisms, including selective recruitment, binding by kinase-associated factors, and 
sequestration by inhibitory factors.  Although somewhat promiscuous in vitro (for 
example the “Ser2-specific” CTD kinase Ctk1 can phosphorylate both Ser2 and Ser5 in 
vitro (Jones et al., 2004), in vivo the CTD kinases are selective for particular residues 
within the heptad repeat and stages of transcription.  Thus the various CTD kinases are 
most conveniently presented in the context of a segmented transcription cycle; however, 
it should be made clear that in reality the various kinase activities lack the clearly 
delineated boundaries that such a presentation suggests.  It should also be kept in mind 
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that the CTD kinases function in conjunction with the slightly more enigmatic CTD 
phosphatases, several of which have been characterized in yeast:  Fcp1 which targets 
Ser2P (Cho et al., 2001), Ssu72 which targets S5P and has been implicated in targeting 
S7P (Krishnamurthy et al., 2004; Reyes-Reyes and Hampsey, 2007; Zhang et al., 2012) , 
and the controversial Rtr1 which targets S5P (deletion of Rtr1 reduces S5P levels in vivo, 
but in vitro experiments have failed to identify an Rtr1 CTD phosphatase activity 
implying that Rtr1 has a noncatalytic/structural role in CTD dephosphorylation) (Mosley 
et al., 2009; Ni et al., 2014; Xiang et al., 2012). 
1.4.1 Initiation and the promoter – the serine 5 position and CDK7 
The phosphorylation of CTD Ser5 and Ser7 residues during the formation of the 
preinitiation complex is mediated by the CTD kinase subunit of the general transcription 
factor TFIIH:  Kin28/Ccl1 in yeast and CDK7/CyclinH in metazoa (Akhtar et al., 2009; 
Glover-Cutter et al., 2009; Kim et al., 2009; Komarnitsky et al., 2000; Schroeder et al., 
2000); see (Fig. 1.4) for clarification on the CTD kinases in various organisms.  In an 
elegant interplay, the kinase activity of Kin28 is stimulated by the mediator coactivator 
complex which binds to, and delivers, unphosphorylated RNAPII to the promoter 
(Guidi et al., 2004).  The resulting phosphorylation of the CTD leads to the dissociation 
of mediator (Max et al., 2007); thus after fulfilling its function, mediator is able to use the 
CTD and Kin28 to induce its own release from transcriptionally active RNAPII.  Once 
thought to be essential for promoter clearance, the activity of Kin28 has been shown to 
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be dispensable for global gene transcription (Hong et al., 2009; Kanin et al., 2007).  
Despite this, Kin28 has been found to enhance polymerase progression through long 
genes in yeast (over 2kb), suggesting that it plays a role in transcriptional elongation or 
in the inhibition of premature termination (Kim et al., 2010).  CDK7 also takes part in the 
phosphorylation and activation of other CDKs (Fisher, 2005); however, its (and Ser5P’s) 
most clearly defined transcriptional role is the recruitment of the 5’ end capping 
machinery.  Not only does this ensure the proper processing of the nascent mRNA, it 
has also been shown to mediate the recruitment of the Ser2 CTD kinases in some 
organisms (either directly or through recruitment of the capping machinery) (Pei et al., 
2006; Qiu et al., 2009; Viladevall et al., 2009); this suggests that phosphorylation of Ser5 
plays a role in triggering the onset of Ser2 phosphorylation. 
1.4.2 Elongation – the serine 2 position CTD kinases 
Subsequent to Kin28 activity at the promoter, phosphorylation of Ser2 of the 
CTD heptad occurs downstream of the transcription start site (TSS) and coincides with 
RNAPII entry into productive elongation.  Coupled with the activity of Ser5P-specific 
phosphatases this leads to a transition from high Ser5P to high Ser2P (as characterized 
by ChIP).  The Ser5P to Ser2P crossover point, defined as the point at which the ChIP 
signals for the two CTD marks cross, is on average ~450 bp downstream of the TSS and 
appears to be independent of the overall gene length (Kim et al., 2010).  This implies that 
the dynamics of Ser2 and Ser5 phosphorylation are not scaled to gene length; however 
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the significance of the crossover point in terms of the actual phosphorylation state of the 
CTD is obscure5. 
In Saccharomyces cerevisiae, the phosphorylation of Ser2 is primarily mediated by 
CTDK-I, a three subunit enzyme (consisting of Ctk1, a CDK homologue; Ctk2, a cyclin 
homologue; and Ctk3, whose function is unknown) (Lee and Greenleaf, 1991; Sterner et 
al., 1995).  Although it is responsible for the bulk of Ser2 phosphorylation in vivo, Ctk1 is 
not essential for viability under standard growth conditions, or for transcriptional 
elongation.  The CTD kinase activity of Ctk1 has been linked to several transcription-
associated processes, including the recruitment of the Set2 histone methyltransferease 
(Xiao et al., 2003; Youdell et al., 2008), 3’ end processing (Ahn et al., 2004; Kim et al., 
2010; Skaar and Greenleaf, 2002) , splicing (Phatnani et al., 2004), termination (reviewed 
in (Buratowski, 2009)), and the termination of small non-coding RNAs (Lenstra et al., 
2013).  In addition to its role as a CTD kinase, Ctk1 (independent of its kinase activity) 
has also been shown to be involved in the dissociation of basal transcription factors from 
RNAPII (Ahn et al., 2009).  Despite having a principal role in CTD Ser2 phosphorylation, 
Ctk1 is not the only Ser2 kinase in yeast; it coexists with the essential Bur1 kinase (which 
consists of the CDK homologue Bur1 and the cyclin Bur2) (Yao et al., 2000).  While it has 
been proposed that Bur1’s primary transcription-related substrate is the elongation 
                                                     
5 All of these conclusions depend on signals from particular antibodies via ChIP and there are significant 
ambiguities inherent in these signals, see (Phatnani et al., 2006) and (Bartkowiak et al., 2011) for further 
discussion). 
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factor Spt4/5(Keogh et al., 2003; Pei and Shuman, 2003), rather than the CTD, more 
recent evidence indicates that Bur1 binds to the Ser5P CTD and contributes to Ser2 
phosphorylation during early elongation, possibly stimulating subsequent Ctk1 activity 
(Liu et al., 2009; Qiu et al., 2009).  Bur1 has also been found to exhibit an elongation 
phase Ser7 kinase activity which appears to counteract the activity of a yet unidentified 
Ser7 phosphatase (Tietjen et al., 2010).  Another pair of Ser2 elongation kinases is also 
present in the fission yeast Schizzosaccharomyces pombe (Sp), where Lsk1, the Sp 
orthologue of Ctk1, has been shown to be responsible for the bulk of Ser2 
phosphorylation while SpCDK9, the Sp orthologue of Bur1, is able to phosphorylate both 
the CTD and Spt5 (Karagiannis and Balasubramanian, 2007; Viladevall et al., 2009). 
Until recently, higher eukaryotes appeared to have only one Ser2 CTD kinase:  P-
TEFb (which is composed of CDK9 and cyclinT).  P-TEFb is able to phosphorylate both 
the Ser2 position of the CTD and the elongation factor Spt5 and is essential for 
transcriptional elongation, as it overcomes transcriptional pausing:  RNAPII is “paused” 
near the promoter by the activity of negative transcription elongation factors (DSIF and 
NELF) which trap the elongation complex in an arrested state, P-TEFb is required to 
overcome the influence of these negative elongation factors (Marshall et al., 1996; 
Marshall and Price, 1992; Marshall and Price, 1995)6.   
                                                     
6 For detailed discussions see (Lenasi and Barboric, 2010), (Peterlin and Price, 2006), and (Nechaev and 
Adelman, 2011) 
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Figure 1.3:  CDK evolutionary relationships as determined by Liu and Kipreos (Liu and Kipreos, 2000) 
using the neighbor-joining method (NJ).  Bootstrap support values are given at branch points and are 
derived from maximum-likelihood/NJ/gamma-rate-corrected NJ analyses.  Modified from (Liu and 
Kipreos, 2000) by Dr. Arno Greenleaf  (Bartkowiak et al., 2010). 
The substrate specificity of P-TEFb, coupled with its equal sequence similarity to 
both Bur1 and Ctk1, has led to the proposal that P-TEFb reconstitutes the activities of 
both yeast kinases in higher eukaryotes (Wood and Shilatifard, 2006).  However, there 
was some evidence that this may not be the case; two evolutionary studies concluded 
that while Sc Bur1 is the closest Sc relative of metazoan CDK9 proteins, Sc Ctk1 is 
actually more closely related to another set of relatively little studied metazoan CDK 
proteins (Guo and Stiller, 2004; Liu and Kipreos, 2000) (Fig 1.3).  Therefore the 
previously unstudied Drosophila CDK12 (dCDK12) and the little-studied human CDK12 
(hCDK12) and human CDK13 (hCDK13) have surfaced as the potential missing partners 
to P-TEFb, conceivably extending the paradigm of Ser2 CTD kinase pairs to higher 
eukaryotes (Fig. 1.4). 
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Figure 1.4:  A summary of the kinase and cyclin homologs of the CTD kinases in the yeast Saccharomyces 
cerevisiae, Drosophila, and human.  CDKs are shown as large ovals, cyclin partners are illustrated by 
smaller ovals which are offset to the lower right; accessory factors are depicted like cyclins, but are offset 
to the lower left. 
 
1.4.3 CDK12 and CDK13 
The hCDK12 and hCDK13 kinases were discovered serendipitously by probing 
of cDNA libraries for cholinesterase and CDK related sequences (Ko et al., 2001; 
Lapidot-Lifson et al., 1992; Marques et al., 2000).  Interestingly, hCDK12 and hCDK13 
are uncharacteristically large for CDKs with molecular weights of 160 and 180 kDa  
 
 28 
 
Figure 1.5:  Schematics of hCDK12, hCDK13, dCDK12, hCDK9, and yCtk1 primary structures.  Relative 
amino acid positions are indicated below each sequence with the kinase homology domain highlighted 
as an oval.  Unlike most CDKs, CDK12 and CDK13 contain long N and C terminal arms that extend from 
the Ser/Thr kinase homology domain. These arms contain stretches of low complexity sequence (marked 
in red) and RS domains; motifs characteristic of splicing factors and believed to mediate protein-protein 
interactions. 
respectively (most CDKs are about 50 kDa), and contain large N and C terminal 
extensions that flank the CDK kinase domain (Even et al., 2006; Ko et al., 2001).  These  
extensions contain multiple stretches of low complexity sequence and RS domains; 
domains characteristic of splicing factors and believed to mediate protein-protein 
interactions (Zhong et al., 2009) (Fig 1.5). Although hCDK12 had been shown to have an 
in vitro CTD kinase activity in an early study (Ko et al., 2001), subsequent research 
focused on the role of hCDK12 and 13 in splicing.    As expected of RS proteins, hCDK12 
and hCDK13 were found to localize in nuclear speckles (believed to be storage sites for 
splicing factors (Zhong et al., 2009)) and their overexpression or knockdown was shown 
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to alter the splicing of the E1A reporter minigene in vivo (Berro et al., 2008; Chen et al., 
2006; Chen et al., 2007).  The mechanism for this splice site modulation was largely 
unexplored, as was any potential role of the kinases in transcription.  Based on the 
previously discussed phylogenetic data, the aim of this dissertation was to determine 
whether the previously unstudied dCDK12 and little-studied hCDK12 and hCDK13 
were elongation phase CTD kinases, the metazoan orthologues of yeast Ctk1, and to 
characterize their functions in vivo and in vitro. 
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2. Characterization of Drosophila and Human CDK12 as 
Elongation Phase RNA Polymerase II C-terminal Domain 
Kinases
1
 
2.1 Introduction 
The C-terminal repeat domain (CTD) of RNA polymerase II (RNAPII) is an 
intrinsically unstructured extension of the enzyme’s largest subunit, Rpb1.  The CTD is 
composed of a tandem array of seven amino acid repeats with the consensus sequence 
Y1S2P3T4S5P6S7; the number of heptad repeats varies from organism to organism and 
appears to correlate with genomic complexity (Corden, 1990).  Although dispensable for 
polymerase activity in vitro, the CTD is conserved throughout evolution and is essential 
to life (Zehring et al., 1988).  The CTD’s function is to coordinate transcription with 
nuclear processes such as mRNA processing and chromatin modification; it fulfills this 
role by serving as a selective binding scaffold for nuclear factors2.  The binding 
specificity of the CTD for particular factors is determined by its phosphorylation state, 
which varies during the transcription cycle; Ser2, Ser5, and Ser7 of the heptad repeat 
have been identified as the primary targets of phosphorylation, with Tyr1 and Thr4 
phosphorylation being recently recognized as functionally relevant (Chapman et al., 
2007; Egloff et al., 2007; Eick and Geyer, 2013; Hintermair et al., 2012; Hsin et al., 2014; 
                                                     
1 Adapted from, and published in, Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. 
H., Adelman, K., Lis, J. T., Greenleaf, A. L., 2010. CDK12 is a transcription elongation-associated CTD 
kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 24, 2303-16. 
 
2 See (Bartkowiak et al., 2011; Corden, 2013; Phatnani and Greenleaf, 2006) for reviews. 
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Hsin et al., 2011; Mayer et al., 2012).  Initiating and early-transcribing polymerases are 
thought to be phosphorylated at Ser5 positions in the CTD repeats, whereas actively-
elongating polymerases carry phosphates on both Ser2 & Ser5 residues.  Toward the 3’ 
end of pre-mRNA transcription units Ser2P appears to predominate (Eick and Geyer, 
2013; Phatnani and Greenleaf, 2006). 
The phosphorylation of CTD Ser5 residues during initiation and early 
transcription is mediated by the TFIIH CTD kinase subunit:  Kin28 in yeast and CDK7 in 
metazoans (Komarnitsky et al., 2000; Schroeder et al., 2000).  The majority of Ser2 
phosphorylation on productively elongating RNAPII in Saccharomyces cerevisiae (Sc) 
appears to be catalyzed by CTDK-I (Buratowski, 2009; Qiu et al., 2009), whose kinase 
subunit is Ctk1 (Lee and Greenleaf, 1991; Sterner et al., 1995).  Although it is responsible 
for the bulk of Ser2 phosphorylation in vivo, Ctk1 enzyme is not the only elongation-
phase kinase in yeast; it coexists with the essential Bur1 kinase (Yao et al., 2000).  It has 
been proposed that Bur1 kinase phosphorylates the transcription elongation factor 
subunit Spt5, rather than the CTD of Rpb1 (Zhou et al. 2009).  However, the evidence 
suggests that the situation is more complex and that, in addition to acting on Spt5, Bur1 
phosphorylates Ser2 positions in the CTD (Qiu et al., 2009).  A similar pair of Ser2 CTD 
kinases is also present in the fission yeast Schizzosaccharomyces pombe (Sp):  Lsk1, the Ctk1 
ortholog in Sp, phosphorylates Ser2 positions in the CTD (Coudreuse et al., 2010; 
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Karagiannis and Balasubramanian, 2007), whereas SpCDK9, the Bur1 homologue 
phosphorylates both Rpb1 (on its CTD) and Spt5 (Viladevall et al., 2009).  
With respect to the principal Ser2 kinases in metazoa, the situation has been less 
clear cut.   It was previously thought that there is only one Ser2 CTD kinase in higher 
organisms called P-TEFb (consisting of CDK9 and a cyclin, usually cyclinT but also 
cyclinK) (Fu et al., 1999; Peterlin and Price, 2006).  P-TEFb is able to phosphorylate both 
the CTD and the elongation factor subunit Spt5 (Kim and Sharp, 2001).  The dual 
functionality of CDK9, coupled with its equal sequence similarity to both Bur1 and Ctk1, 
has led to the assumption that CDK9 reconstitutes the activities of both Bur1 and Ctk1 in 
higher eukaryotes (Wood and Shilatifard, 2006).  On the other hand, two independent 
molecular evolution studies concluded that Sc Bur1 is the closest Sc relative of metazoan 
CDK9, while Sc Ctk1 is closer to a set of largely unstudied metazoan CDKs (Guo and 
Stiller, 2004; Liu and Kipreos, 2000), the “Ctk1” group (Fig. 1.3).  The genomes of 
Drosophila melanogaster (Dm) and Caenorhabditis elegans each encode one member of the 
Ctk1 group (genes CG7597, and B0285.1, respectively), while the genome of Homo sapiens 
encodes two (genes CRKRS and CDC2L5; see Fig 1.3).  The human “Ctk1” proteins have 
been renamed CDK12 and CDK13 (Chen et al., 2006; Chen et al., 2007).  We will refer to 
them as hCDK12 and hCDK13 and to the Dm protein as dCDK12.  
The evolutionary studies thus suggest that the metazoan ortholog of Ctk1 is 
dCDK12 in Drosophila and the isozyme pair, hCDK12 and hCDK13 in humans.  Both the 
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evolutionary arguments and the recent experimental work mentioned above suggest 
that the metazoan ortholog of Bur1 is CDK9.  We tested these suggestions with a set of 
diverse experiments which lead us to conclude that, indeed, the human and Drosophila 
orthologs of yeast Ctk1 are CDK12 and CDK13.  Because the metazoan orthologs of 
yeast Ctk1 have not previously been studied as CTD kinases, these experiments open the 
door to investigating a vast array of transcription-related events in metazoa that are 
critical to many aspects of proper gene expression and other nuclear functions. 
2.2 Materials and methods 
2.2.1 Antibodies and western blotting 
Anti –IIo: Goat affinity-purified IgGs directed toward the hyperphosphorylated 
CTD of Dm Rpb1 (Morris et al., 1997; Weeks et al., 1993). rAP anti-dCDK12:  Rabbit 
affinity-purified IgGs directed against a peptide comprising amino acids 705–722 of 
dCDK12 (CG7597; NP_649325.2). rAP anti-hCDK13:  Rabbit affinity-purified IgGs 
directed against a peptide comprising amino acids 294–312 of hCDK13 (CDC2L5. NCBI 
RefSeq: NP_003709.3). rAP anti-hCDK12:  Rabbit affinity-purified IgGs directed against 
a peptide comprising amino acids 1058–1077 of hCDK12 (CRKRS. NCBI RefSeq: 
NP_057591.2).  Anti-dCyclin T:  Affinity-purified sheep IgG against purified dCyclin T. 
Anti-NonP:  Mouse monoclonal 8WG16 (Abcam). Anti-Ser2P:  Rat monoclonal (3E10) 
from D.Eick (Chapman et al., 2007), or mouse monoclonal (H5) from Covance. Anti-
Ser5P: mouse monoclonal (H14) from Covance.  Antibody to b-actin:  A mouse 
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monoclonal from Abcam.  gAP-anti-dRpb2:  Affinity-purified goat IgG against a 
segment from dRpb2 (amino acids 519–992) (Skantar and Greenleaf, 1995).  Western blot 
analysis was performed using the Odyssey infrared scanner and secondary antibodies 
from Li-Cor. 
2.2.2 Polytene immunofluorescence 
Visualization of proteins on fixed polytene chromosomes (Weeks et al., 1993) was 
carried out as described previously (Schwartz et al., 2004).  Briefly, Drosophila were 
grown in bottles with yeast glucose media at 23 °C and wandering third instar larvae 
were collected.  For heat shock, larvae were wrapped in plastic and submerged in a 36.5 
°C water bath for the indicated amount of time.  Larvae were dissected in 100 μL of 
dissection buffer (0.7% NaCl) and the salivary glands were isolated and transferred to 40 
μL of fix buffer (50 μl 37% paraformaldehyde, 450 μl acetic acid, 500 μl H2O) on a 
microscope slide.  After 10-20 min of incubation the salivary glands were squashed 
using a coverslip and visualized using a microscope; well-spread and clearly banded 
chromosomes were frozen in liquid nitrogen, and then stained. 
For staining, slides were removed from liquid nitrogen, coverslips were 
removed, and slides were washed (PBS and then PBS with 1% Triton-X 100).  Blocking 
was performed using PBS with 5% non-fat milk powder for 60 min and primary 
antibodies were added in PBS and 1% BSA overnight at 4 °C.  Slides were then washed 
and secondary antibody solution was added (antibodies in PBS, 1% BSA, and 2% 
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donkey or goat serum) for 1 hour at room temp; secondary antibodies were from 
Jackson ImmunoResearch - conjugated with RhodamineRedX and Cy2.  Slides were 
washed using 300 and then 400 mM NaCl, 0.2% NP40, 0.2% Tween20, stained with 
DAPI, and imaged using a Zeiss Axioplan Microscope with a 25x or 100x lens; images 
were processed with Openlab software. 
2.2.3 Chromatin Immunoprecipitation 
Drosophila S2 cells were grown in M3 media + BPYE (Bacto-peptone, yeast 
extract) with 10% FBS to a density of 6x106 to 7x106 cells per mL. To prepare the 10 min 
heat-shock chromatin, 4 mL of 48 °C  M3 + BPYE (no serum) was added to 4 mL of 
culture and incubated for 10 min at 36.5 °C, and then 4 mL of 4 °C M3 + BPYE (no 
serum) was added to bring the cells to room temperature. Immediately, formaldehyde 
was added to a final concentration of 1% and mixed for 2 min at room temperature. The 
reaction was quenched with 675 μL of 2.5 M glycine and immediately cooled on ice. The 
cells were centrifuged for 5 min at 4 °C and resuspended in sonication buffer (20 mM 
Tris-Cl at pH 8.0, 2 mM EDTA, 0.5 mM EGTA, 0.5% SDS, 0.5 mM PMSF, Roche complete 
protease inhibitor cocktail [catalog no. 05 056 489 001]) at 108 cells per milliliter. The cells 
were sonicated 12 times for 20 sec each, with a 1 min rest in between at 4 °C using a 
Bioruptor sonicator; the material was centrifuged at 20,000xg for 10 min at 4 °C, and 25 
μL of the supernatant was used per immunoprecipitation.  Pol II was 
immunoprecipitated with 4 μL of rabbit anti-Rpb3 antisera (Lis laboratory stock) and 
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dCDK12 was immunoprecipitated with 7 μL of rAP anti-dCDK12.  The non-heat-shock 
chromatin was prepared in the same manner, except 8 mL of room temperature M3 + 
BPYE (no serum) was added to 4 mL of culture. The amount of immunoprecipitated 
DNA was quantified using a Roche LightCycler 480 by comparing the quantification 
cycle of the immunoprecipitated DNA to the quantification cycle of serial dilutions of 
input DNA to obtain the percent input. 
2.2.4 Immunoprecipitation and purification of hCDK13 and dCDK12 
2.2.4.1 dCDK12 purification 
2 mL of Kc cell nuclear extract (Price et al., 1987) were diluted to a final volume 
of 4 mL in ice-cold HGEDPF (25 mM HEPES, 8% glycerol, 0.1 mM EDTA, 1 mM DTT, 
phenylmethylsulfonyl fluoride [1:1000 dilution of saturated solution in isopropanol], 10 
mM NaF); NaCl and TritonX-100 were added to a final concentration of 0.5 M NaCl and 
0.4% Triton X-100. The extract was then centrifuged at 23,000xg for 1 hour at 4 °C, and 
the supernatant was precleared by rocking end-over-end with 20 μL of protein A/G bead 
slurry (Thermo Scientific) for 1 h at 4 °C. Approximately 50 μL of protein A/G beads 
(Thermo Scientific, Ultra-Link resin) were saturated with rAP anti-dCDK12 IgG and 
added to the precleared extract, and then allowed to rock end-over-end overnight at 4 
°C.  The beads were recovered, transferred to a small disposable column (Bio-Rad), and 
washed at 4 °C with 10 mL of PBS + 0.2% Tween 20, then with 10 mL of HGEDPF at 0.5 
M NaCl, followed by another 10 mL of PBS + 0.2% Tween20. The beads were then 
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transferred to a fresh microfuge tube and resuspended in 100 mM NaCl/HGEDPF. Beads 
used directly for kinase assays were further washed in 0.8 M NaCl/HGEDPF before 
being rinsed and resuspended in 1x kinase buffer (25 mM HEPES at pH 7.6, 10 mM 
MgCl2, 5 mM NaF). 
For dCDK12 protein elution, protein A acrylic beads (Sigma, catalog no. P1052) 
were saturated with anti-dCDK12 antibody and 100 μL of beads were incubated with 2.5 
mL of KcN extract for 2 hours at 4 °C with end-over-end rocking in a Bio-Rad disposable 
column. The beads were washed in HGEDP (same as HGEDPF, but without NaF) with 
0.5% NP40 and 100 mM KCl, followed by 400 mM KCl/HGEDP and 100 mM 
KCL/HGEDP without detergent. Elution was carried out by an 1 hour incubation with 
end-over-end rocking at 4 °C with 1 mM antigenic peptide (ABR/Thermo Scientific) in 
100 μL of 100 mM KCl/HGEDP. Elutions 2 and 3 were performed in the same manner, 
but with a concentration of 100 mM antigenic peptide. For assays, 5 μL of each elution 
was used. 
2.2.4.2 hCDK13 purification  
HeLa nuclei were prepared, extracted with 0.15 M NaCl, and centrifuged 
(Longley et al., 1997).  25 mL of the pellet was used to prepare a 0.5 M NaCl extract of 
the nuclear pellet as described previously (Carty et al., 2000). The 0.5 M NaCl extract 
was filtered through Miracloth (Chicopee Mills, Inc.) to remove floating lipid, and 
protein concentration was determined using the Bradford method (Bio-Rad Protein 
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Assay).  Ion exchange chromatography was performed on a 25 mL Macro-Prep CM (Bio-
Rad) column.  Extract containing 400 mg of protein was diluted to 0.15 M NaCl with 
HGEDPF and batch-bound to the equilibrated Macro-Prep CM slurry for 2 hours at 4 °C. 
The slurry was then loaded back into the column, washed with 0.15 M NaCl/HGEDPF, 
and eluted using steps of 0.25, 0.4, 0.6, and 1 M NaCl in HGEDPF. The bulk of hCDK13 
was found to elute in the 0.6 M NaCl fraction (monitored by Western blot). The 0.6 M 
fractions containing hCDK13 were pooled and frozen at -80 °C in 1 mL aliquots. 
Antibody-saturated beads were prepared with Ultra-Link protein A/G beads (10–100 μL 
of slurry) or magnetic protein G Dynabeads (50 μL of slurry) and rAP anti-hCDK13 were 
mixed with the 0.6 M NaCl CM column fractions (1–8 mL) and allowed to rock end-
over-end for 8 hours to overnight. The beads were then washed with multiple bead bed 
volumes of each of the following: PBS/0.2% Tween-20, 0.8 M NaCl/HGEDPF, PBS/0.2% 
Tween20, and, finally, 1x kinase reaction buffer (25 mM HEPES at pH 7.6, 10 mM MgCl2, 
5 mM NaF). The beads were resuspended in 1x kinase reaction buffer, frozen in liquid 
nitrogen, and stored at -80 °C. 
2.2.5 CTD kinase assays 
CTD kinase assays were performed essentially as described (Jones et al., 2004; 
Morris et al., 1997), with minor variations.  Briefly, dCDK12 bound to Protein A/G 
UltraLink beads (Thermo Scientific) and hCDK13 bound to magnetic Protein G 
Dynabeads (Invitrogen) were used to assay for in vitro CTD kinase activity (see kinase 
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purification).  5 μL of Dynabeads (from 50 μL of antibody saturated dynabead slurry 
incubated with 1 mL of pooled hCDK13 CM column fractions) or Ultralink (from 100 μL 
of antibody saturated protein A/G bead slurry incubated with 2 mL of KCN extract) 
slurry was used for the kinase assay.  Each reaction was performed in a final 
concentration of 25 mM HEPES pH 7.6, 10 mM MgCl2, 5 mM NaF, and 60 μM ATP, in 
the presence of [γ-32P]ATP (1 μL at 10 μCi), with or without ~2 μg GST-yCTD substrate, 
in a total volume of 10 μL.  The reactions were allowed to proceed for 1 hour at 30 °C, 
and were stopped by the addition of 10 μL 2xSDS and boiling for 10 min at 95 °C.  The 
reactions were then run on a 10% SDS-PAGE gel (Biorad).  The gel was stained with 
coomassie and exposed to a storage phosphor screen (Molecular Dynamics) for 15 min. 
2.2.6 RNAi depletion of dCDK12 in S2 cell culture 
dsRNA constructs targeting CG7597 were designed using the SnapDragon 
program (http://www.flyrnai.org/cgi-bin/RNAi_find_primers.pl), which is optimized for 
the design of long dsRNAs for Dm. Three constructs were selected (targeting exon 2, 
exon 4, and exon 7 of CG7597), and the primers were extended with the sequence of the 
T7 promoter. Constructs used were as follows:  
E2F, 5’-GAATTAATACGACTCACTATAGGGAATCAATGCCTTACTGGACCG-3’; 
E2R, 5’-GAATTAATACGACTCACTATAGGGATGGTATCGTGACTGCTCGAC-3’;  
E4F, 5’-GAATTAATACGACTCACTATAGGGAGTGTGCAGCACTCACGAAGT-3’; 
E4R, 5’-GAATTAATACGACTCACTATAGGGACTCTTGCCGCTCAATGATTT-3’;  
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E7F, 5’-GAATTAATACGACTCACTATAGGGACTCCTACGGTGATAGCCTCG-3’;  
E7R, 5’-GAATTAATACGACTCACTATAGGGAATCTGATGCTGTGTGCGTTC-3’. 
The primers were used to amplify DNA from Drosophila genomic DNA (a gift from Dr. 
Tao Hsieh’s laboratory).  dsRNA was made using a MEGAScript T7 Kit (Ambion, Inc.) 
following the manufacturer’s instructions; the resulting RNA was purified using phenol 
chloroform extraction and annealed.  S2 cells were grown in M3 + BPYE with 10% 
serum. Cells (1.5 mL of 1x106 cells per milliliter) were silenced by addition of 15 μg of 
dsRNA in a sixwell plate format for 48 hours. Anti-LacZ dsRNA (Adelman lab) was 
used as a control.  After 48 hours, cells were resuspended, pelleted, washed in PBS, 
repelleted, and lysed using 2x SDS loading buffer. 
2.2.7 RNAi depletion of hCDK12 and hCDK13 in human cell culture 
The HeLa R-19 cell line was a gift from Dr. Shelton Bradrick.  HeLa R-19 was 
cultured in DMEM with 10% FBS and 1x PenStrep (all from GIBCO). Experimentally 
verified FlexiTube siRNAs targeting hCDK13 (Hs_CDC2L5_5 and Hs_CDC2L5_6) and 
hCDK12 (Hs_CRK7_5 and Hs_CRK7_6) were purchased from Qiagen. The control 
siRNA was AllStarsNegative Control siRNA from Qiagen. HeLa R-19 cells were reverse-
transfected in six-well plates and/or 60-mm dishes using RNAi Max (Invitrogen) 
transfection reagent following the manufacturer’s instructions.  One siRNA targeting 
hCDK12 (Hs_CRK7_5) was found to have an off-target effect that resulted in cell death, 
and was not used. The second hCDK12 siRNA and a pool of the two hCDK13 siRNAs 
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were used for the knockdown experiments. Knockdown experiments were conducted 
with seeding densities calculated so that the cells reach ~90% confluence before being 
harvested.  Final siRNA concentrations of 5 nM and 12.5 nM (total concentrations for 
both the pooled [CDK13] and single [CDK12] siRNAs) and time points of 48 and 72 
hours were found to yield the same results.  Cells were harvested by trypsinization with 
0.05% Trypsin-EDTA (GIBCO) for 3 min at 37 °C, followed by neutralization of the 
trypsin with complete medium.  The resulting cell slurry was centrifuged at low speed, 
and the cell pellet was washed by resuspension in 5 mL of PBS.  The cells were pelleted, 
resuspended in 1 mL of PBS, and repelleted.  After removing the supernatant, the cell 
pellet was lysed with RIPA buffer or hot 2x SDS loading buffer (final volume ~130 μL). 
Successful knockdown of the kinases was confirmed by Western blot analysis. 
2.3 Results 
2.3.1 dCDK12 colocalizes with actively transcribed genes on 
Drosophila polytene chromosomes 
In order to visualize the genome-wide distribution of dCDK12 on chromatin, we 
began our studies with indirect immunofluorescence labeling of Drosophila polytene 
chromosomes.  According to our hypothesis and previous experiments examining the 
distribution of yeast Ctk1 (Cho et al., 2001; Qiu et al., 2009), we expected to find dCDK12 
localized across actively transcribing loci in parallel with hyperphosphorylated RNAPII 
(Pol II0, a marker that correlates with actively elongating polymerase).  In collaboration 
with Dr. John Lis’s lab, the following immunoflourescence experiments were performed 
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by Janis Werner.  Salivary glands were dissected from Drosophila larvae, with and 
without prior heat shock3, fixed with formaldehyde, and squashed on a microscope 
slide.  The spread polytene chromosomes were then stained with antibodies against 
dCDK12 and Pol II0 (Weeks et al., 1993).  dCDK12 colocalized extensively with 
hyperphosphorylated RNAPII in both heat shocked (Fig. 2.1 a.) and non-heat shocked 
animals (Fig. 2.1 b.).  Split chromosome arm views further demonstrate the extent of this 
colocalization (Fig. 2.1 c. and d.); practically all elongating RNAPII is accompanied by 
 
Figure 2.1:  Distribution of dCDK12 (red) and hyper-phosphorylated RNAPII (Pol II0; green) on 
Drosophila melanogaster polytene chromosomes from (a.) non-heat shocked animals and (b.) heat 
shocked animals; DNA is stained with DAPI (blue) and the merge contains both the green and red 
images.  Split chromosome arm views from (c.) non-heat shocked and (d.) heat shocked animals; the 87A 
and 87C heat shock puffs are labeled.  Images created by Dr. Arno Greenleaf. 
                                                     
3 20 min at 37 °C; heat shock results in the suppression of the majority of transcription, with the exception of 
the heat shock genes which are strongly upregulated. 
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dCDK12.  This indicates that dCDK12 is present at sites of active transcription and 
suggests that it is likely to play a role during transcriptional elongation. 
2.3.2 The global distributions of dCDK12 and P-TEFb on Drosophila 
polytene chromosomes are distinct 
In an effort to begin to deconvolute the relationship between P-TEFb and CDK12 
we also compared the genome-wide distributions of dCDK12 and P-TEFb.   Due to the 
lack of an antibody against CDK9 itself, we obtained antibodies against dCyclinT, the 
cyclin subunit of P-TEFb (Cdk9 + cyclinT) from Dr. David Price’s lab.  dCDK12 and P-
TEFb exhibited very different distribution patterns on both heat shocked and non-heat 
shocked chromosomes (Fig. 2.2).  Interestingly the long, intron rich, ecdysone induced 
developmental genes stained very strongly for dCDK12, and weakly for dCyclinT.   
Other regions of the chromosome showed the inverse relationship, and although clearly 
distinct, the distributions of the two kinases did share some areas of overlap (see merge 
in Fig. 2.2 a. and Fig 2.2 d.).  It is worth noting that the kinase distributions can change 
drastically across a single transcription puff.  In (Fig 2.2 d.) the heat shock puff, located 
between the two dotted lines, appears to be flanked by a very strong dCyclinT signal 
(green) with virtually no signal from dCDK12 (red).  Moving further up the puff, the 
strong dCyclinT signal then intersects with the appearance of a robust dCDK12 signal, 
creating an area of overlap (yellow band in the merged image).  The dCyclinT signal  
 44 
 
Figure 2.2:  Distribution of dCDK12 (red) and P-TEFb (CDK9+CyclinT; green) on Drosophila 
melanogaster polytene chromosomes from (a.) non-heat shocked animals and (b.) heat shocked animals; 
DNA is stained with DAPI (blue) and the merge contains both the green and red images, white arrows 
indicate developmental puffs that stain strongly for dCDK12, but weakly for P-TEFb.  Chromosome arm 
views from (c.) non-heat shocked (the 75B and 74E ecdysone developmental puffs are labeled) and (d.) 
heat shocked animals (the 87A, 87C, and 87E heat shock puffs are labeled).  Images created by Dr. Arno 
Greenleaf. 
then drops off, and gives way to the strong dCDK12 signal (red, near top dotted line), 
which dominates through the rest of the puff.  These results strongly support the idea 
that dP-TEFb and dCDK12 have distinct functions at specific locations within the 
transcription unit. 
2.3.3 The distribution of dCDK12 across the Hsp70 loci is distinct 
from P-TEFb 
In order to verify the polytene immunofluorescence results and to determine the 
distribution of dCDK12 at higher resolution we set out to perform dCDK12 and RNAPII 
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ChIP at the heat shock inducible Hsp70 loci.  The following set of ChIP experiments was 
performed in collaboration with Dr. John Lis’s lab by Nicholas Fuda.  Using Drosophila 
S2 cell culture, we find that on the well-studied Hsp70 gene, anti-Rpb3 antibody detects 
the expected presence of promoter-proximally paused polymerase near the TSS prior to 
heat shock (Fig 2.3 a.; +96 position, blue bars).  After a 10 min heat shock, RNAPII 
occupancy increased dramatically along the entire transcription unit due to RNAPII 
recruitment and its release into productive elongation; however, it is important to note 
that a peak of RNAPII occupancy persists at the +96 position as pause release remains a 
rate limiting step (Fig 2.3 a.; red bars).  As opposed to RNAPII ChIP, dCDK12 ChIP 
revealed no signal above background before heat shock, but displayed a robust signal 
along virtually the entire gene after heat shock (Fig 2.3 b.).  Significantly, the results 
indicate no presence of dCDK12 with the paused RNAPII before gene activation, and no 
dCDK12 peak at the +96 position following gene activation.  Maximum levels of 
dCDK12 are not reached until the +379 position and remain high throughout the 
transcription unit (Fig 2.3 b.). These results contrast with those for P-TEFb, which reveal 
a concentration that peaks at the 5’ end of the gene (at the +58 position in (Boehm et al., 
2003)) and steadily declines, as would be expected due to P-TEFb’s role in pause release.  
The ChIP results, therefore, are consistent with our polytene chromosome-staining 
results in showing different distributions for dCDK12 and dP-TEFb and reveal a 
dCDK12 occupancy pattern reminiscent of an elongation phase Ser2 CTD kinase. 
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Figure 2.3: ChIP analysis of (a.) RNAPII and (b.) dCDK12 at the Hsp70 loci.  Cells were either non-heat 
shocked (in blue) or heat shocked for 10 minutes (red).  A schematic of the HSP70 gene with the positions 
of the assessed regions is included at the bottom of the figure.  Error bars are standard error of the mean, 
n=3. 
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2.3.4 Drosophila CDK12 and human CDK13 manifest CTD kinase 
activity in vitro 
Having investigated the distribution of dCDK12 on chromatin, we next wanted 
to see whether CDK12 and CDK13 were capable of phosphorylating the CTD.  In order 
to obtain purified endogenous hCDK13 and dCDK12 for in vitro CTD kinase assays we 
employed a mixture of standard and immuno-affinity purification methods.  We first 
turned our attention to the human proteins (hCDK12 and hCDK13), which we 
attempted to purify from HeLa cell nuclear pellets. 
HeLa nuclear pellets were extracted in a 0.5 M NaCl extraction buffer as 
described in (Carty et al., 2000); the extract was then cleared and bound to a Macro-Prep 
CM ion exchange chromatography column.  The column was eluted using a step 
gradient of NaCl and the bulk of hCDK13 and hCDK12 (pI 9.7 and 9.48) was found to 
elute in the 0.6 M NaCl fraction (monitored by western blot).  In order to further purify 
and separate the two paralogues we employed affinity purified antibodies.  Protein A/G 
beads were saturated with anti-hCDK13 antibodies and mixed with the 0.6 M NaCl CM 
column fractions for several hours.  After incubation, the beads were stringently 
washed, resuspended in kinase reaction buffer, and assayed for CTD kinase activity 
(successful hCDK13 pulldown was confirmed via western blots, data not shown).  
Kinase assays were performed with a GST-yeastCTD (GST-yCTD) fusion protein:  The 
yeast CTD (26 heptad repeats) fused to GST and expressed in E. Coli.  ~2 ug of the 
purified fusion protein, 5 μL of protein A/G bead slurry, 1 µCi of [γ-32P]ATP, and cold 
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ATP were mixed in kinase reaction buffer for a final reaction volume of 20 μL with 60 
uM ATP4.  The resulting mixture was incubated for 1 hour at 30 °C, after which the 
reaction was stopped with the addition of 5μL of 5x SDS loading buffer.   The reaction 
mix was then submitted to SDS-PAGE, and the coomassie stained gel exposed to film.  
Reactions without fusion protein or without kinase beads were used as controls.  The 
presence of a strong mobility shifted band (above the molecular weight of the 
unphosphorylated GST-yCTD protein) in the autoradiogram indicated that hCDK13 
does indeed exhibit CTD kinase activity (Fig. 2.4).   
Several attempts have been made to affinity purify hCDK12 from both raw 
nuclear extract and CM column fractions; unfortunately the hCDK12 antibody used at 
the time (rAP anti-hCDK12:  Rabbit affinity-purified IgGs directed against a peptide  
 
Figure 2.4:  hCDK13 kinase assay.  Corresponding coomassie-stained gel and autoradiograph with the 
position of the unphosphorylated GST-yCTD substrate indicated by a dashed line.  Substrate and 
enzyme-bead only control lanes are labelled CTD and Beads respectively.  The mobility shifted signal 
above the position of the GST-yCTD is indicative of CTD hyperphosphorylation. 
                                                     
4 The Km of Ctk1 is ~25 uM (Jones et al., 2004). 
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comprising amino acids 1058–1077 of hCDK12) was unable to pull down hCDK12 in any 
of the conditions that were tried.  This may be due to the poor specificity of this hCDK12 
antibody which clearly cross-reacts with many other proteins in western blots (data not 
shown).  Fortunately, hCDK12 CTD kinase activity has been shown previously in the 
literature (Ko et al., 2001), indicating that it too is capable of CTD phosphorylation in 
vitro. 
dCDK12 was also purified via an immuno-affinity approach using Drosophila Kc 
cell nuclear extracts as starting material.  The Kc nuclear extracts (Price et al., 1987) were 
diluted, precleared, and mixed with anti-dCDK12 antibody saturated protein A/G beads.  
The beads were then washed exhaustively using high salt and detergent, then 
resuspended in either kinase buffer or 100 mM KCl HGEDP (see 2.2.4.1 for buffer 
composition).   Beads resuspended in kinase buffer were assayed for CTD kinase activity 
in the same manner as hCDK13 (Fig. 2.5 a.).  In an attempt to further isolate the kinase, 
dCDK12 was eluted from the 100 mM KCl HGEDP resuspended beads using the 
dCDK12 antibody’s antigenic peptide.  The beads were sequentially incubated in 100 μL 
of HGEDP containing 1 mM (elution 1 - E1), 100 μM (elution 2 - E2), and 100 μM (elution 
3 - E3) antigenic peptide, for a total time of 1 hour per elution.  5 μL of the resulting 
elutions were used in lieu of bead slurry for CTD kinase assays using a βgal-
DrosophilaCTD fusion protein (Fig 2.5 b.).  dCDK12 exhibited in vitro CTD kinase 
activities on both GST-yCTD and βgal-dCTD substrates (Fig 2.5).  Therefore, these  
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Figure 2.5:  dCDK12 kinase assays.  Corresponding coomassie-stained gels and autoradiographs with the 
position of the unphosphorylated substrate indicated by a dashed line/arrow.  (a.) Bead bound dCDK12 
assayed using GST-yCTD; substrate and enzyme-bead only control lanes are labelled CTD and Beads 
respectively.  (b.) dCDK12 elutions assayed using a βgal-dCTD fusion protein.  Coomassie bands below 
the full length substrate are degradation products.  E1, E2, and E3 are subsequent elution fractions and 
noE is a no enzyme control lane.  The mobility shifted signals above the position of the unmodified 
substrates are indicative of CTD hyperphosphorylation. 
results clearly demonstrate that hCDK13 and dCDK12 immunoprecipitates exhibit CTD 
kinase activity in vivo. 
2.3.5 Drosophila and human cells require CDK12 for normal 
phosphorylation of the CTD 
In order to determine whether dCDK12 was necessary for proper CTD 
phosphorylation in vivo, we used siRNA to knockdown dCDK12 in Drosophila cell 
culture.  Three dsRNA PCR primer pairs, designed to target exons 2, 4, and 7 of 
dCDK12, were amplified using PCR of Drosophila DNA and in vitro transcribed into  
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Figure 2.6:  Western blots of Drosophila S2 whole cell extracts 48hrs post dsRNA treatment.  (a.) Anti-
dCDK12 western confirming dCDK12 knockdown using three dsRNA constructs (E2, E4, E7); dRpb2 is 
used as a loading control.  (b.) Anti-Ser2P western using the H5 antibody (in red).  (c.) Anti-Ser5P western 
using the H14 antibody (in red). Mock cells are treated with anti-LacZ dsRNA and dRpb2 (green) is used 
as a loading control. 
dsRNA; anti lac-Z dsRNA obtained from Dr. Adelman’s lab was used as a negative 
control (mock).  The transfected cells were incubated for 48 hours and then harvested for 
western blotting of whole cell extracts.  Westerns with anti-dCDK12 antibodies revealed 
that almost complete dCDK12 knockdown was obtained with all three dsRNA 
constructs (Fig. 2.6 a.). 
In order to determine global CTD phosphorylation levels, we probed whole cell 
extracts with the anti-phospho-CTD antibodies H5 and H14.  The H5 antibody is specific 
for Ser2 phosphorylated heptad repeats, while the H14 antibody reacts with Ser5 
phosphorylated heptads (Jones et al., 2004).  Knockdown of dCDK12 resulted in an 
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almost complete loss of Ser2 CTD phosphorylation as measured by the H5 antibody 
(Fig. 2.6 b.), and had no significant effect on Ser5 CTD phosphorylation as measured by 
H14 (Fig. 2.6 c.).  These results clearly demonstrate that the majority of Ser2 CTD 
phosphorylation (as detected by the H5 antibody, see discussion) is mediated through 
dCDK12 and strongly support the idea that dCDK12 is a Ser2 specific CTD kinase. 
In order to test the in vivo function of the human kinases, we also used siRNAs to 
knockdown hCDK12 and/or hCDK13 in HeLa cell culture.  HeLa cells were reverse 
transfected with five different sets of siRNAs: no siRNA (RNAiMAX lipofectamine only, 
mock), a non-targeting siRNA pool (si-con), or siRNA pools targeting hCDK12, hCDK13, 
or both.  The cells were then incubated for three to five days, harvested by 
trypsinization, and analyzed by western blotting of whole cell extracts (Fig. 2.7).  Final 
siRNA concentrations of 5 nM and 12.5 nM, and time points of 48 and 72 hours were 
found to yield the same results.  Western blots confirmed that we were able to 
successfully knockdown both hCDK12 and hCDK13, alone and in tandem.  Based on our 
experiments in Drosophila, we expected to see a significant decrease in Ser2P upon the 
knockdown of the kinases.  However, our results proved to be much more nuanced.  
Due to reasons previously discussed (see 1.1), the CTD containing Rpb1 subunit of 
RNAPII runs as two distinct bands on SDS gels:  Nonphosphorylated (IIa) and 
hyperphosphorylated (IIo).  Western blots of whole cell extracts for Ser2 phosphorylated 
CTD repeats probed with the 3E10 antibody (another antibody specific for Ser2  
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Figure 2.7:  Western blots of HeLa whole cell extracts 72hr after RNAi knockdown of hCDK12 and/or 
hCDK13.  Cells are treated with siRNA targeting hCDK12 (si-12), hCDK13 (si-13), or both (si-12+13).  
Mock and si-con are untreated and nontargeting controls; β-actin is used as a loading control.  (a.) Anti-
hCDK12 western confirming hCDK12 depletion (b.) Anti-hCDK13 western confirming hCDK13 
depletion.  (c.) Anti-Ser2P western using the 3E10 antibody (green) and anti-NonPhospho CTD repeat 
western using the 8WG16 antibody (red); note the changed reactivity of the 8WG16 antibody toward 
Rpb1 after hCDK12 depletion. 
phosphorylated heptads (Chapman et al., 2007)) reveal that the Ser2 phosphorylated 
CTD signal undergoes a slight mobility shift (faster mobility) upon knockdown of 
hCDK12 (Fig. 2.7 c., In green).  No discernable effect was seen after hCDK13 knockdown 
and an effect of similar magnitude to that of depleting hCDK12 alone is seen upon the 
depletion of both kinases.  Fortunately, these unexpectedly middling results were 
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coupled with much more striking changes in the reactivity of the 8WG16 antibody, 
which specifically detects nonphosphorylated CTD heptad repeats (Jones et al., 2004) 
(Fig. 2.7 c., in red).  Normally the 8WG16 antibody reacts with open epitopes in both the 
phosphorylated and unphosphorylated forms of the CTD (see Fig 2.7 c., α-NonP view 
only).  However, hCDK12 depletion increased 8WG16 reactivity with the lower mobility 
IIo (hyperphosphorylated) band.  One interpretation of these results is that hCDK12 
depletion leads to an increase in unphosphorylated repeats (or Ser5 only 
phosphorylated repeats) in the elongating RNAPII.  The decrease in phosphorylation is 
not large enough to drop the IIo band down to the IIa form, but is significant enough 
that the 8WG16 antibody reactivity towards the IIo band increases.  Interestingly a 
similar 8WG16 detected Rpb1 mobility shift has been previously observed in Ctk1Δ 
yeast strains (Patturajan et al., 1999).  Although subtle, the effect is highly reproducible, 
and has been also observed using HEK293T/17 cells.  Therefore, the data from the 
knockdown experiments support the idea that hCDK12 is a bona fide CTD kinase in 
human cells.  Because knockdown of hCDK13 does not appear to cause significant 
changes in global CTD phosphorylation, we cannot currently conclude that hCDK13 is a 
CTD kinase in vivo; however, in vitro, it clearly manifests CTD kinase activity. 
2.4 Discussion 
Through the co-transcriptional phosphorylation of its heptad repeats, the CTD of 
RNAPII coordinates transcription with a number of nuclear processes such as mRNA 
 55 
processing and chromatin modification.  Although Drosophila melanogaster CDK12 and 
human CDK12 and CDK13 have been previously identified by phylogenetic approaches 
as the closest homologs of the major transcription elongation-associated yeast Ser2 CTD 
kinase Ctk1 (Guo and Stiller, 2004; Liu and Kipreos, 2000), their status as functional CTD 
kinases was unclear.  In this study we show that Dm CDK12 and human CDK12 are 
CTD kinases; the metazoan orthologs of yeast Ctk1. 
In situ localization of dCDK12 on Dm polytene chromosomes presents a dramatic 
genomewide co-occurrence of dCDK12 with hyperphosphorylated RNAPII. The 
dCDK12 kinase appears to be closely associated with Pol II0, both at loci expressed 
during normal development, but also at heat-shock loci (Fig. 2.1). In contrast, the 
chromosomal distributions of dCDK12 and the Bur1 related Ser2 CTD kinase dP-TEFb 
are distinct (Fig. 2.2).  In addition, ChIP studies show that whereas the amount of dP-
TEFb peaks early in the gene (with paused polymerase), dCDK12 amounts peak later in 
the transcription unit (Fig. 2.3), resembling the behavior of yCtk1.  Because the functions 
of P-TEFb, such as releasing RNAPII from elongation arrest early in transcription 
(Peterlin and Price 2006), are reflected in its localization patterns, we propose that the 
chromosomal localization patterns of dCDK12 similarly reflect its functions during 
transcription.  
The fact that dCDK12 displays CTD kinase activity in vitro supports the idea that 
the primary function reflected in its chromosomal distribution is phosphorylation of the 
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CTD on elongating RNAPII.  Given that hCDK12 also displays in vitro CTD kinase 
activity, CTD phosphorylation on elongating RNAPII is also the most likely function of 
the human homolog hCDK12.  The changes in kinase distributions across transcription 
units, combined with ChIP data from Boehm et al. (Boehm et al., 2003), support a model 
in which P-TEFb prepares the polymerase for productive elongation near the promoter 
(through pause release, which occurs within 100bp of the TSS, and priming of the CTD 
for further phosphorylation (Qiu et al., 2009)) and then disassociates, allowing CDK12 to 
take over as the primary transcription elongation associated CTD kinase. 
Knockdowns of dCDK12 and hCDK12 support the hypothesis that these kinases 
phosphorylate the CTD of Rpb1 in vivo.  In Drosophila cells, which contain only one Ctk1 
ortholog, the results are dramatic; over two-thirds of Ser2 phosphorylation, as detected 
by the mAb H5, is lost after knockdown of dCDK12 (Fig. 2.6 b.).  Although these results 
are striking, it should be noted that despite being generally accepted by the Drosophila 
transcription field, the H5 antibody is raised against consensus sequence Ser2 
phosphorylated CTD repeats.  The Drosophila CTD only contains 2 consensus repeats 
and it is not known which, if any, of the phosphorylated nonconsensus repeats is 
detected by H5 (Fig 1.1).  Thus, the precise epitope(s) of the H5 antibody in Drosophila 
are unknown.  However, even with this caveat in mind, the results offer very strong 
evidence in favor of our initial hypothesis.  
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Looking at total RNAPII in whole-cell extracts of human cells, we also observe a 
change in CTD phosphorylation state after hCDK12 knockdown (Fig. 2.7 c.). As 
previously discussed (Munoz et al., 2010; Phatnani and Greenleaf, 2006) (also see 1.2.1), 
it is impossible to obtain a detailed understanding of phosphorylation patterns from 
antibody reactivities, but in this particular context, the important finding is that 
knockdown of hCDK12 results in alteration of the phosphorylation status of the CTD. 
Although the increase in the 8WG16 non-phospho antibody reactivity after knockdown 
of hCDK12 (Fig. 2.7 c.) may at first seem counterintuitive, it can be explained by the 
appearance of non-phospho epitopes within the repetitive CTD structure; an analogous 
observation was made previously in ctk1Δ strains of yeast (Patturajan et al., 1998a).  
Why the subtle, especially when compared to the dCDK12 knockdown results, change 
in CTD phosphorylation in human cells? Although we do not have a clear answer, it is 
worth repeating that the analysis of CTD phosphorylation states via western blotting of 
whole cell extracts is extremely complicated due to the presence of multiple forms of 
post-translationally modified CTDs in both the IIa and IIo bands (Munoz et al., 2010) 
and the limitations of the anti-phosphoCTD antibodies whose reactivity is affected by 
the modifications of neighboring residues and the residues in neighboring heptad 
repeats.  Possible explanations include the previously mentioned divergence of the Dm 
CTD or the prospect of compensating kinase activities in human cells (e.g. P-TEFb may 
increase in promiscuity upon dCDK12 knockdown).  Nevertheless, our results clearly 
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show that the CTD phosphorylation state is affected by hCDK12 knockdown which 
supports the hypothesis that hCDK12 is a functional orthologue of yCtk1 in humans.  
Tantalizingly, the knockdown experiments suggest that hCDK12 and hCDK13 play 
different functions in vivo, although hCDK13 does exhibit CTD kinase activity in vitro. 
Overall we demonstrate that dCDK12 is a major elongation-associated CTD 
kinase in Drosophila, the ortholog of yCtk1.  Furthermore, our results support the 
proposal that, in human cells, hCDK12 is a functional counterpart of yCtk1; hCDK13 is 
clearly a CTD kinase in vitro, but its functions in vivo are not yet clear.  Our findings help 
clarify the relationships between two yeast CDKs, Ctk1 and Bur1, and their metazoan 
homologues and, most importantly, they draw attention to major metazoan CTD kinase 
activities that have gone unrecognized and unstudied until now.  The identification of 
these elongation-phase Ser2 CTD kinases in metazoa enables us to study the link 
between CTD phosphorylation and transcription elongation-associated processes in 
higher eukaryotes.  Therefore, further study of CDK12 and CDK13 promises to greatly 
expand our knowledge of both CTD phosphorylation and RNAPII transcription.  
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3. Identification of hCDK12 and dCDK12 Associated 
Proteins 
3.1 Introduction 
The majority of Ser2 CTD phosphorylation on productively elongating RNAPII 
in yeast (Saccharomyces cerevisiae) appears to be catalyzed by CTDK-I, a three subunit 
cyclin dependent kinase consisting of Ctk1 (a CDK homolog), Ctk2 (a cyclin homolog), 
and Ctk3 (function unknown).  Ctk1 is not the only Ser2 CTD kinase in yeast, the 
essential Bur1 kinase (Bur1 is a CDK homolog and its cyclin partner is Bur2) has also 
been shown to contribute to Ser2 phosphorylation.  Likewise, two primary Ser2 position 
CTD kinases have been identified in higher eukaryotes: The Bur1 related P-TEFb, 
composed of CDK9 and cyclinT, and the CTDK-I related CDK12/CyclinK complex.  P-
TEFb is recruited near the 5’ end of the transcription unit and in addition to Ser2 of the 
CTD it is able to phosphorylate Negative Elongation Factor (NELF) and the elongation 
factor Spt5, making it essential for entry into productive transcriptional elongation.  The 
more recently discovered CDK12/CyclinK, on the other hand, appears to act further 
downstream within the transcription unit and currently its best studied function has 
been the phosphorylation of the Ser2 position of the CTD (Bartkowiak et al., 2010; Blazek 
et al., 2011).   
Interestingly, human CDK12 (hCDK12) and Dm CDK12 are uncharacteristically 
large with molecular weights in excess of 160 kDa (most CDKs are about 50 kDa) and 
contain large N and C terminal extensions that flank the CDK kinase domain (Fig. 1.5).  
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These extensions contain multiple stretches of low complexity sequence and RS domains 
(domains characteristic of splicing factors believed to mediate protein-protein 
interactions (Zhong et al., 2009));  as expected of RS domain containing proteins, 
hCDK12 is found in nuclear speckles, which are believed to be storage sites for splicing 
factors (Zhong et al., 2009; Ko et al., 2001). 
Much akin to their cell cycle regulating counterparts, the transcriptional CDK’s 
activity depends on their interaction with their regulatory cyclin partners.  Because 
members of the cyclin L class also colocalize to nuclear speckles and contain RS 
domains, it was postulated that they would be good candidates for the cyclin partners of 
hCDK12 and hCDK13.  In order to test this proposal, previous studies overexpressed 
myc-tagged hCDK12 and hCDK13 in tandem with flag-tagged hCyclinL in HEK293 
cells.  When the overexpressed CDKs were immunoprecipitated, they were found to pull 
down the overexpressed hCyclinL (Chen et al., 2006; Chen et al., 2007).  
Beyond the proposed interactions with CyclinL, no other CDK12 associated 
proteins have been identified.  Due to the presence and sequence composition of 
CDK12’s terminal extensions we hypothesized that CDK12 would mediate numerous 
protein-protein interactions which were likely to play a role both in the proper 
recruitment of CDK12 to the elongation complex and “non-catalytic”, structure 
dependent, CDK12 functions.  In order to gain more insight into the in vivo activity of 
hCDK12 and to inform future studies we set out to purify endogenous hCDK12 and 
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dCDK12 and to identify associated complexes and proteins using mass spectrometry.  
Functional annotation of the mass spectrometry identified CDK12 associated candidates 
reveals a strong enrichment of mRNA processing factors, nucleosome remodeling 
complexes, mRNA binding proteins, and nuclear speckle components.  These results 
suggest that CDK12 is involved in multiple aspects of pre-mRNA processing, as is its 
yeast ortholog, Ctk1.  Therefore we propose that CDK12 may affect RNA processing 
events in two distinct ways:  indirectly through generating factor-binding phospho-
epitopes on the CTD of elongating RNAPII, and directly through binding to specific 
factors. 
3.2 Materials and methods 
3.2.1 Antibodies and western blotting 
rAP anti-hCDK12:  Affinity-purified rabbit IgGs directed against a peptide 
comprising amino acids 201-220 of hCDK12; note that this antibody is distinct from the 
antibody used previously (see 2.2.1).  rAP anti-dCDK12:  Affinity-purified rabbit IgGs 
directed against a peptide comprising amino acids 705–722 of dCDK12 (CG7597; 
NP_649325.2).  Anti-Ser2P:  Mouse mAb (H5) from Covance. gAP anti-dRpb2:  Affinity-
purified goat IgG against a segment from dRpb2 (amino acids 519–992) (Skantar and 
Greenleaf, 1995).  Western blot analysis was performed using the Odyssey infrared 
scanner and secondary antibodies from Li-Cor.  
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3.2.2 Identification of cyclin component of dCDK12 
For dCDK12 cyclin identification, dCDK12 was purified as described previously 
(see 2.2.4.1).  15 μL of dCDK12 bead slurry was subjected to PAGE using a 4%–15% SDS 
gel (Biorad). After staining with Coomassie blue, gel bands of interest were excised and 
submitted for LC MS/MS analysis at the Duke Proteomics Facility 
(http://www.genome.duke.edu/cores/proteomics). 
3.2.3 RNAi depletion of dCyclinK in S2 cell culture and qPCR 
Primer design and RNAi treatment of S2 cell culture was performed as described 
previously (see 2.2.6).  dsRNA construct primers were as follows:  
 CycKF 5’- GAATTAATACGACTCACTATAGGGAACAAATTCCTTCCAACGACG-3’ 
and  
CycKR 5’- GAATTAATACGACTCACTATAGGGAACAGGTCCAGAACTTGGTGG-3’. 
RNA was isolated using the RNeasy mini kit (Quiagen) (The optional on-column 
DNAse step was performed) and cDNA synthesis was performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using 1.5 μg of total 
RNA as input. 
Quantitative PCR (qPCR) was performed using Power SYBR Green PCR master 
mix (Applied Biosystems) and the StepOnePlus real-time PCR system (Applied 
Biosystems); each sample was normalized based on the amount of Rp49 and changes in 
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gene expression were calculated using the ΔΔCt method.  The forward and reverse 
primers used to detect each target are listed below. 
CDK12: AGCTTCCGGTTCGCATCACTATCA & ATCTCTTGACGTTGGTGATCGGCT 
CyclinK: AAACCTGGACCACACAAAGC & GCCCACATCAAAGATGAACC 
Rp49: CCCAAGGGTATCGACAACAGA & CGATGTTGGGCATCAGATACTG 
3.2.4 Immunopreciptation of dCDK12 
2 L of Drosophila S2 cells were grown to 8x106 in a spinner flask in M3 + BPYE 
with 10% serum.  Nuclei were extracted following the method of (Weake et al., 2009), all 
steps were performed at 4 °C with protease inhibitors and 1 mM DTT present in all 
buffers.   Briefly, cells were pelleted, subjected to a hypotonic swell, and disrupted with 
40 strokes with a dounce homogenizer using the tight pestle; greater than 90% lysis was 
confirmed via microscopy.  Nuclei were then pelleted, washed, and resuspended in a 
350 mM NaCl, 0.1% Triton X-100 extraction buffer, and extracted for 1 hour (with end 
over end rocking).  Nuclear extracts were cleared via centrifugation and stored at -80 °C 
until use; protein concentration was determined to be ~7 mg/mL by Bradford assay 
(BioRad).  
The nuclear extracts were diluted to ~4 mg/mL total protein and the salt 
concentration was adjusted to 400 mM NaCl (all steps are performed at 4 °C with 
protease inhibitors (Sigma P8340) and 1 mM DTT present in all buffers).  The dilute 
solution was cleared via centrifugation (20,000xg at 4 °C for 30 min) and 1 mL was used 
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for each pulldown.  SoftLink Soft Release Avidin Resin (Promega), which was selected 
due to its low background binding, was saturated with a biotinylated goat anti-rabbit 
IgG antibody (Jackson ImmunoResearch Laboratories, Code #111-065-008).   10 μL of the 
resulting anti-rabbit IgG resin was used to preclear each 1 mL aliquot of the diluted S2 
cell nuclear extract (1 hour of end over end rocking, 4 °C).  The rest of the anti-rabbit IgG 
resin was either saturated with the rabbit anti-dCDK12 antibody or with total rabbit 
IgGs (purified using protein A agarose from rabbit pre-immune serum) as a negative 
control; 20 μg of antibody was used per 10 μL of the anti-rabbit IgG resin.  The resulting 
bead-antibody-antibody complexes were then crosslinked using dimethyl pimelimidate 
(DMP) as described in Antibodies: A Laboratory Manual (Harlow and Lane, 1999).  
Following crosslinking, the beads were thoroughly washed with 1x PBS, 0.02% 
Tween20.  The crosslinked anti-dCDK12 and total IgG beads were then used for 
overnight pulldowns using the precleared nuclear extracts as input (10 μL of the resin 
was used per 1 mL of nuclear extract). 
Following the immunoprecipitation each 10 μL set of beads was washed 5x 1 mL 
of 400 mM NaCl extraction buffer, 1x 1 mL of 1x PBS with 1% NP-40, 3x 1 mL 1x PBS 
0.02% Tween20 and 5x 1 mL 1x PBS.  The beads were spun down, supernatant was 
completely removed, and the beads were eluted two times with 50 μL of 50 mM 
ammonium bicarbonate with 0.15% Rapigest detergent, for 5 min at room temperature 
with agitation per elution.  The supernatant was then removed and pooled for each 
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sample (total rabbit IgG control and anti-dCDK12) and submitted to the Duke 
Proteomics Facility for subsequent analysis (LC MS/MS). 
3.2.5 Immunoprecipitation of hCDK12 
Dignam-Roeder nuclear extracts (Carey et al., 2009) (protein concentration at ~16 
mg/mL)  of HeLa cells were kindly provided by Dr. Irina Evsyukova from Dr. Mariano 
Garcia-Blanco’s lab.  The nuclear extracts were diluted to ~4 mg/mL total protein and the 
salt concentration was adjusted to 400 mM NaCl (All steps are performed at 4 °C with 
protease inhibitors (Sigma P8340) and 1 mM DTT present in all buffers).  The dilute 
solution was cleared via centrifugation (20,000xg at 4 °C for 30 min) and 2 mL was used 
for each pulldown.  For RNAse treatment, the 2 mL of nuclear extract was treated with 
60 μL of RNAse cocktail (Ambion AM2246) or with 10 μL of RNAse inhibitor (RNAse 
inhibitor, Murine, NEB) and incubated at room temperature for 30 min before 
proceeding with the preclear and immunoprecipitation steps.  RNAse amounts were 
determined in a pilot experiment using a spiked in 1000 bp RNA, which after RNAse 
treatment was phenol chloroform extracted and visualized via EtBr agarose gel 
electrophoresis to monitor RNA degradation. 
SoftLink Soft Release Avidin Resin (Promega), which was selected due to its low 
background binding, was saturated with a biotinylated goat anti-rabbit IgG antibody 
(Jackson ImmunoResearch Laboratories, Code #111-065-008).   10 μL of the resulting 
anti-rabbit IgG resin was used to preclear each 2 mL aliquot of the diluted HeLa nuclear 
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extract (1 hour of end over end rocking at 4 °C).  The rest of the anti-rabbit IgG resin was 
either saturated with the rabbit anti-hCDK12 antibody or with total rabbit IgGs (purified 
using protein A agarose from rabbit pre-immune serum) as a negative control; 20 μg of 
antibody was used per 10 μL of the anti-rabbit IgG resin.  The resulting bead-antibody-
antibody complexes were then crosslinked using dimethyl pimelimidate (DMP) as 
described in Antibodies: A Laboratory Manual (Harlow and Lane, 1999).  Following 
crosslinking the beads were rinsed with 100 mM formic acid and thoroughly washed 
with 1x PBS, 0.02% Tween20.  The crosslinked anti-CDK12 and total IgG beads were 
then used for overnight pulldowns using the precleared HeLa nuclear extracts as input 
(10 μL of the resin was used per 2mL of nuclear extract). 
Following the immunoprecipitation each 10 μL set of beads is washed 5x 1 mL of 
IP buffer (Dignam-Roeder buffer D supplemented to 400 mM NaCl, see (Carey et al., 
2009)), 1x 1 mL of 1x PBS with 1% NP40, 3x 1 mL 1x PBS 0.02% Tween20 and 5x 1mL 1x 
PBS.  The beads were spun down, supernatant was completely removed, and the beads 
were eluted with 100 mM formic acid (100 μL of 100 mM formic acid per 10 μL of beads, 
5 min, room temperature, with agitation).  The supernatant was then removed and 200 
μL of each sample (total rabbit IgG control and anti-hCDK12) was submitted to the Duke 
Proteomics Facility for lyophilization and subsequent analysis (LC MS/MS).  For SDS-
PAGE analysis of elution fractions the formic acid was neutralized using fresh 1 M 
NaOH. 
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3.3 Results 
3.3.1 Identification of dCDK12’s cyclin subunit1 
Because Drosophila CDK12 (CG7597) had not been previously studied, we were 
interested in identifying its endogenous (not overexpressed) cyclin partner.  dCDK12 
was again immuno-affinity purified from Kc cell nuclear extracts as described in the 
preceding section (see 2.2.4.1); the resulting bead slurry was exhaustively washed, 
boiled in SDS loading buffer, and loaded onto an SDS-PAGE gel (Fig 3.1).  Although we 
were wary of the methods used in the studies characterizing CyclinL as CDK12’s partner 
(CDKs have been shown to be promiscuous for different cyclins (Fu et al., 1999) and 
tandem overexpression of both a cyclin and a CDK in the same system could “force” a 
non-native CDK/cyclin interaction) we still expected the cyclin subunit of dCDK12 to be 
dCyclinL.  Since dCyclinL has a calculated MW of 63 kDa and RS domains, which tend 
to decrease mobility in SDS-PAGE gels due to their unique sequence compositions, 
bands “c,” “d,” and “e” were cut from the gel and submitted for protein identification by 
LC MS/MS mass spectroscopy (Duke Proteomics Facility) (Fig. 3.1).  Gel slice “a” was 
also submitted for mass spectroscopy as it contained two distinct protein bands, as was 
gel slice “b,” which contained strong protein bands and the dCDK12 protein as 
determined by western blotting (Fig. 3.1). 
                                                     
1 The initial cyclin identification is adapted from, and published in, Bartkowiak, B., Liu, P., Phatnani, H. P., 
Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., Greenleaf, A. L., 2010. CDK12 is a transcription 
elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 24, 2303-16. 
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Figure 3.1:  dCDK12 immunoprecipitation for cyclin partner identification.  Coommasie-stained gel with 
molecular weight marker shown on the left (MW) and immunoprecipitation on the right (IP).  H 
designates anti-dCDK12 antibody heavy chain.  dCDK12 position (as determined by western blotting) is 
marked on right, and bands excised for mass spectroscopy are labeled a through e. 
The mass spectroscopy results confirmed the presence of dCDK12 (28 tryptic 
peptides identified, 33% coverage of the protein, and ‘‘100% probability’’ of correct 
identification) and no other CDKs were identified in any of the excised bands.  
Surprisingly, the only cyclin identified in this analysis was Drosophila Cyclin K 
(dCyclinK) (Isoform a, in gel slice “c”; two tryptic peptides, ‘‘100% probability’’ of 
correct identification). 
 In order to further validate our result we used the NCBI non-redundant protein 
database to perform a BLAST search for metazoan sequences most similar to the yCtk2 
protein, the cyclin subunit of yCtk1.  The top ranked hits were all cyclins of the K class, 
implicating dCyclinK as a probable cyclin partner for dCDK12.  We also searched the 
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DroID database of gene and protein interactions in Drosophila, for proteins that interact 
with dCDK12 (Yu et al., 2008).  We were excited to discover that a DroID yeast two-
hybrid screen picked up dCyclinK as the highest scoring interaction partner for 
dCDK12, out of 7 other (non-cyclin) positive hits (Finley Laboratory YTH results).  Thus, 
our results suggest that dCDK12’s cyclin partner is dCyclinK. 
 In order to confirm that dCyclinK was the actual cyclin partner of dCDK12 we 
used siRNA to deplete dCyclinK from Drosophila cell culture.  Three dsRNA constructs 
were used:  Anti CycK, anti E2 CDK12 (see 2.2.6 and Fig. 2.6) as a positive control, and 
anti lac-Z dsRNA obtained from Dr. Adelman’s lab was used as a negative control 
(mock).  The transfected cells were incubated for 72 hours and then harvested for 
western blotting of whole cell extracts.  Although there is no antibody available for 
dCyclinK, we were able to confirm successful knockdown of both dCyclinK and 
dCDK12 at the mRNA level via qPCR (Fig. 3.2).  In order to determine global CTD 
phosphorylation levels after dCyclinK depletion, we performed western blot analysis of 
dsRNA treated Dm whole cell extracts using the anti-Ser2P CTD antibody H5.  
Knockdown of dCyclinK resulted in an almost complete loss of H5 antibody reactivity, 
exactly analogous to dCDK12 knockdown.  These results are clearly indicative of a CDK-
cyclin partnership between dCDK12 and dCyclinK. 
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Figure 3.2:  Quantification of dCDK12 and dCyclinK mRNA levels in Drosophila S2 cells 72 hours post 
dsRNA treatment using qPCR.  Expression values are standardized to the untreated sample whose value 
was set at 1.  Error bars are +/-2 standard errors of the mean, n=3. 
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Figure 3.3:  Western blots of Drosophila S2 whole cell extracts 72 hours post dsRNA treatment.  Anti-
Ser2P western using the H5 antibody (top); dRpb2 is used as a loading control(bottom).  Mock cells are 
treated with anti-LacZ dsRNA. 
3.3.2 Identification of dCDK12 associated proteins via mass 
spectrometry 
In the course of our identification of dCyclinK as the cyclin partner of dCDK12 
we also identified several other proteins of interest which co-precipitated with dCDK12 
from Drosophila Kc cell nuclear extracts (Fig. 3.1), including components of the Brahma 
complex (dBRM); a SWI/SNF related chromatin remodeling complex previously shown 
to facilitate global transcription by, and to colocalize with, RNAPII (Armstrong et al., 
2002).  In order to confirm these results and to further explore dCDK12 interacting 
proteins, we immunopurified dCDK12 from Drosophila melanogaster S2 nuclear extracts 
using an affinity purified anti-dCDK12 antibody tethered to streptavidin beads.  
Immunopurified complexes were eluted and analyzed by mass spectrometry (LC 
MS/MS; Duke Proteomics Facility).  Removing proteins present in control  
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Figure 3.4:  Coomassie-stained gel of dCDK12 immunoprecipitations and elutions submitted for mass 
spectrometric analysis.  The “Preclear Beads” lane contains uncrosslinked, biotinylated goat anti-rabbit 
IgG antibody, saturated beads used to preclear the nuclear extract.  The “Pre-elution” and “Post-Elution” 
lanes contain crosslinked anti-dCDK12 or anti-total rabbit IgG antibody saturated beads, before and 
after elution.  The “ELUTION” lanes are representative of the samples sent for analysis; dCDK12 is the 
top band of the doublet located at ~160kDa. 
immunoprecipitations (using total rabbit IgG instead of anti-dCDK12 IgG) results in a 
final hit list composed of 81 proteins (See Appendix A) (Fig 3.4). 
Functional annotation of this list using the DAVID database (Huang da et al., 
2009a; Huang da et al., 2009b) reveals a strong enrichment for mRNA processing and 
chromatin remodeling factors.  As expected we find almost every component of the 
dBRM complex coprecipitating with dCDK12; this includes Brahma, Moira, OSA, 
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Polybromo, and the various Brahma associated proteins or BAPs (BAP 60kD, BAP 
170kD, BAP 11kD, and BAP 55kD).   In the RNA processing category the most highly 
enriched DAVID annotation cluster was that of the exosome components; Rrp4, 6, 40, 45, 
and 46, Mtr3, and Ski6 were all present in the dCDK12 elutions.  The exosome is a 
complex of exoribonucleolytic and RNA binding proteins involved in 3’ end RNA 
degradation and processing; much like dCDK12 and the dBRM complex, it is also 
recruited to actively transcribed loci and colocalizes with elongation factors.  
Additionally, the mass spectrometry identified eIF4A3, a component of the exon 
junction complex, and a number of proteins implicated in splicing, including the 
spliceosomal component Prp19.   Intriguingly, the nuclear speckle localized SC35 
splicing factor (also known as Serine/arginine-rich splicing factor 2 or SRSF2 in humans) 
was also identified, but was discarded from the final analysis as it was also detected in 
the control (albeit at lower levels; 3 peptides in dCDK12 versus 1 peptide in the total 
rabbit IgG pulldown). 
3.3.3 Identification of hCDK12 associated proteins via mass 
spectrometry 
 In order to identify hCDK12 interacting proteins we also immunopurified 
CDK12 from Dignam Roeder nuclear extracts of HeLa cells (Carey et al., 2009) using an 
affinity purified anti-hCDK12 antibody tethered to streptavidin beads.  Immunopurified 
complexes were eluted and analyzed by mass spectrometry (LC MS/MS; Duke 
Proteomics Facility).  Filtering out proteins present in control immunoprecipitations  
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Figure 3.5:  Coomassie-stained gel of hCDK12 immunoprecipitations and elutions submitted for mass 
spectrometric analysis.  The “Pre-elution” and “Post-Elution” lanes contain crosslinked anti-hCDK12 or 
anti-total rabbit IgG antibody saturated beads, before and after elution.  The “ELUTION” lanes are 
representative of the samples sent for analysis; hCDK12 is the prominent band located at ~200kDa in the 
“ELUTION” lane. 
(again, using total rabbit IgG instead of anti-CDK12 IgG) results in a total of 309 
identified proteins in the final hit list (See Appendix B) (Fig 3.5).  
Functional annotation of the positive hits using the DAVID database (Huang da 
et al., 2009a; Huang da et al., 2009b) reveals a strong enrichment of mRNA splicing 
factors, mRNA binding proteins, and nuclear speckle components.  In agreement with 
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this functional annotation, the presence of RS domains in hCDK12’s N-terminus, and 
hCDK12’s localization to nuclear speckles (Blazek et al., 2011; Ko et al., 2001) we find 
Serine/arginine repetitive matrix protein 1 and 2, and many SR Splicing Factors (SRSF1, 
3, 4, 5, 6, 7, 8, 9, and 10) coprecipitating with hCDK12. In addition, the mass 
spectrometry identified several other proteins of interest including PCF11 (a 3’ end 
processing factor), Prp19, several exosome components, and components of the exon-
junction complex (eIF4A3, MGN, RNPS1, and RBM8; previously shown to interact with 
SR proteins (Singh et al., 2012)).  In order to confirm these interactions and to determine 
whether they are mediated via RNA, the experiment was repeated again, this time 
incorporating an RNAse treatment step.  Unfortunately the final elutions in this repeat 
experiment did not contain as much material (both in the RNAse treated and untreated 
samples) resulting in a much lower depth of coverage in the mass spectrometric 
analysis.  Despite this we were still able to verify many of the above interactions and 
determine that they were not dependent on RNA:  Of the proteins listed above, only 
Serine/arginine repetitive matrix protein 1 was found to be RNA dependent; PCF11, all 
of the components of the exon junction complex except for RBM8, and SRSF4, 6, 7, 9, and 
10 repeated.  Although this initial list of CDK12 associated proteins will require further 
validation, it affirms an interaction between CDK12 and other RS domain containing 
proteins and reinforces the role of CDK12 as an important actor in cotranscriptional 
mRNA processing.   
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3.4 Discussion 
Intrigued by the N and C terminal arms which extend away from CDK12’s 
kinase homology domain, we hypothesized that CDK12 was likely to be associated with 
a large number of accessory factors.  Because these factors could potentially play a role 
in the targeting of CDK12 to the elongation complex and were likely to offer insights 
into potential non-catalytic roles of CDK12, we have identified proteins that co-
immunoprecipitate with CDK12 from HeLa and Dm cell nuclear extracts under fairly 
stringent conditions.   
Our experiments began with an effort to identify the cyclin partner of dCDK12, 
which was previously hypothesized to be CyclinL.  Surprisingly mass spectrometric 
analysis of slices from an SDS-PAGE gel of immunopurified dCDK12 implicated 
dCyclinK as its potential partner.  Followup analysis using dsRNA confirmed this 
interaction and several subsequent studies in human cells have determined that the 
cyclin partner of hCDK12 is also hCyclinK (Blazek et al., 2011; Cheng et al., 2012).  
Pertinently, human CyclinK was previously found to associate with CDK9 via a yeast 
two hybrid screen and was shown to stimulate CDK9’s CTD kinase activity in vitro (Fu 
et al., 1999).  Further investigation into the proposed CDK9/CyclinK complex implicated 
CyclinK as playing a role in replication stress and genome integrity, however these 
functions were attributed to CDK9 (Yu and Cortez, 2011; Yu et al., 2010).  As several 
studies have now confirmed that the endogenous human CyclinK is actually non-
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promiscuous and associates exclusively with CDK12 and CDK13 (Blazek et al., 2011; 
Cheng et al., 2012), the genome integrity functions of CyclinK are currently being 
reassessed  from a CDK12 centered perspective (Bartkowiak et al., 2011; Blazek, 2012; 
Blazek et al., 2011; Joshi et al., 2014; Winsor et al., 2013). Exactly what role 
hCDK12/CyclinK plays in the response to DNA damage is still being investigated, but it 
promises to be a field of intense research in the coming years (see chapter 6 for more 
discussion).   
In view of the SR protein-like “arms” of the CDK12 protein, it is perhaps not 
surprising that RNA processing factors are by far the most abundant functional class of 
CDK12-associating proteins. In the human pulldown, over 30 splicing proteins are 
represented, including SRRM1 & 2, TRA2A & B, U2AF2, and SRSF1, 3, 4, 5, 6, 7, 8, 9 & 
10.  Also present are components of the PRPF19-CDC5L complex, a number of DDX and 
DHX helicases, and members of the exon junction complex.  Beyond splicing, several 3’ 
end-formation factors are also represented including Pcf11 and numerous subunits of 
the RNA exosome, which are also heavily enriched in the Drosophila CDK12 pulldown.  
In terms of nucleosome remodeling we find that dCDK12 appears to have a strong 
interaction with the SWI/SNF related dBRM complex; although we do not observe this 
strong enrichment with hCDK12, the SWI/SNF complex subunit SMARCC1 and the 
SWI/SNF related SMCA5 are present in the human hit list. 
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On a final note of interest, mass spectrometry of the human pulldowns identified 
PAP1L and PABP4; putative human homologues (by Uniprot Blast) of the yeast Ctk1 
interacting protein GBP2 (Ho et al., 2002).  Yeast contains only three proteins with 
canonical SR structures (RNA recognition motifs and an RS dipeptide rich region):  
Gbp2, its paralog Hrb1, and Npl3.  Intriguingly, all three of these proteins have been 
shown to interact with Ctk1 (Ho et al., 2002), suggesting an early evolutionary link 
between the Ser2 CTD kinases and the SR proteins.   
Although the mass spectrometry results will require additional experimental 
validation, they suggest that CDK12 is involved in multiple aspects of pre-mRNA 
processing.  As an example, in terms of splicing, we suggest that a number of SR 
proteins are recruited to the transcription elongation complex by virtue of RS domain 
interactions with CDK12.  Therefore, we propose that CDK12 affects RNA processing 
events in two distinct ways:  Indirectly through generating factor-binding phospho-
epitopes on the CTD of elongating RNAPII, and directly through binding to specific 
factors via its extended N and C terminal domains. 
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4. Expression, Purification, and Characterization of the 
hCDK12/CyclinK Complex and Mutants 
4.1 Introduction 
The C-terminal domain (CTD) of RNA polymerase II undergoes a cycle of 
phosphorylation which allows it to temporally couple transcription with a wide array of 
transcription associated processes.  Most of the Ser2 CTD phosphorylation that occurs 
during transcriptional elongation in the yeast Saccharomyces cerevisiae has been shown to 
be mediated by CTDK-I, an enzyme consisting of three subunits:  Ctk1 (a CDK 
homolog), Ctk2 (a cyclin homolog), and Ctk3 (an essential accessory factor of unknown 
function).  Ctk1 coexists with the essential Bur1/Bur2 complex (Bur1 and 2 are, 
respectively, CDK and cyclin homologs) which has also been shown to contribute to 
Ser2 phosphorylation and to prime the CTD for further phosphorylation near the 5’ end 
of the gene.   
Correspondingly, two Ser2 position CTD kinases have also been identified in 
metazoa: The Bur1 related P-TEFb (composed of CDK9 and cyclinT) and the CTDK-I 
related CDK12/CyclinK complex.  Like Bur1, P-TEFb is recruited near the 5’ end of the 
transcription unit, and in addition to phosphorylating Ser2 of the CTD, is involved in 
mediating entry into productive transcriptional elongation by releasing RNAPII from 
promoter proximal pausing.  In contrast, CDK12/CyclinK acts towards the 3’ end of the 
transcription unit and currently its best studied phosphorylation target is the Ser2 
position of the CTD (Bartkowiak et al., 2010; Blazek et al., 2011). 
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Recent studies have elucidated the structure of a truncated form of the 
CDK12/CyclinK complex and implicated the complex in the 3’ end processing of the 
MYC gene (Bosken et al., 2014; Davidson et al., 2014).  In addition, hCDK12 has been 
identified as a tumor suppressor for ovarian cancer (Joshi et al., 2014); however, much is 
still unknown about the in vivo roles of CDK12/CyclinK.  Given our analysis of dCDK12 
and hCDK12 associated proteins, it is likely that CDK12/CyclinK plays both catalytic 
and noncatalytic (structural) roles in mRNA processing and other transcription related 
functions.  Additionally, due to the fact that the sensitivity profile of hCDK12/CyclinK to 
CDK inhibitors has not been previously investigated and that P-TEFb 
inhibition/depletion has drastic consequences on global transcription (due to the 
inhibition of pause release near the TSS), it is challenging to determine which of the 
functions attributed to P-TEFb are actually due to the lack of downstream CDK12 
activity.  In an effort to further characterize CDK12s roles in vivo, and to help dissect its 
catalytic and non-catalytic functions, we have purified to near homogeneity full-length, 
active, human CDK12/CyclinK, created an analog sensitive CDK12 mutant, and 
characterized CDK12’s substrates specificity and sensitivity to the “CDK9 specific” 
inhibitor flavopiridol (FVP). 
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4.2 Materials and methods 
4.2.1 Antibodies and western blotting 
rAP anti-hCDK12:  Affinity-purified IgGs directed against a peptide comprising 
amino acids 201-220 of hCDK12 (NCBI RefSeq: NP_057591.2).  The anti-CyclinK 
antibody was purchased from Abcam (ab130475).  The anti-gp64 antibody against 
baculovirus envelope protein was purchased from eBioscience.  Western blot analysis 
was performed using the Odyssey infrared scanner and secondary antibodies from Li-
Cor. 
4.2.2 GST-CTD substrates 
GSTy-CTD was purified as previously described (Morris et al., 1997).  Mutant 
GST-CTD substrate constructs (WT, S2A, S2E, S5A, and S5E (originally designed by Dr. 
Jeff Corden’s lab (Patturajan et al., 1998a)) were kindly provided by Dr. Aseem Ansari’s 
lab.  The S7E construct was created by gene synthesis of DNA containing 16 CTD heptad 
repeats with each S7 position replaced with E, followed by an HA tag (YPYDVPDYA), a 
single glutamate and a stop codon (in order to be identical to the WT GST-CTD substrate 
originally designed by the Corden lab).  The sequence also incorporates a BamHI and 
SalI site at the 5’ and 3’ end respectively (IDT).  The S7E CTD sequence was cloned into 
the pGEX-5X-1 vector (GE Healthcare: Life Sciences) using the BamHI and SalI 
restriction sites.  Expression of all constructs was performed in BL21-Codon Plus (DE3)-
RIPL cells (expression conditions were 25 °C with 1 mM IPTG; Stratagene).  After 16 
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hours of expression, cells were sonicated and the fusion protein was purified using a 
glutathione-agarose (Pierce) column following the manufacturer’s protocol.  Peak 
elution fractions were then pooled and submitted to size exclusion chromatography 
(Superdex 200 HR 10/30, Amersham).  Peak size exclusion fractions were pooled and 
buffer exchanged (Amicon Ultra Centrifugal Filters) into 25 mM HEPES pH 7.6 with 50 
mM NaCl to a final protein concentration of 0.5 μg/μL. 
4.2.3 CTD kinase assays 
CTD kinase assays were performed essentially as described previously (Jones et 
al., 2004), with minor variations:  Kinase reactions included either 30 or 300 μM ATP, 10 
μCi of  [γ-32P]ATP, 5 mM MgCl2, 25 mM Tris pH 7.6, 5% Glycerol, 2 mM DTT, 150 mM 
NaCl, 1 μg of GST-yCTD, and 50-100 ng of hCDK12/CyclinK in a 25 μL reaction volume.  
Reactions were performed for 15-45 min (specified in each figure) at 37 °C.  Reaction 
times and enzyme amounts were selected to be in the range where phosphate 
incorporation is linear with time.  Phosphorylated products were visualized using film 
(Kodak Biomax MR) or a PhosphorImager; quantification was performed using a 
PhosphorImager and ImageQuant software.  Ess1 was provided by Dr. Pei Zhou’s 
laboratory. 1-NM-PP1 was purchased from Axon Medchem and dissolved in DMSO.  
For DRB and flavopiridol (FVP) inhibition, equal activity of CDK9, provided by the 
laboratory of Dr. David Price, and CDK12/CyclinK was used (0.6 μM final concentration 
of CDK9/CyclinT in the reaction mixture).  FVP was purchased from Sigma Aldrich 
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(F3055) and DRB was provided by Dr. Shudong Wang from the University of 
Nottingham.  Inhibitors were dissolved in DMSO and then aliquoted at the appropriate 
concentrations in 4% DMSO.  1 μL of either 4% DMSO or the appropriate concentration 
of each inhibitor in 4% DMSO was added to the reaction mixture for a final volume of 25 
μL.  Analysis of the inhibition data was performed using GraphPad Prism 6. 
4.2.4 Construction of CDK12/CyclinK expression constructs and 
mutants 
The cDNA for hCDK12 was purchased from Open Biosystems (Clone ID: 
9021722; NCBI accession BC140854), as was the cDNA for the short, 40 kDa, form of 
hCyclinK (Clone ID: 3907416 NCBI accession BC015935).  The full length hCyclinK 
cDNA was a very kind gift from Dr. Grace Cheng and Dr. Gregg Morin (Cheng et al., 
2012).   
The hCDK12 cDNA was then extended using PCR:  The forward primer 
contained an upstream NarI extension 
(GTAGCAGGCGCCATGCCCAATTCAGAGAGACA) and the reverse primer annealed 
just upstream of the hCDK12 stop codon, replacing it with an extension containing a 
part of the P2A sequence with a BamHI restriction site 
(TTGCTTTAACAGAGAGAAGTTCGTGGCTCCGGATCCGTAAGGAACTCCTCTCCC
TCTTC).   
The hCyclinK cDNAs were also extended using PCR:  The forward primer 
contained part of the P2A sequence 
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(CAAGCAGGAGACGTGGAAGAAAACCCCGGTCCTATGAAGGAGAATAAAGAAA
ATTCAAGC) and the reverse primer contained an extension containing a NotI 
restriction site (GTAGCAGCGGCCGCTTATCTCATCCAGGCTGCCC).  This extended 
hCyclinK PCR product was then extended again using the reverse primer from above 
and another forward primer which added more of the P2A sequence, including the 
aforementioned BamHI restriction site: 
GGATCCGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGA.   
The hCDK12 PCR product was then cloned into the pFastBac HT B (Invitrogen) 
vector using NarI and BamHI restriction sites.  The resulting plasmid was further 
modified by the addition of the full-length or 40 kDa, fully extended, hCyclinK PCR 
products using the BamHI and NotI restriction sites; the resulting plasmids were the 
final pFastBac HT B hCDK12/CyclinK and the pFastBac HT B hCDK12/CyclinK(40kDa) 
expression constructs. 
Mutations (D877N, K756A, and F813G) were introduced into the pFastBac HT B  
hCDK12/CyclinK expression construct using the QuikChange Site-Directed Mutagenesis 
Kit (Stratagene). 
4.2.5 Expression and purification of hCDK12 
Expression was performed essentially as described in the Bac-to-Bac Baculovirus 
Expression System instruction manual (Invitrogen).  Miniprepped pFastBac HT B 
hCDK12/CyclinK plasmids were transformed into DH10Bac E. coli for transposition into 
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the expression bacmid. Transformed colonies were screened for the CDK12/CyclinK 
insert by PCR using M13 primers and a primer internal to hCDK12 
(GACTGACCGACTGCCTTCTC). Bacmids were prepared from 150 mL DH10Bac 
cultures with the NucleoBond Xtra Midi kit (Macherey-Nagel) and transfected into 
Spodoptera frugiperda (Sf9) insect cells using CellfectinII (Life Technologies) following the 
manufacturer’s protocol.  Sf9 cells were maintained in Hyclone SFX-Insect Media 
(Thermo Scientific) at 27 °C. 
Virus amplification was performed as described in the Bac-to-Bac manual for 3 
rounds of amplification. Viral titer was determined via western blotting of the cell 
culture supernatant with the anti-gp64 antibody against baculovirus envelope protein 
(eBioscience). Expression was optimized by varying the amount of virus (using western 
blotting for gp64 for relative quantification) and time of expression; expression was 
monitored through western blotting for hCDK12.  For purification, 500 mL of Sf9 cells at 
1x106 cells/mL were infected with baculovirus, incubated for 96 hours, and cells were 
collected by centrifugation at 730xg for 15 min at 4 °C (all subsequent steps at 4 °C), 
washed with ice cold 1x PBS, and pelleted again. 
Cells were resuspended in cytoplasmic lysis buffer (10 mM HEPES, pH 8.0, 320 
mM sucrose, 3 mM calcium chloride, 2 mM magnesium acetate, 1 mM DTT, 5 mM NaF, 
and 0.5% NP40) with protease inhibitor mixture for tissue extracts (P8340, Sigma).   The 
resulting slurry was homogenized using 20 strokes with a tight fitting pestle of a dounce 
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homogenizer.  Nuclei were then pelleted by centrifugation at 1,500xg for 15 min.  The 
supernatant was removed and the nuclei were resuspended in 6 mL of nuclear 
resuspension buffer (20 mM HEPES, pH 8.0, 1.5 mM MgCl2, 20 mM KCl, 25% glycerol, 1 
mM DTT, 5 mM NaF, and protease inhibitor mixture for tissue extracts). Nuclei were 
then lysed by the dropwise addition (with stirring) of 6 mL of nuclear extraction buffer 
(80 mM HEPES, pH 7.6, 1.2 M NaCl, 20% glycerol, 0.06% TritonX-100, 1 mM DTT, 5 mM 
NaF, and protease inhibitor mixture for tissue extracts). 6 mL of PEG solution (18% PEG 
8000, 1 M NaCl, 1 mM DTT, 5 mM NaF, and protease inhibitor mixture) was then added, 
and the solution was incubated at 4 °C for 45 min with rotation. The insoluble fraction 
was removed by centrifugation at 20,000xg for 30 min. The soluble lysate containing 
hCDK12/CyclinK was then adjusted to 20 mM Imidazole and bound in bulk to a 
preequilbrated Ni Sepharose 6 Fast Flow column (GE Healthcare)  for 2.5 hours at 4 °C 
rocking end over end. The resin was collected and washed with 10 column volumes of 
high salt wash buffer (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, and 20 mM imidazole). 
The protein was eluted with 50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 250 mM imidazole, 
1 mM DTT, 5 mM NaF, 8% glycerol, and protease inhibitor mixture. The elution peak 
from the Ni-Sepharose was pooled and, using a 500 μL loading loop, applied to an 
ÄKTA FPLC system equipped with a Superdex 200 10/30 HR column (GE Healthcare) at 
a flow rate of 0.25 ml/min with 25 mM HEPES pH 7.6, 8% Glycerol, and 300 mM NaCl as 
the running buffer.  500 μL fractions were collected and fractions containing 
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hCDK12/CyclinK were identified by SDS-PAGE and flash frozen for storage at -80 °C 
until use. 
4.2.6 Phosphatase treatment 
20 μL of a CDK12/CyclinK Ni-Sepharose elution fraction was treated with 10 
units of FastAP Thermosensitive Alkaline Phosphatase (Thermo Scientific) at 37 °C for 1 
hour.  The reaction was stopped by the addition of 5x SDS loading buffer (Laemmli 
buffer) and analyzed by SDS-PAGE. 
4.3 Results 
4.3.1 Construction of the hCDK12 expression construct 
It has been previously reported in the literature that full length human CDK12 
expressed in baculovirus-infected cells is highly insoluble or inactive (Bosken et al., 2014; 
Ko et al., 2001).  We hypothesized that this may be due to the lack of appropriate levels 
of hCDK12’s cyclin partner, which would be likely to affect the stability of the kinase.  
To address this problem we employed a “2A” peptide-linked multi-cistronic construct 
(Szymczak-Workman et al., 2012).  The “2A” peptide sequence results in a site specific, 
sterically induced, cleavage of the fusion protein as it is produced on the ribosome:  This 
allows for the expression of both hCDK12 and hCyclinK, in an exact one to one ratio, 
from a single open reading frame.  The final construct contained the His-tagged hCDK12 
transcript variant 2 sequence (Genbank accession NM_015083) lacking the final stop 
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codon (1481AA; transcript variant 1 [Genbank accession NM_016507] contains an extra 
9AAs from exon 14, which map to the C-terminal arm of the kinase), the 2A sequence  
 
Figure 4.1:  The hCDK12/CyclinK baculovirus construct and its expression.  (a.) Schematic of the 
hCDK12/CyclinK expression construct, which consists of the full length human CDK12 gene (lacking its 
stop codon) fused to the P2A sequence from porcine teschovirus and followed by the full length 
sequence for hCyclinK.  The complete construct was cloned into the MCS of the pFastBac HT B insect 
cell expression vector (Invitrogen), which led to the inclusion of a 6xHis tag followed by a TEV protease 
site at the N-terminal end of hCDK12.  (b.) Coomassie stained gels and western blots of Ni column 
elution fractions of hCDK12/CyclinK baculovirus infected and uninfected Sf9 cell culture lysates.  
Infection of Sf9 cells with hCDK12/CyclinK baculovirus results in the appearance of two additional 
bands on the coomassie stained elution fractions (red dots).  Western blot analysis of infected elution 
fractions with anti-hCDK12 (in yellow) and anti-hCyclinK (in green) antibodies indicate the presence of 
soluble hCDK12/CyclinK complex in the infected lysates. (c.) Coomassie stained gel of Ni column 
fractions of hCDK12/CyclinK baculovirus infected Sf9 cell lysates untreated and treated with Alkaline 
Phosphatase (AP). 
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from porcine teschovirus-1 (19AA), and the full sequence for CyclinK (580AA) (Fig. 4.1 
a.) (Cheng et al., 2012). Co-expression of both the CDK and its cyclin partner in 
baculovirus-infected Sf9 cells followed by Ni Column purification resulted in the 
appearance of two new bands in coomassie gels of the elution fractions; a diffuse band at 
~180 kDa and a sharp band at ~75 kDa.  These bands were confirmed to be CDK12 and 
CyclinK by western blotting (Fig. 4.1 b.).  The diffuse nature of the CDK12 band is likely 
due to a high degree of post translational modification; phosphorylation of CDK12 has 
been reported previously (Ko et al., 2001) and phosphatase treatment of Ni column 
elutions of CDK12 resulted in a mobility shift and partial collapse of the CDK12 
coomassie band (Fig. 4.1 c.).  Therefore, co-expression of CDK12 with its cyclin partner 
alleviates solubility issues and is a viable strategy for the production of recombinant 
enzyme. 
4.3.2 Purification and kinase assays of WT hCDK12, kinase dead, and 
analog sensitive mutants 
His-tagged CDK12 was purified from baculovirus infected cells via isolation of 
nuclei, followed by nickel column chromatography and size exclusion chromatography 
(see 4.2.5).  Serendipitously, the large size of the CDK12/cyclinK complex, coupled with 
the high likelihood of non-globular structural elements in the N and C-terminal arms of 
its components, led it to elute near the void volume of the size exclusion column.  
Therefore, a simple two-step purification strategy yielded highly purified complex  
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Figure 4.2:  Purification and CTD Kinase activity of hCDK12/CyclinK complex and mutants. (a.) 
Coomassie stained gel of size exclusion chromatography (Superdex 200 HR 10/30) fractions from a 
hCDK12/CyclinK purification.  Onput (lane one) consists of pooled Ni column elution fractions of 
hCDK12/CyclinK baculovirus infected Sf9 cell nuclear extracts. The majority of fraction #10 (lane two) 
consists of column void volume while fraction #11 (lane three) is the first true elution fraction.  (b.) 
Purified hCDK12/CyclinK CTD kinase activity was assayed in the presence of [γ-32P]ATP using 1 ug of a 
GST-yCTD fusion protein (26 heptad repeats) as substrate and reaction mixtures were analyzed by SDS-
PAGE.  Autoradiograms of the SDS-PAGE gels revealed a time (ATP at 300 μM) and (c.) ATP dependent 
(reaction time at 45 min) CTD kinase activity.  The SDS-PAGE mobility of the unphosphorylated GST-
yCTD substrate is indicated via a dashed line. (d.) Autoradiograms of CTD kinase assays using purified 
mutants of the hCDK12/CyclinK complex.  Equal amounts of each construct are used in the reactions; 
hCDK12/CyclinK complex containing a shortened form of CyclinK exhibited comparable activity to full 
length wild-type complex (compare lanes one and two), while a kinase dead double (lane 3) and single 
mutant (lane 4) exhibited little to no residual activity. 
which could be employed in subsequent studies (Fig. 4.2 a.).  Purified CDK12/CyclinK 
exhibited a time and ATP dependent CTD kinase activity when assayed using GST-
yeastCTD (GST-yCTD) fusion proteins as substrate in the presence of [γ-32P]ATP (Fig. 
4.2 b. and c.).  Unlike CTDK-I, which is inhibited by the presence of additional salt in the 
kinase buffer, CDK12/CyclinK activity was stimulated by salt (NaCl and KCl were tested 
at 0, 150, and 200 mM) and strongly inhibited by detergents (0.05% TritonX-100, NP40, 
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and Tween20 were tested) (Lee and Greenleaf, 1989) (Fig. 4.3).  We also tested 
hCDK12/CyclinK activity towards the GST-yCTD in the presence of the yeast proline 
isomerase Ess1, but observed no stimulation of activity (Fig 4.4).  In addition to the full 
length construct, we also constructed and purified a CDK12/CyclinK complex 
containing the originally identified 40 kDa form of CyclinK lacking a C-terminal, proline 
rich domain (this isoform was subsequently proven to be an artifact) (Bartkowiak et al., 
2010; Blazek et al., 2011; Cheng et al., 2012; Edwards et al., 1998); however we could not 
 
Figure 4.3:  hCDK12/CyclinK complex CTD kinase activity is highly sensitive to detergents.  
Autoradiograms of SDS-PAGE gels of hCDK12/CyclinK kinase assays using GST-yCTD as substrate.  
Reaction conditions are 1 ug of GST-yCTD, 45min reaction time, 37 °C, and 30 μM ATP in 25 μL total 
reaction volume.  Standard reaction buffer composition is given and the position of unphosphorylated 
GST-yCTD in the SDS-PAGE gel is indicated via a dashed line.  Lane one contains the standard reaction 
conditions, while lanes 2-6 modify the salt, salt concentration, and buffering agent composition/pH.  
Lanes 7-9 represent the standard reaction buffer supplemented with the various detergents at the 
indicated concentrations. 
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Figure 4.4:  The effect of a prolyl isomerase on the activity of hCDK12. (a.) A representative 
autoradiogram of a SDS-PAGE gel from an hCDK12/CyclinK kinase assay with increasing amounts of 
the prolyl isomerase Ess1.  Assays were performed using 1 ug of GST-yCTD as a substrate at 30 μM ATP, 
37 °C, and 15/30 min reaction times.  (b.) Quantification of the degree of phosphorylation of each mutant 
substrate using a PhoshpoImager and ImageQuant software (normalized to a value of 1.0 for the 0 uM 
Ess1).  No stimulation of hCDK12 activity was observed. 
detect any difference in GST-yCTD kinase activity between the full length and shortened 
CDK12/CyclinK complex (Fig. 4.2 d.). 
In the interest of creating a negative control for our assays we also set out to 
generate a kinase dead mutant of CDK12.  Based on the literature we focused our 
attention on mutating the conserved aspartate residue known to be essential for the 
phospho-transfer reaction in other CDKs (examples include:  D145 of CDK2 and D167 of 
CDK9) (Garriga et al., 1996; van den Heuvel and Harlow, 1993); alignment of the 
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sequences of several CDKs identified the most probable candidate residue to be 
aspartate 877 of CDK12.  Mutation of this residue to asparagine drastically reduced 
kinase activity to almost background levels, although some residual activity was 
observed on longer exposures and with high amounts of enzyme (Fig. 4.2 d., and data 
not shown).  Following up on this result, we eliminated the possibility of a copurifying 
CTD kinase activity by purifying and assaying the D867N mutant using antibody 
saturated beads (size exclusion fractions were used as input and beads were 
subsequently washed with 1 M NaCl and 0.5% NP40); however the slight residual 
activity persisted.  In view of this we made an additional mutation in the nucleotide 
binding site of CDK12:  K756A modelled on the CDK2 K33A mutation (Leroy et al., 
1996).  The double mutant kinase had even less background activity, although some 
slight residual activity could still be detected at extremes of exposure and enzyme 
amounts (Fig. 4.2 d. and data not shown).  Despite this slight residual activity, compared 
to wild-type kinase, for most intents and purposes both the single and double mutants 
can be considered to be inactive (also see (Joshi et al., 2014)).  Accordingly, mutation of 
D877N and D877N/K756A inhibits the vast majority of kinase activity and confirms the 
purity of our CDK12/CyclinK purification. 
In order to inform future experiments we also engineered an analog sensitive 
mutant of CDK12.  Analog sensitive kinases are created by mutating a large 
phenylalanine residue, termed the “gatekeeper” residue, near the enzyme active site to a 
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much smaller glycine; the mutated enzyme is then able to accept bulky adenine 
analogues in its active site, allowing for specific inhibition of its activity (Blethrow et al., 
2004; Shah et al., 1997).  Alignment of CDK12 with other CDKs and comparison to other 
analog sensitive kinases (Larochelle et al., 2012) implicated Phenylalanine 813 of CDK12 
as a candidate “gatekeeper” residue (Fig. 4.5 a.); this residue was mutated to glycine to 
create CDK12as.  Purified CDK12as /CyclinK kinase activity was assayed alongside wild-
type kinase in the presence of increasing amounts of the bulky adenine analog 1-NM-
PP1.  Addition of 1-NM-PP1 had no effect on the activity of the wild-type kinase in the 
GST-yCTD kinase assay; however, addition of 1-NM-PP1 to reactions containing 
CDK12as resulted in a virtually complete loss of enzyme activity (Fig. 4.5 b.).  
Consequently, the two step purification process results in highly purified 
CDK12/CyclinK devoid of contaminating kinase activities.  In addition, the high 
sensitivity of CDK12as to 1-NM-PP1 suggests that it will be a useful tool for future 
studies of CDK12 kinase activity in vivo. 
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Figure 4.5:  Developing an analog sensitive mutant of CDK12. (a.) Sequence alignment (UniProt 
[www.uniprot.org]) of CDKs (yeast Ctk1 and human CDK2, CDK9, and CDK12) identifying the potential 
“gatekeeper” residue of hCDK12.  Relative amino acid positions are indicated at the beginning and end 
of each sequence and each protein’s UniProt accession number and name are displayed on the right.  
Conserved phenylalanine residues that have been previously mutated to make analogue sensitive 
kinases are highlighted with a red box. (b.) Purified hCDK12/CyclinK (CDK12) and F813G 
hCDK12/CyclinK mutant (CDK12as) CTD kinase activity was assayed using 1 ug of GST-yCTD fusion 
protein at 30 μM ATP, 37 °C, and a 30 min reaction time with increasing concentrations of the bulky 
adenine analogue 1-NM-PP1 in DMSO; the reactions were analyzed by SDS-PAGE and visualized using 
a PhosphorImager. 
4.3.3 CDK12 substrate specificity and activity in the presence of DRB 
and FVP 
Using a series of synthetic three heptad repeat phospho-peptides and truncated 
forms of the hCDK12/CyclinK complex, previous studies have reported that hCDK12 
exhibits a marked preference towards a CTD phosphorylated at the Ser7 position within 
the heptad repeat (Bosken et al., 2014).  In order to investigate the substrate specificity of 
the full length hCDK12/CyclinK complex towards a longer CTD substrate, we used 
bacterially expressed GST-CTD fusion proteins carrying ~15 wild-type or Ser-substituted 
repeats:  WT (YSPTSPS), S2A (YAPTSPS), S2E, S5A, S5E, and S7E.  These constructs 
either eliminate a potential phosphoacceptor (serine to alanine) or act as a 
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phosphomimetic (serine to glutamate, which resembles phospho-serine).  Under our 
standard kinase assay conditions (300 μM ATP, 1 μg GST-CTD fusion protein substrate, 
30 min reaction time), we find that hCDK12/CyclinK does exhibit a preference towards 
the S7E GST-CTD construct when compared to the other mutant CTD constructs, but not 
when compared to wild-type CTD construct which was phosphorylated to a similar  
 
 
Figure 4.6:  Phosphorylation of mutant GST-CTD substrates by hCDK12/CyclinK. (a.) A representative 
autoradiogram of a SDS-PAGE gel from an hCDK12/CyclinK kinase assay using mutant GST-CTD 
substrates.  The composition and number of the CTD heptad repeats in the GST-CTD fusion protein is 
indicated below the appropriate lanes.  (b.) Quantification of the degree of phosphorylation of each 
mutant substrate using a PhoshpoImager and ImageQuant software (normalized to a value of 1.0 for the 
wild-type GST-CTD fusion protein). Error bars are +/- 2 standard errors of the mean, n=3. 
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extent (Fig. 4.6 a. and b.).  Kinase activity is significantly weaker towards the S2E and 
S5A substrates (~50% as compared to WT) with the S5E presenting itself as the worst 
substrate (~30% activity as compared to WT).  The S2A construct was also a somewhat 
weaker substrate than WT or S7E (~75% activity as compared to WT) (Fig. 4.6 a. and b.). 
Many studies of CDK9’s role in RNAPII transcription and CTD phosphorylation 
employed the CDK9 inhibitor flavopiridol (FVP) (Chao and Price, 2001).  FVP has been 
shown to exhibit significant selectivity for CDK9 as compared to the other 
transcriptional CDKs (IC50 of 3-20 nM as compared to ~300 nM for CDK7) and because 
of this presumed selectivity, the effects of FVP treatment have often been interpreted to 
be due to inhibition of CDK9 alone.  However several other non-transcriptional CDKs 
(CDK1, 2, 4, and 6) are highly sensitive to FVP (IC50s at ~40 nM) (Schmerwitz et al., 
2011) and experiments using a dominant negative form of CDK9 have suggested that the 
potent effects of FVP on transcription may be due to the inhibition of additional CTD 
kinases other than FVP (Garriga et al., 2010).  Therefore, we set out to determine if full 
length CDK12 also exhibited sensitivity to FVP.  The binding of FVP to CDK9 is 
characterized by a very strong, long lived, hydrophobic interaction, resulting in a one to 
one binding of inhibitor to kinase (even at nanomolar concentrations of inhibitor) 
(Baumli et al., 2008; Chao and Price, 2001).  We decided to leverage this non-canonical 
inhibitor-kinase interaction, coupled with the more general behavior of the competitive  
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Figure 4.7:  CDK9 and CDK12 activity in the presence of 5,6-Dichlorobenzimidazole Riboside (DRB) and 
Flavopiridol (FVP).  (a.) Concentration series of (a.) DRB and (b.) FVP for CDK12/CycK and CDK9/CycT1 
activity assayed using 1 ug of GST-yCTD (30 μM ATP, 37 °C, 30 min reaction time).  Activity of each 
kinase is normalized to a value of one for 0 nM DRB or 0 nM FVP respectively.  Error bars are +/- 1 
standard error of the mean, n=3 (except for DRB 25 nM and 5000 nM, where n=1 and 2 respectively) 
CDK inhibitor 5,6-Dichlorobenzimidazole riboside (DRB) in order to determine if 
CDK12 exhibits a similar susceptibility to inhibition by FVP.  Assayed using GST-yCTD, 
under the same buffer conditions and activity, both CDK12 and CDK9 responded in the 
same way to increasing concentrations of the competitive inhibitor DRB (Fig. 4.7 a.).  
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Table 1:  IC50 calculations for CDK9 and CDK12 activity in the presence of flavopiridol (FVP).  IC50 
values were determined using GraphPad Prizm 6. 
 CDK9 CDK12 
log(inhibitor) vs. normalized response   
Best-fit values   
IC50 26.03 147.6 
95% Confidence Intervals   
IC50 18.01 to 37.62 104.6 to 208.2 
Goodness of Fit   
Degrees of Freedom 14 14 
R square 0.9180 0.9010 
Absolute Sum of Squares 1628 1553 
Sy.x 10.78 10.53 
Number of points   
Analyzed 15 15 
 
However, the behavior of CDK12 and CDK9 diverged when treated with FVP (Fig. 4.7 
b.):  Under the conditions used, CDK9 exhibited an IC50 of ~25 nM versus an IC50 of 
~150 nM for CDK12 (Table 1).  This suggests that the inhibition of CDK12 by FVP does 
not result in the tight interaction mode exhibited by FVP and CDK9.  Despite this 
difference, the activity of CDK12 is clearly inhibited by the higher concentrations of FVP; 
therefore whether CDK12 is inhibited by FVP in vivo will depend on intracellular 
inhibitor and ATP concentrations and remains an open question. 
4.4 Discussion 
 In order to further characterize CDK12’s roles in vitro, and to inform future 
experiments in vivo, we have purified to near homogeneity full-length, active, human 
CDK12/CyclinK, the RNAPII CTD kinase orthologous to yeast CTDK-I.  It is highly 
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likely that the key to heterologous expression of the full length CDK12 protein in the 
baculovirus/Sf9 expression system is the one to one expression of both the kinase and its 
cyclin partner.  With this in mind, we used a “2A” peptide-linked multi-cistronic 
construct in order to co-express both hCDK12/CyclinK subunits and overcome 
previously reported solubility and post-translational modification problems.  The over-
expressed enzyme is heavily post-translationally modified, definitely by 
phosphorylation (probably on its N and C terminal extensions), but also through other 
modifications as phosphatase treatment does not completely resolve the diffuse nature 
of the hCDK12 band in SDS-PAGE gels.  Although we do not know the exact degree of 
activating T-loop phosphorylation (a characteristic modification of CDKs that enables 
kinase activity) of the recombinant enzyme complex, the purified enzyme clearly 
exhibits CTD kinase activity towards an unmodified substrate (GST-yCTD); it would be 
interesting to see if co-expression of a CDK activating kinase (such as yeast CAK) further 
enhanced this activity.  Fortuitously, due to its uncharacteristically large size, the 
purification of the recombinant His tagged hCDK12/CyclinK protein can be performed 
from nuclear extracts with a straightforward two step procedure yielding highly 
purified complex. 
Enzymatic characterizations of the purified kinase in vitro reveal features 
important to understanding CTD phosphorylation in vivo.  We find that the activity of 
hCDK12/CyclinK towards a GST-yCTD substrate is independent of the proline-rich 
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region C-terminal to the cyclin box of CyclinK and, unlike the activity of some CTD 
phosphatases (Werner-Allen et al., 2011; Xiang et al., 2010), is not stimulated by proline 
isomerization.  Additionally, we observe that CDK12 kinase and CDK9 kinase (P-TEFb) 
show identical sensitivities to the inhibitor DRB and similar sensitivities to the inhibitor 
flavopiridol (FVP); consequently, when either DRB or FVP is used to inhibit CDK9 in 
vivo, it is likely that CDK12 is also inhibited.  Therefore, attributing a particular event to 
either one of these kinases based on inhibitor studies is not straightforward and the 
studies that have done so merit a degree of re-evaluation.   
We have also investigated the substrate specificities of full-length hCDK12 using 
GST-CTD fusion protein substrates with nominally 15 heptad repeats which are all WT 
(YSPTSPS) or are all altered at one position (S2A, S2E, S5A, S5E, S7E). The WT and S7E 
substituted CTDs are phosphorylated to fairly similar extents by hCDK12/CyclinK, 
while the S2A, S2E, S5A, and S5E present themselves as weaker substrates (75%, 50%, 
50%, and 25% activity respectively).  These data argue that in vitro hCDK12/CyclinK, 
much like CTDK-I (Jones et al., 2004) and P-TEFb (Czudnochowski et al., 2012), is a 
promiscuous kinase that can phosphorylate multiple serine positions within the CTD (as 
an example, with the S2A substrate the complex must phosphorylate either the S7 
and/or S5 position within the heptad repeats).  Although our data agree with the 
previously reported preference towards a substrate prephosphorylated at the Ser7 
position of the CTD (Bosken et al., 2014) as compared to that of Ser2 or Ser5, we do not 
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observe this preference when comparing S7E to WT.  The reason for this difference 
could be due to the nature of the substrate (our substrate is more reminiscent of the 
wild-type CTD in the number of heptad repeats [16 as compared to 3 in the other study], 
however, the use of glutamate as a phosphomimetic is inferior to a true phospho-serine) 
or due to the use of a full length hCDK12/CyclinK complex.  Regardless, the preference 
of CDK12 for S7P and unphosphorylated repeats is interesting; it is likely to be 
indicative of the phospho-CTD patterns recognized by CDK12 in vivo and, with further 
study, may play a role in furthering our understanding of the phospho-patterning of the 
CTD. 
Finally, as a tool for future studies, we have engineered, expressed, and purified 
an analog sensitive form of hCDK12/CyclinK.  Not all kinases are amenable to the 
creation of analog sensitive mutants; therefore we were very excited to find that the 
mutated form of CDK12 was stable and highly sensitive to the cell permeable, bulky 
adenine analog 1-NM-PP1.  We anticipate that the availability of full length enzyme and 
its analog sensitive mutant will be useful in teasing apart the structural and catalytic 
roles of hCDK12/CyclinK (allowing for comparisons between total CDK12 
depletion/knockout versus kinase activity inhibition) and will lead to an improved 
understanding of hCDK12/CyclinK activities within the cell and CTD modification and 
RNAPII transcription in general.  
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5. Insertion of a CDK12 Analog Sensitive Mutation into a 
Human Cell Line 
5.1 Introduction 
Since our initial characterization of CDK12/CyclinK as a Ser2 CTD kinase the 
structure of its kinase homology domain has been elucidated, it has been shown to play 
a role in the 3’ end processing of the MYC gene and it has been identified as a tumor 
suppressor for ovarian cancer (Bosken et al., 2014; Davidson et al., 2014; Joshi et al., 
2014).  Most intriguingly, and particularly relevant to its role as a tumor suppressor, 
CDK12/CyclinK has been implicated in the maintenance of genomic stability through 
the regulation of DNA damage response genes and as a determinant of PARP1/2 
inhibitor sensitivity in the treatment of cancer (Bajrami et al., 2014; Blazek, 2012; Blazek 
et al., 2011).  Despite this progress there is still much that is not known about the in vivo 
roles of CDK12/CyclinK at the molecular level.  As an example, its role in the regulation 
of DNA damage response genes has not been fully elucidated:  Is the downregulation of 
these mRNAs following CDK12 depletion a result of the polymerase occupancy changes 
at the 5’ end of the genes as posited by Blazek et al., or is it actually due to errors in 
mRNA processing or a consequence of long-term secondary effects?  Given our list of 
dCDK12 and hCDK12 associated proteins (see chapter 3), it is likely that 
CDK12/CyclinK plays both catalytic and noncatalytic roles in mRNA processing and 
other transcription related functions, further complicating analysis.  Because there is no 
specific hCDK12 inhibitor, and because RNAi mediated depletion affects both the 
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structural and catalytic elements of CDK12 function, gaining a better understanding of 
CDK12’s role in transcription will be challenging without the development of additional 
molecular tools.  Having shown that an analog sensitive form of hCDK12/CyclinK 
(CDK12as) is stable, highly sensitive to the adenine analog 1-NM-PP1, and exhibits wild-
type levels of activity prior to inhibition in vitro, we wanted to come full circle and 
reintroduce CDK12as into a human cell line.  Therefore, the recent discovery and 
utilization of the CRISPR/Cas9 system as a genome engineering tool presented itself as 
an exciting opportunity for the creation of a powerful tool for future experiments (Mali 
et al., 2013; Ran et al., 2013).   
In its natural state CRISPR/Cas is a microbial immune system which employs a 
RNA-guided nuclease in order to cleave foreign genetic elements.  The system’s name 
comes from an array of Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR), which are separated by short variable sequences from exogenous DNA 
targets called protospacers.  Each protospacer is associated with a Protospacer Adjacent 
Motif (PAM) which varies according to the specific CRISPR system in question:  In the 
type II CRISPR system, which consists of the Cas9 nuclease, a CRISPR RNA array that 
encodes a guide RNA and a trans-activating crRNA that facilitates the processing of the 
array into discrete units, the target DNA must precede a 5’ NGG PAM.  Once it is 
transcribed and processed, each discrete unit of the CRISPR array contains a 20 
nucleotide guide sequence which then directs Cas9 to a 20bp DNA target by Watson-
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Crick base pairing.  In mammalian cells this RNA-guided nuclease system can be 
reconstituted through the heterologous expression of human codon optimized Cas9 and 
the appropriate RNA components (the guideRNA and trans-activiating crRNA), which 
are fused together to create a chimeric single guide RNA (gRNA).  Thus Cas9 can be 
targeted toward any genomic region of interest resulting in a site specific double strand 
break.  Cleavage and repair of the DNA at the targeted site by nonhomologous end 
joining (NHEJ) can stochastically generate frameshifts in a targeted open reading frame 
(ORF) and result in knockout; or if an appropriate repair template is provided, 
homology-directed repair can generate specific gene modifications at the targeted loci 
(see protocol by Ran et al. for more details) (Ran et al., 2013).   Therefore, in order to 
dissect the indirect and direct roles of CDK12 in RNA processing and other events, we 
set out to engineer CDK12 knockout and analog sensitive human cell lines using the 
CRISPR/Cas9 system. 
5.2 Materials and methods 
5.2.1 Knockout cell line creation 
The Cas9 expression plasmid (pcDNA3_3 TOPO_CAS9) and gRNA expression 
vector (pCR_BluntII_TOPO_U6_gRNA) were obtained from Nicholas Barrows and Dr. 
Mariano Garcia-Blanco (originally ordered from Addgene; designed by the Church lab). 
In order to create a knockout cell line a protocol similar to the one found in Ran 
et al. was followed (Ran et al., 2013).  In detail:  3 guide RNAs were selected (from 
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computationally designed gRNAs in the Mali et al. supplemental materials (Mali et al., 
2013) and at http://arep.med.harvard.edu/human_crispr/) to target exon 1 of hCDK12.  
Guide RNA #1: GAGCTGCCGCCTCCCGATGACGG 
Guide RNA #2: GCTTGTGCTTCGATACCAAGCGG 
Guide RNA #4: GGCCTTCAAACTAGACCGAAGGG 
Each guide RNA was ordered as a “top” and “bottom” segment designed to be 
annealed and extended (see below) in order to form a double stranded construct that 
could be integrated into the gRNA vector plasmid.  The “top” segment consists of 
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACC followed by the guide 
RNA sequence (lacking the final 3 nucleotides representing the PAM site (NGG) as these 
are included in the vector).  The “bottom” segment consists of 
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC followed by the reverse 
complement of the 20 nt guide RNA sequence (again lacking the final 3 nucleotides).  
The final top and bottom segments are 60 bp in length and were ordered from IDT and 
are shown below (Table 2) with the extensions italicized and highlighted in blue.  The 
pairs of guide RNA segments were resuspended at 100 μM, mixed, and 
annealed/extended using PWO Master (A 2x high fidelity PCR master mix; Roche).   
This was done by performing 5 cycles of PCR with a 55 °C annealing and a 30 second 
extension step.  The pCR Blunt II TOPO U6 gRNA vector was linearized with AflII  
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Table 2:  hCDK12 guide RNA segment sequences.  gRNA expression vector sequence used for sequence 
independent ligation (Gibson reaction) is shown in blue. 
Guide RNA 
 #- Strand 
Sequence 
1-Top 
1-Bottom 
5’-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGAGCTGCCGCCTCCC
GATG-3’ 
5’-
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTCATCGGGAGGCGGC
AGCTC-3’ 
2-Top 
2-Bottom 
5’-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTTGTGCTTCGATA
CCAAG-3’ 
5’-
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCTTGGTATCGAAGCA
CAAGC-3’ 
4-Top 
4-Bottom 
5’-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCCTTCAAACTAG
ACCGAA-3’ 
5’-
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTTCGGTCTAGTTTGAA
GGCC-3’ 
 
restriction endonuclease (NEB).  The annealed gRNA insert and cut vector were purified 
using the QiaQuick PCR Purification Kit (Quiagen) and the products eluted in 30 μL 
dH2O.  The linearized gRNA vector was then diluted to 8.65 ng/μL and the 100 bp 
gRNA insert to 1.11 ng/μL.  Gibson assembly was used to incorporate the gRNA insert 
into the gRNA vector; briefly 5 μL of diluted gRNA vector was added to 5 μL of diluted 
insert, then 10 μL of 2x Gibson assembly master mix was added (NEB) and the reaction 
was incubated for 1 hour at 50 °C.  The reaction mixture was then diluted 1:4 with dH2O 
and 2 μL was used to transform XL-1 blue chemically competent cells.  The 
transformation reactions were selected on Kanamycin and the resulting colonies were 
 108 
screened for successful incorporation of the gRNA inserts by sequencing of plasmid 
DNA via the M13R primer. 
HeLa cells were then transfected using 1.5 μg of pcDNA3_3 TOPO_CAS9 and 
0.75 μg of two gRNA vectors (guideRNA 1 and 4; 1 and 2; and 2 and 4) in a 6 well plate 
format using Lipofectamine 2000 (Life Technologies),  following the manufacturers 
protocol.  24 hours after transfection, the cells were passaged to T-75 flasks and placed 
under G418 (Gibco) selection (1 mg/mL; effective concentration of G418 was determined 
beforehand) for 4 days.   Following selection, each transfected cell line was analyzed for 
Cas9 activity via genomic DNA purification (DNeasy Blood and Tissue Kit, Quiagen) 
followed by PCR using primers outside of the targeted region (Forward Primer:  
TTCTTCAGGTCAGGGGAAAG; Reverse Primer:  CTGGTGGTGACGATGTTTGT).  
Single clones were then isolated by low density plating, propagated, and analyzed for 
the presence of hCDK12 via western blotting. 
5.2.2 Analog sensitive cell line creation 
In order to create an analog sensitive cell line another guide RNA targeting 
exon6 of hCDK12 was designed by locating a unique 20 bp sequence with the 
appropriate PAM motif (NGG) as near to the F813 codon as possible. 
AS gRNA:  GGTCCATATACTCAAATACAAGG 
As in 5.2.1, two oligonucleotides were ordered from IDT (Table 3). 
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Table 3:  hCDK12 analog sensitive mutant guide RNA segment sequences.  gRNA expression vector 
sequence used for sequence independent ligation (Gibson reaction) is shown in blue. 
Guide 
RNA 
 #- Strand 
Sequence 
AS-Top 
AS-Bottom 
5’- 
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGTCCATATACTCAAA
TACA-3’ 
5’- 
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTGTATTTGAGTATATGG
ACC-3’ 
 
The final AS gRNA vector was produced as detailed for the other constructs and HeLa 
cells were transfected with the Cas9 and AS gRNA plasmids as detailed above (see 
5.2.1).  Cas9 activity and targeting were confirmed through isolation of genomic DNA 
and the Surveyor Assay (Transgenomics) (For details refer to (Ran et al., 2013) and 
manufacturer’s protocol; surveyor assay primers were as follow:  Forward- 
AGAACCTGTGGTCAACTCCAA and Reverse – TCCCACACTGAACGTAGGAA, data 
not show). 
200 ng of a double stranded 850 bp homologous repair template was ordered 
from IDT (gBlocks Gene Fragment service) containing ~425 bp of the genomic sequence 
flanking either side of the cut site with the analog sensitive mutation and a few 
modifications (Fig. 5.1). 
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Figure 5.1:  Sequence surrounding Exon6 of hCDK12 and the analog sensitive repair template.  Genomic 
sequence was obtained using the UCSC genome browser (https://genome.ucsc.edu/). Exons are displayed 
in caps, introns in lowercase.  Red letters are the PAM sequence (required for targeting of the Cas9 
nuclease), the bolded AT is the Cas9 cut site.  The WT sequence and analog sensitivity inducing repair 
template (shortened from its full 850bp for display purposes) is shown up top and below respectively.  
The gRNA complementary sequence used to target Cas9 to Exon6 is shown in yellow.  The repair 
template includes a TTT to GGT (in red) which results in F813G.  There is also a silent mutation in the 
PAM to ensure that Cas9 does not cut the repair template or the repaired sequence (C->T in blue). 
HeLa cells were transfected with the Cas9 expression plasmid, AS gRNA 
expression plasmid, (as detailed above) and 50 ng of the repair template.  Following 
selection, single clones were isolated by low density plating and propagated.  Genomic 
DNA from each clone was assayed using PCR with forward primers specific for WT 
(GGTGCCTTTTACCTTGTATTTGA) and analog sensitive 
(GTGCCTTTTATCTTGTAGGTGAG ) sequence and a reverse primer outside the region 
 111 
encompassed by the repair template (CCAATGCAGTATAGGCAAATAAA).  A single 
clone was found which did not yield a WT PCR product, but did yield an analog 
sensitive PCR product.   The region of interest was then PCR’d from the genomic DNA 
of this cell line (Forward Primer:  AGAACCTGTGGTCAACTCCAA and Reverse 
Primer:  CCAATGCAGTATAGGCAAATAAA) and sequenced (sequencing primer:  
ATAGAGCCGAGCAAGTCCAA). The resulting PCR product and TA clones of the 
product in pCR2.1-TOPO (Topo TA cloning kit, Invitrogen) were then sequenced (Duke 
DNA analysis facility) 
5.2.3 Antibodies and qPCR 
rAP anti-hCDK12:  Affinity-purified IgGs directed against a peptide comprising 
amino acids 201-220 of hCDK12 (NCBI RefSeq: NP_057591.2). 
RNA was isolated using the RNeasy mini kit (Quiagen) (The optional on-column 
DNAse step was performed) and cDNA synthesis was performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using 1.5 μg of total 
RNA as input.  Quantitative PCR (qPCR) was performed using Power SYBR Green PCR 
master mix (Applied Biosystems) and the StepOnePlus real-time PCR system (Applied 
Biosystems); each sample was normalized based on the amount of β-Actin and changes 
in gene expression were calculated using the ΔΔCt method.  The forward and reverse 
primers used to detect each target are listed below. 
CDK12: AACACTGATGGGCCTGAAAC and GTTCTTCACCAGGGTCTGGA 
 112 
CyclinK: AAACCTGGACCACACAAAGC and GCCCACATCAAAGATGAACC 
β-actin: GCTCGTCGTCGACAACGGCTC and CCTCGTCGCCCACATAGGAATC 
5.3 Results 
5.3.1 Constructing a CDK12 knockout cell line 
As a true CDK12 knockout cell line was likely to exhibit informative phenotypes 
and be very useful for rescue experiments, we began our foray into gene engineering by 
attempting to delete CDK12 through the isolation of a clone harboring a Cas9 induced 
frameshift mutation.  HeLa cells were transfected with Cas9 expression vector and two 
guide RNA (gRNA) expression vectors (gRNA #1 & #4, #1 & #2, and #2 & #4; see 5.2.2 for 
details).  The use of two separate gRNA vectors targeting two closely spaced regions can 
result in a deletion of the sequence separating the two sites (through NHEJ), allowing 
 
Figure 5.2:  Analysis of gRNA targeting and Cas9 activity via PCR.  A schematic of hCDK12 exon 1 with 
the gRNA target sites and PCR primer positions indicated, is displayed on the right; the PCR product 
from wild type HeLa cells is expected to be 368 bp.  PCR results from pooled genomic DNA of Cas9 and 
gRNA transfected cells are visualized on the left using a 1.5% agarose gel stained with EtBr.  HeLa cells 
were transfected with the indicated pairs of gRNA vectors (Empty is an empty vector control).  PCR is 
performed on pooled genomic DNA from each transfection; note the appearance of NHEJ mediated 
deletions in the 1/2, 1/4, and 2/4 lanes. 
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for an easy way to assess if Cas9 is correctly targeted and active, via PCR.  
Following selection and propagation, total genomic DNA was isolated from the pools of 
transfected cells and analyzed; all 3 of the gRNA constructs were found to be active (Fig. 
5.2).  Single clones were then isolated by low density plating, propagated, and analyzed 
for the presence of hCDK12 via western blotting. Unfortunately, attempts at creating 
CDK12 knockout HeLa cells by targeting the 5’ end of the CDK12 ORF were not 
successful; we were able to isolate several clones that exhibited truncations due to NHEJ 
events (even in cells transfected with a single gRNA), but no frameshift mediated null 
clones were isolated (~40 clones were assayed in total) (Fig 5.3).  This may be due to the 
essential nature of CDK12; although our failure to isolate a null clone does not prove 
that CDK12 is necessary for viability in HeLa cells, it does agree with previously  
 
 
Figure 5.3:  hCDK12 westerns of whole cell extracts from putative CDK12 knockout HeLa cell clones.  
Western blotting with an anti-hCDK12 antibody reveals the presence of truncated forms of hCDK12 
protein in several clones targeted for CDK12 knockout via CRISPR-Cas9.  The top band (above the 250 
kDa molecular weight marker (lane1)) is an off target, cytoplasmic protein recognized by the anti-CDK12 
antibody (also see Fig. 5.6).  Compare the molecular weight of the CDK12 signal from the clones in lanes 
2, 5, and 3 to WT HeLa cells (lane 4).  Clone 2/4(5) (lane3) was subsequently re-assayed and found to 
contain a shortened hCDK12 protein present at about 50% of the wild type amounts (a likely 
heterozygote with a null at one allele). 
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reported data using CDK12 knockout mice and Drosophila (Blazek et al., 2011; 
Rodrigues et al., 2012) which found the gene to be essential for development. 
5.3.2 Constructing an analog sensitive CDK12 cell line 
In order to create an analog sensitive CDK12 cell line HeLa cells were transfected 
with the Cas9 expression vector, a guide RNA expression vector targeting the genomic 
position of P813 of CDK12, and a repair template harboring a mutation in the PAM (to 
avoid Cas9 targeting to the repair template and repaired regions) and the analog  
 
Figure 5.4:  Analysis of putative analog sensitive clones via PCR.  A schematic of hCDK12 exon 6 with the 
positions of the homologous repair template (blue box), the analog sensitive mutation (red star), and the 
PCR primers specific to the analog sensitive (AS) and wild type (WT) sequences indicated is displayed 
on the right; the PCR product is expected to be 560 bp.  PCR of genomic DNA from 6 putative analog 
sensitive clones is visualized on the left using a 1.5% agarose gel stained with EtBr; the top section of the 
gel displays the results using AS specific primers while the bottom section of the gel displays the results 
using the WT primers.  Note clone #5, which appears to be homozygous for the analog sensitive 
mutation. 
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Figure 5.5:  Sequences of hCDK12 exon 6 genomic DNA from the putative CDK12 analog sensitive cell 
line.  Plasmids containing TA cloned PCR fragments from hCDK12 genomic DNA surrounding exon 6 
were submitted for Sanger sequencing.  Alignment to the canonical sequence, the translated protein 
sequence of the ORF, and chromatographs are shown; in the alignment template exons are displayed in 
upper case and introns in lower case; in the chromatographs the codon for F/G 813 is highlighted in blue.  
8 TA clones were analyzed and only the two displayed sequences were observed (6 analogue sensitive 
and 2 wild-type with the premature stop codon).  TA clone #7 (top) exemplifies the analogue sensitive 
allele, TA clone #8 exemplifies the truncated wild-type allele (The * in the translation indicates a stop 
codon). 
sensitive mutation P813G (see Figure 5.1 and section 5.2.2).   Selection, followed by the 
isolation of single colonies by low density plating and propagation, led to the 
identification of a single clone which appeared to be homozygous for CDK12as via PCR 
using analog sensitive and wild type specific primers (Figure 5.4).  
Sequencing of genomic DNA confirmed this putative CDK12as cell line to be a 
heterozygote consisting of two alleles, one harboring a NHEJ induced stop codon in the 
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targeted position and one containing a clean analog sensitive mutation (Fig 5.5).  This 
genotype was confirmed via western blotting of whole cell extracts for hCDK12 and 
through mRNA quantification by qPCR which showed ~50% decreased levels of CDK12 
and CDK12 mRNA as compared to the parental cell line (the premature stop codon 
induces nonsense mediated decay of the associated mRNA) (Fig. 5.6). 
 
Figure 5.6:  hCDK12 expression in the putative CDK12 analog sensitive cell line.  (a.) hCDK12 western 
blot on whole cell (lanes 1-2) and nuclear (lanes 3-4) extracts from the parental (WT) and putative CDK12 
analog sensitive (AS) cell line.  The amount of hCDK12 in the analog sensitive cells was quantified to be 
~50% to that of the parental cell line (on the right; Licor Odyssey software). The anti-hCDK12 antibody 
targets the N-terminal arm of hCDK12 (amino acids 201-220), well before the stop codon at amino acid 
813 (b.) mRNA quantification of hCDK12 and CyclinK mRNA levels using qPCR.  Expression values are 
standardized to the parental cell line (WT) whose value was set at 1, error bars are +/-2 standard errors of 
the mean, n=3. 
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Unfortunately, kinase assays of immunoprecipitated CDK12 isolated from the 
engineered cell line (data not shown) and sequencing of hCDK12 cDNA revealed an 
unforeseen problem.  Mutation of the P813 codon to glycine results in the formation of 
an alternative splice acceptor site, which was now employed by the mutant cell line 
resulting in a protein containing an 18 amino acid deletion (Fig. 5.7); this protein exhibits 
 
Figure 5.7:  Schematic of splicing issues in the putative hCDK12 analog sensitive cell line.  Mutation of 
the TTT codon encoding P813 of hCDK12 to GGT (P813G) results in the creation of a novel splice 
acceptor site downstream of the canonical one between exon5 and exon6 of hCDK12.  Consensus splicing 
sequences are shown at the upper right of the figure.  A schematic of exon 5 (black text), the intron 
between exons 5 and 6 (gray lowercase text), and exon 6 (blue text) is depicted in the parental (WT) and 
putative analog sensitive cell line (AS).  The PAM and analog sensitive mutations are highlighted in red.  
Note how mutation of P813G with TTT->GGT results in the formation of a “tgtag” sequence motif 
exactly the same as the motif present at the end of the intron.  Chromatographs of TA cloned cDNA 
sequences from this site are shown below the mis-spliced sequence; the end of exon 5 is highlighted in 
blue. This unanticipated splicing results in an 18AA truncation of the hCDK12 protein; the resultant 
protein retains residual activity, but is not analog sensitive (data not shown).  As all codons encoding 
glycine begin with GG, a silent mutation in the preceding codon could potentially rectify this problem. 
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residual kinase activity, but is not analog sensitive.  We are currently working to 
determine whether further modification of the alternative splice acceptor site or the 
nuclease targeting site mutation will resolve this issue.  Therefore, construction of a 
CDK12 analog sensitive cell line using the CRISPR-Cas9 system is likely to be a lucrative 
endeavor; however, simply inserting the analog sensitive mutation into the genome can 
perturb the splicing of CDK12 exon 5 and 6. 
5.4 Discussion 
In order to create a set of tools to further study hCDK12/CyclinK’s role in 
transcription and to test the proposals posited in chapter 3, we set out to use the 
CRISPR-Cas9 system to engineer knockout and analog sensitive CDK12 HeLa cells.  
Although we were unable to isolate a knockout clone of hCDK12, likely due to the 
essential nature of the kinase, we have demonstrated the feasibility of creating analog 
sensitive hCDK12 cell lines using this approach.  Unfortunately, the verification of our 
haploid CDK12as cell line failed at the final stages due to the creation of an unforeseen 
splice acceptor site at the position of the F813G mutation. We hope that our problems 
with the splicing of the analog sensitive hCDK12 cell line are a useful cautionary tale to 
others attempting similar experiments and aim to complete the construction of a true 
analog sensitive cell line in the near future.  We anticipate that this tool will be useful in 
teasing apart the structural and catalytic roles of hCDK12/CyclinK and will lead to an 
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improved understanding of hCDK12/CyclinK activities within the cell and CTD 
modification and RNAPII transcription in general. 
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6. Conclusions and Future Directions 
6.1 Conclusions 
The primary aim of this dissertation was to explore the comparative genomics-
based hypothesis that the previously-unstudied Drosophila CDK12 (dCDK12) and little-
studied human CDK12 and CDK13 (hCDK12 and hCDK13) proteins are RNAPII CTD 
elongation-phase kinases, the metazoan orthologs of yeast Ctk1.  By combining the 
evolutionary and functional evidence from previous studies with a variety of 
experimental techniques, we have determined that both dCDK12 and hCDK12 are 
indeed responsible for proper CTD phosphorylation in vivo, and concluded that CDK12 
is indeed a bona fide CTD kinase, the metazoan ortholog of yeast Ctk1; intriguingly the 
function of hCDK13 remains ambiguous.  These findings have clarified the evolutionary 
and functional relationships between the two yeast CDKs, Ctk1 and Bur1, and their 
metazoan homologues; but most importantly they have drawn attention to major 
metazoan CTD kinase activities that have gone unrecognized and unstudied until now.  
The recognition of these activities allows for a better informed investigation of the links 
between cotranscriptional processes and RNAPII transcription in higher eukaryotes. 
Over the course of the last few years, several of our initial expectations, which 
assumed that any process or event dependent on normal phosphorylation of the CTD on 
elongating RNAPII will be affected in cells deficient for CDK12, have been verified.  
Specifically, hCDK12 has been shown to be important for the 3’ end processing of the 
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MYC gene (Davidson et al., 2014) and dCDK12 has been shown to help mediate splicing 
decisions in Drosophila blood brain barrier differentiation (Rodrigues et al., 2012).  In 
addition to splicing and 3’ end processing, we also anticipate that other events such as 
transcription-coupled chromatin modification, snRNA termination, and mRNA export 
out of the nucleus will be affected by loss of CDK12 activity.  However, it is worth 
noting that the extent of these effects is likely to be influenced by the specific transcripts 
and/or cell types in question:  It has been shown that in C. Elegans, CDK12 mediated Ser2 
CTD phosphorylation is highly enriched in the germline as compared to somatic cells 
(Bowman et al., 2013) and CDK12 expression is variable, with the highest mRNA levels 
present in testis and ovaries (Edwards et al., 1998; Ko et al., 2001).  Despite such 
challenges we expect that the full extent of CDK12 mediated co-transcriptional 
processing will become apparent over the next few years. 
In conjunction with its roles in mRNA processing, since our initial 
characterization, CDK12 has been implicated in two interesting phenomena.  The first is 
the maintenance of self-renewal in embryonic stem cells, where depletion of CDK12 
resulted in differentiation (Dai et al., 2012), and the second is in the maintenance of 
genomic stability (Blazek, 2012).  In accordance with the latter of these activities, CDK12 
has been identified as a tumor suppressor for ovarian cancer (Joshi et al., 2014) and as a 
determinant of PARP1/2 inhibitor sensitivity (Bajrami et al., 2014).  Intriguingly, 
alterations in transcription-associated homologous recombination events have been 
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observed in Ctk1Δ yeast strains (Grenetier et al., 2006; Westmoreland et al., 2009), and 
certain proteins important to genome stability are linked to transcription via direct 
interaction with the hyperphosphorylated CTD (Islam et al., 2010; Kanagaraj et al., 2010; 
Winsor et al., 2013); mice missing one of these phospho-CTD associating genome 
stability proteins (RECQ5) exhibit an increased incidence of cancer (Hu et al., 2007).  
However, it is not known whether the effects of CDK12 depletion on genomic stability 
are mediated through the loss of direct phospho-CTD interactions by proteins involved 
in the DNA damage response or through the deregulation of transcription and mRNA 
processing (or both).  Thus, we anticipate that further characterization of CDK12 and its 
functions will be of broad scientific interest and significant medical relevance.  
Therefore, in order to further expand on our initial characterization and to 
facilitate future studies, we have also identified putative CDK12 associated proteins, 
expressed and purified the full-length active hCDK12/CyclinK complex, and attempted 
to design an inhibitable version of CDK12 for in vitro and in vivo studies.   Our in vitro 
characterizations of the hCDK12/CyclinK complex offer additional insights into CDK12 
substrate preference and highlight the issue of inhibitor specificity in previous studies.  
Most intriguingly, our identification of CDK12 associated proteins suggest that CDK12 
affects RNA processing events in two distinct ways:  Indirectly through generating 
factor-binding phospho-epitopes on the CTD of elongating RNAPII and directly through 
binding to specific factors.  In terms of differentiating between these possibilities, we 
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hope that our design and characterization of an analog sensitive hCDK12 mutant will 
prove a powerful tool for future studies and that our splicing problem in the analog 
sensitive hCDK12 cell line is a useful cautionary tale to others attempting similar 
experiments.   
Overall, this dissertation has helped to fill important gaps in our understanding 
of eukaryotic transcription, its associated processes, and the links between them.  We 
have highlighted the metazoan Ser2 CTD kinases as an area ripe for further investigation 
and developed useful tools for teasing apart the structural and catalytic roles of CDK12.  
We hope that these discoveries will continue to lead to an improved understanding of 
hCDK12/CyclinK activities within the cell and CTD modification and RNAPII 
transcription in general. 
6.2 Future directions 
As discussed in previous sections, the characterization of the in vivo roles of 
CDK12 and CDK13 is still a work in progress, especially at the molecular level.  In the 
long term, many important questions will need to be answered including, but not 
limited to the following: Where exactly, and when, do these kinases add phosphates 
along the CTD? Why are there two Ctk1 homologues in humans and what is the actual 
function of CDK13? To what extent do these kinases act at specific subsets of genes or in 
particular cell types?  What is the actual mechanism behind CDK12 mediated genomic 
stability? How much of CDK12’s function is due to its catalytic activity versus its 
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structural elements?  Over the next several years, further study of CDK12 and CDK13 
will likely answer these and other questions and should lead to many fascinating 
discoveries. 
In terms of more immediate short-term goals, we believe that the creation of an 
analog sensitive human cell line would be an extremely powerful tool for answering 
many of the above questions.  Having shown the efficacy of the analog sensitive 
mutation, we aim to overcome the splicing issues discussed in section 5.3.2 and to create 
a true, hopefully homozygous, CDK12as cell line.  Simultaneously, recognizing that the 
creation of such a cell line will be very challenging, we will also attempt to create a 
CDK12 knockout cell line (or a shRNA depleted CDK12 cell line) rescued with plasmid 
expressed CDK12as/CyclinK.  As previously touched upon, a CDK12as cell line will allow 
for the differentiation between catalytic and non-catalytic effects and for the temporal 
control to parse the immediate and long-term (secondary) consequence of CDK12’s 
inhibition. 
Concurrently we are also interested in the verification and further investigation 
of the CDK12 associated proteins that we identified by mass spectrometry.  In addition 
to further developing our understanding of CDK12 function, we hope to use these 
associations to further explore the functions of hCDK13.  The similarities between the 
kinase domains of hCDK12 and hCDK13, coupled with the in vitro data suggest that 
hCDK13 is capable of in vivo CTD kinase activity.  Thus the lack of observed in vivo 
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activity is probably due to the targeting of the hCDK13 kinase to other substrates, 
splicing factors being the most likely candidates based on current evidence in the 
literature (Berro et al., 2008; Even et al., 2006; Ko et al., 2001).  We expect that the 
targeting of hCDK12 and 13 is mediated through their divergent N and C terminal 
extensions, which probably associate with different sets of factors.  In order to gain more 
insight into the in vivo activity of both kinases, we will attempt to purify endogenous 
hCDK13 to identify its associated complexes and proteins.  We anticipate that the 
differences between hCDK12 and hCDK13 associated proteins will be informative. 
Finally, in the mid-term, we recognize that a more indepth understanding of the 
functions of both CDK12 and CDK13 will require the leverage of new, genome wide, 
deep sequencing techniques that interrogate nascent RNA, such as PRO-Seq.  We hope 
that through the development of inhibitable cell lines and through the deployment of 
these genome wide techniques, we will be able to contribute to the rapidly growing 
body of knowledge regarding CDK12, the CTD of RNAPII, and transcription. 
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Appendix A 
Table 4: dCDK12 associate proteins identified by mass spectrometry; proteins present in control 
immunoprecipitations have been removed from the list with the exception of SC35 (in red, 1 peptide in 
control). 
Identified Proteins Accession CDK12 IP: # 
of peptides 
identified 
brahma protein [Drosophila melanogaster] gi|157012 56 
moira, isoform A [Drosophila melanogaster] gi|17737997 36 
osa, isoform A [Drosophila melanogaster] gi|24647755 29 
FI03643p [Drosophila melanogaster] gi|218505869 27 
brahma associated protein 60kD [Drosophila melanogaster] gi|24641689 24 
brahma associated protein 170kD [Drosophila melanogaster] gi|19921692 24 
Microtubule-associated protein 60 [Drosophila melanogaster] gi|17136860 22 
Brahma-associated protein 111kD [Drosophila melanogaster] gi|13591766 21 
GE14195 [Drosophila yakuba] gi|195488752 18 
scully [Drosophila melanogaster] gi|17737361 17 
Calcium/calmodulin-dependent protein kinase II, isoform B [Drosophila 
melanogaster] 
gi|24638772 17 
SF2 [Drosophila melanogaster] gi|21358097 16 
CG7154 [Drosophila melanogaster] gi|19920888 16 
GG12837 [Drosophila erecta] gi|194898751 12 
d4, isoform A [Drosophila melanogaster] gi|19921648 11 
phosphoglycerate mutase 5 [Drosophila melanogaster] gi|18543249 6 
LD10526p [Drosophila melanogaster] gi|21391996 6 
Prp19 [Drosophila melanogaster] gi|17647459 6 
CG9776, isoform A [Drosophila melanogaster] gi|21356019 6 
stonewall [Drosophila melanogaster] gi|24664166 6 
hook-like, isoform A [Drosophila melanogaster] gi|20129613 6 
GM11367 [Drosophila sechellia] gi|195350482 6 
Rrp40 [Drosophila melanogaster] gi|24580923 5 
eIF4AIII [Drosophila melanogaster]] gi|125775187 5 
CG7597 [Drosophila melanogaster] gi|17862948 5 
GM01970p [Drosophila melanogaster] gi|16183595 5 
cyclin K, isoform A [Drosophila melanogaster] gi|195354127 4 
CG1621 [Drosophila melanogaster] gi|21687080 4 
fruitless type-A [Drosophila melanogaster] gi|11066442 4 
GE15779 [Drosophila yakuba] gi|195480143 4 
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SC35, isoform B [Drosophila melanogaster] gi|21358099 3 
modifier of mdg4, isoform E [Drosophila melanogaster] gi|24648734 3 
CG6459 [Drosophila melanogaster] gi|116806184 3 
protein on ecdysone puffs, isoform B [Drosophila melanogaster] gi|17864514 3 
GM23813 [Drosophila sechellia] gi|195330384 3 
CG6654 [Drosophila melanogaster] gi|21357595 3 
CG6617 [Drosophila melanogaster] gi|24643081 3 
SRm160 [Drosophila melanogaster] gi|24663664 3 
CG11266, isoform B [Drosophila melanogaster] gi|19920866 3 
heterochromatin protein 5, isoform B [Drosophila melanogaster] gi|24641302 2 
CG2926 [Drosophila melanogaster] gi|24644293 2 
GG15416 [Drosophila erecta] gi|194868191 2 
putative exoribonuclease DIS3 [Drosophila melanogaster] gi|13446610 2 
GG20559 [Drosophila erecta] gi|194882669 2 
GA21150 [Drosophila pseudoobscura pseudoobscura] gi|125811459 2 
Rrp6 [Drosophila melanogaster] gi|161078302 2 
suppressor of variegation 205, isoform A [Drosophila melanogaster] gi|17136528 2 
RE67757p [Drosophila melanogaster] gi|17946442 2 
small ribonucleoprotein particle protein SmG, isoform A [Drosophila 
melanogaster] 
gi|18860007 2 
GM15529 [Drosophila sechellia] gi|195347132 2 
CG14711 [Drosophila melanogaster] gi|24646011 2 
pinin, isoform B [Drosophila melanogaster] gi|161078140 2 
xl6 [Drosophila melanogaster] gi|24582360 2 
EG:133E12.4 [Drosophila melanogaster] gi|2661513 2 
Mtr3 [Drosophila melanogaster] gi|24667071 1 
RNA binding protein [Drosophila melanogaster] gi|158224 1 
Rrp45 [Drosophila melanogaster] gi|24642649 1 
toothrin [Drosophila melanogaster] gi|18859713 1 
GG23563 [Drosophila erecta] gi|194862742 1 
diskette [Drosophila melanogaster] gi|17647341 1 
lark, isoform A [Drosophila melanogaster] gi|17647581 1 
Chain A, Structural Analysis Of A Cytoplasmic Dynein Light Chain- 
Intermediate Chain Complex 
gi|149243127 1 
actin 87E, isoform A [Drosophila melanogaster] gi|17137090 1 
microtubule dependent motor protein [Drosophila melanogaster] gi|110808371 1 
GA19319 [Drosophila pseudoobscura pseudoobscura] gi|125777721 1 
GA21399 [Drosophila pseudoobscura pseudoobscura] gi|125809258 1 
GA21317 [Drosophila pseudoobscura pseudoobscura] gi|125809441 1 
GA20724 [Drosophila pseudoobscura pseudoobscura] gi|125977468 1 
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GA19471 [Drosophila pseudoobscura pseudoobscura] gi|125978158 1 
SD04057p [Drosophila melanogaster] gi|15292493 1 
IP18396p [Drosophila melanogaster] gi|159884119 1 
ribosomal protein S5a [Drosophila silvestris] gi|164430966 1 
SD07884p [Drosophila melanogaster] gi|16769882 1 
CKII-alpha [Drosophila yakuba] gi|17016246 1 
GF21187 [Drosophila ananassae] gi|194763266 1 
GD15571 [Drosophila simulans] gi|195567753 1 
GH16479p [Drosophila melanogaster] gi|21428924 1 
LP02069p [Drosophila melanogaster] gi|21430330 1 
SD22208p [Drosophila melanogaster] gi|21430870 1 
CG15784 [Drosophila melanogaster] gi|24639869 1 
CG8928 [Drosophila melanogaster] gi|24642361 1 
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Appendix B 
Table 5: hCDK12 associated proteins identified by mass spectrometry; proteins present in control 
immunoprecipitations have been removed from the list. 
Identified Protein UniProt ID CDK12 IP: # 
of peptides 
identified 
Cell division protein kinase 12 OS=Homo sapiens GN=CDK12 PE=1 SV=2 CDK12_HUMAN 95 
Serine/arginine repetitive matrix protein 2 OS=Homo sapiens GN=SRRM2 PE=1 SV=2 SRRM2_HUMAN 94 
Pre-mRNA cleavage complex 2 protein Pcf11 OS=Homo sapiens GN=PCF11 PE=1 SV=3 PCF11_HUMAN 77 
ELKS/Rab6-interacting/CAST family member 1 OS=Homo sapiens GN=ERC1 PE=1 SV=1 RB6I2_HUMAN 61 
Protein phosphatase 1 regulatory subunit 12A OS=Homo sapiens GN=PPP1R12A PE=1 
SV=1 
MYPT1_HUMAN 56 
Protein BAT2-like 1 OS=Homo sapiens GN=BAT2L1 PE=1 SV=2 BA2L1_HUMAN 55 
Transcription elongation factor B polypeptide 3 OS=Homo sapiens GN=TCEB3 PE=1 SV=2 ELOA1_HUMAN 51 
DNA excision repair protein ERCC-6 OS=Homo sapiens GN=ERCC6 PE=1 SV=1 ERCC6_HUMAN 49 
Antigen KI-67 OS=Homo sapiens GN=MKI67 PE=1 SV=2 KI67_HUMAN 41 
Structural maintenance of chromosomes protein 4 OS=Homo sapiens GN=SMC4 PE=1 
SV=2 
SMC4_HUMAN 39 
Transcriptional regulator ATRX OS=Homo sapiens GN=ATRX PE=1 SV=5 ATRX_HUMAN 38 
Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 PABP1_HUMAN 38 
DNA repair protein RAD50 OS=Homo sapiens GN=RAD50 PE=1 SV=1 RAD50_HUMAN 34 
Dedicator of cytokinesis protein 5 OS=Homo sapiens GN=DOCK5 PE=1 SV=3 DOCK5_HUMAN 34 
Structural maintenance of chromosomes protein 2 OS=Homo sapiens GN=SMC2 PE=1 
SV=2 
SMC2_HUMAN 33 
Protein VPRBP OS=Homo sapiens GN=VPRBP PE=1 SV=3 VPRBP_HUMAN 33 
Apoptotic chromatin condensation inducer in the nucleus OS=Homo sapiens GN=ACIN1 
PE=1 SV=2 
ACINU_HUMAN 32 
U5 small nuclear ribonucleoprotein 200 kDa helicase OS=Homo sapiens GN=SNRNP200 
PE=1 SV=2 
U520_HUMAN 31 
DNA-directed RNA polymerase II subunit RPB1 OS=Homo sapiens GN=POLR2A PE=1 SV=2 RPB1_HUMAN 31 
DNA damage-binding protein 1 OS=Homo sapiens GN=DDB1 PE=1 SV=1 DDB1_HUMAN 31 
RNA exonuclease 1 homolog OS=Homo sapiens GN=REXO1 PE=1 SV=3 REXO1_HUMAN 29 
LIM domain only protein 7 OS=Homo sapiens GN=LMO7 PE=1 SV=3 LMO7_HUMAN 29 
Large proline-rich protein BAT2 OS=Homo sapiens GN=BAT2 PE=1 SV=3 BAT2_HUMAN 29 
Integrator complex subunit 1 OS=Homo sapiens GN=INTS1 PE=1 SV=2 INT1_HUMAN 29 
Protein phosphatase 1 regulatory subunit 12C OS=Homo sapiens GN=PPP1R12C PE=1 
SV=1 
PP12C_HUMAN 29 
BTB/POZ domain-containing protein KCTD3 OS=Homo sapiens GN=KCTD3 PE=1 SV=2 KCTD3_HUMAN 29 
Kinesin-like protein KIF23 OS=Homo sapiens GN=KIF23 PE=1 SV=3 KIF23_HUMAN 27 
Ankycorbin OS=Homo sapiens GN=RAI14 PE=1 SV=2 RAI14_HUMAN 27 
Sorbin and SH3 domain-containing protein 2 OS=Homo sapiens GN=SORBS2 PE=1 SV=3 SRBS2_HUMAN 27 
Zinc finger CCCH domain-containing protein 14 OS=Homo sapiens GN=ZC3H14 PE=1 SV=1 ZC3HE_HUMAN 26 
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Transformation/transcription domain-associated protein OS=Homo sapiens GN=TRRAP 
PE=1 SV=3 
TRRAP_HUMAN 25 
Probable E3 ubiquitin-protein ligase MYCBP2 OS=Homo sapiens GN=MYCBP2 PE=1 SV=3 MYCB2_HUMAN 25 
Zinc finger CCHC domain-containing protein 8 OS=Homo sapiens GN=ZCCHC8 PE=1 SV=2 ZCHC8_HUMAN 24 
Polyribonucleotide 5'-hydroxyl-kinase Clp1 OS=Homo sapiens GN=CLP1 PE=1 SV=1 CLP1_HUMAN 24 
Serine/arginine-rich splicing factor 6 OS=Homo sapiens GN=SRSF6 PE=1 SV=2 SRSF6_HUMAN 23 
Cyclin-K OS=Homo sapiens GN=CCNK PE=1 SV=2 CCNK_HUMAN 23 
Formin-binding protein 1-like OS=Homo sapiens GN=FNBP1L PE=1 SV=2 FBP1L_HUMAN 23 
Bcl-2-associated transcription factor 1 OS=Homo sapiens GN=BCLAF1 PE=1 SV=2 BCLF1_HUMAN 22 
Tripartite motif-containing protein 3 OS=Homo sapiens GN=TRIM3 PE=1 SV=2 TRIM3_HUMAN 22 
Zinc finger and BTB domain-containing protein 11 OS=Homo sapiens GN=ZBTB11 PE=1 
SV=2 
ZBT11_HUMAN 22 
E1A-binding protein p400 OS=Homo sapiens GN=EP400 PE=1 SV=3 EP400_HUMAN 21 
TRIO and F-actin-binding protein OS=Homo sapiens GN=TRIOBP PE=1 SV=3 TARA_HUMAN 21 
Serine/arginine repetitive matrix protein 1 OS=Homo sapiens GN=SRRM1 PE=1 SV=2 SRRM1_HUMAN 21 
Pre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 SV=2 PRP8_HUMAN 20 
Myosin phosphatase Rho-interacting protein OS=Homo sapiens GN=MPRIP PE=1 SV=3 MPRIP_HUMAN 20 
Zinc finger and BTB domain-containing protein 1 OS=Homo sapiens GN=ZBTB1 PE=1 SV=3 ZBTB1_HUMAN 20 
Thyroid hormone receptor-associated protein 3 OS=Homo sapiens GN=THRAP3 PE=1 
SV=2 
TR150_HUMAN 19 
116 kDa U5 small nuclear ribonucleoprotein component OS=Homo sapiens GN=EFTUD2 
PE=1 SV=1 
U5S1_HUMAN 19 
Zinc finger protein 318 OS=Homo sapiens GN=ZNF318 PE=1 SV=2 ZN318_HUMAN 19 
Uveal autoantigen with coiled-coil domains and ankyrin repeats OS=Homo sapiens 
GN=UACA PE=1 SV=2 
UACA_HUMAN 19 
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo 
sapiens GN=DHX15 PE=1 SV=2 
DHX15_HUMAN 18 
Eukaryotic translation initiation factor 4 gamma 1 OS=Homo sapiens GN=EIF4G1 PE=1 
SV=4 
IF4G1_HUMAN 18 
Superkiller viralicidic activity 2-like 2 OS=Homo sapiens GN=SKIV2L2 PE=1 SV=3 SK2L2_HUMAN 18 
Eukaryotic initiation factor 4A-III OS=Homo sapiens GN=EIF4A3 PE=1 SV=4 IF4A3_HUMAN 18 
PRKC apoptosis WT1 regulator protein OS=Homo sapiens GN=PAWR PE=1 SV=1 PAWR_HUMAN 18 
Protein Wiz OS=Homo sapiens GN=WIZ PE=1 SV=2 WIZ_HUMAN 18 
Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 SV=3 YBOX1_HUMAN 17 
La-related protein 1 OS=Homo sapiens GN=LARP1 PE=1 SV=2 LARP1_HUMAN 17 
Zinc finger protein ubi-d4 OS=Homo sapiens GN=DPF2 PE=1 SV=2 REQU_HUMAN 17 
RNA-binding protein 27 OS=Homo sapiens GN=RBM27 PE=1 SV=2 RBM27_HUMAN 16 
Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 SV=1 PABP4_HUMAN 16 
Serine/threonine-protein phosphatase PP1-beta catalytic subunit OS=Homo sapiens 
GN=PPP1CB PE=1 SV=3 
PP1B_HUMAN 16 
Choline-phosphate cytidylyltransferase A OS=Homo sapiens GN=PCYT1A PE=1 SV=2 PCY1A_HUMAN 16 
A-kinase anchor protein 12 OS=Homo sapiens GN=AKAP12 PE=1 SV=3 AKA12_HUMAN 16 
Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 PE=1 SV=4 SF3B3_HUMAN 15 
Ataxin-2-like protein OS=Homo sapiens GN=ATXN2L PE=1 SV=2 ATX2L_HUMAN 15 
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40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 RS3A_HUMAN 15 
Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 MATR3_HUMAN 15 
E3 ubiquitin-protein ligase RNF168 OS=Homo sapiens GN=RNF168 PE=1 SV=1 RN168_HUMAN 15 
PiggyBac transposable element-derived protein 3 OS=Homo sapiens GN=PGBD3 PE=2 
SV=3 
PGBD3_HUMAN 15 
Engulfment and cell motility protein 2 OS=Homo sapiens GN=ELMO2 PE=1 SV=2 ELMO2_HUMAN 14 
5'-3' exoribonuclease 2 OS=Homo sapiens GN=XRN2 PE=1 SV=1 XRN2_HUMAN 14 
Pinin OS=Homo sapiens GN=PNN PE=1 SV=4 PININ_HUMAN 14 
G patch domain-containing protein 8 OS=Homo sapiens GN=GPATCH8 PE=1 SV=2 GPTC8_HUMAN 14 
SH3KBP1-binding protein 1 OS=Homo sapiens GN=SHKBP1 PE=1 SV=2 SHKB1_HUMAN 14 
Histone-lysine N-methyltransferase, H3 lysine-9 specific 5 OS=Homo sapiens GN=EHMT1 
PE=1 SV=3 
EHMT1_HUMAN 13 
Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 PE=1 SV=4 ANM5_HUMAN 13 
Nibrin OS=Homo sapiens GN=NBN PE=1 SV=1 NBN_HUMAN 13 
Splicing factor 3B subunit 1 OS=Homo sapiens GN=SF3B1 PE=1 SV=3 SF3B1_HUMAN 13 
Supervillin OS=Homo sapiens GN=SVIL PE=1 SV=2 SVIL_HUMAN 13 
Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM PE=1 SV=3 HNRPM_HUMAN 13 
Tyrosine-protein kinase SgK223 OS=Homo sapiens GN=SGK223 PE=1 SV=2 SG223_HUMAN 13 
Microprocessor complex subunit DGCR8 OS=Homo sapiens GN=DGCR8 PE=1 SV=1 DGCR8_HUMAN 13 
Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 OS=Homo sapiens GN=EHMT2 
PE=1 SV=3 
EHMT2_HUMAN 12 
Protein capicua homolog OS=Homo sapiens GN=CIC PE=1 SV=2 CIC_HUMAN 12 
Sorbin and SH3 domain-containing protein 1 OS=Homo sapiens GN=SORBS1 PE=1 SV=2 SRBS1_HUMAN 12 
Transcription elongation factor B polypeptide 2 OS=Homo sapiens GN=TCEB2 PE=1 SV=1 ELOB_HUMAN 12 
Nuclear receptor corepressor 1 OS=Homo sapiens GN=NCOR1 PE=1 SV=2 NCOR1_HUMAN 12 
Double-strand break repair protein MRE11A OS=Homo sapiens GN=MRE11A PE=1 SV=3 MRE11_HUMAN 11 
Exosome component 10 OS=Homo sapiens GN=EXOSC10 PE=1 SV=2 EXOSX_HUMAN 11 
SNW domain-containing protein 1 OS=Homo sapiens GN=SNW1 PE=1 SV=1 SNW1_HUMAN 11 
RAB6-interacting golgin OS=Homo sapiens GN=GORAB PE=1 SV=1 GORAB_HUMAN 11 
Round spermatid basic protein 1 OS=Homo sapiens GN=RSBN1 PE=2 SV=2 RSBN1_HUMAN 11 
MAP7 domain-containing protein 3 OS=Homo sapiens GN=MAP7D3 PE=1 SV=2 MA7D3_HUMAN 11 
Rac GTPase-activating protein 1 OS=Homo sapiens GN=RACGAP1 PE=1 SV=1 RGAP1_HUMAN 11 
Cell cycle regulator Mat89Bb homolog OS=Homo sapiens GN=C12orf11 PE=1 SV=2 M89BB_HUMAN 11 
Zinc finger protein 185 OS=Homo sapiens GN=ZNF185 PE=1 SV=3 ZN185_HUMAN 10 
UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit 
OS=Homo sapiens GN=OGT PE=1 SV=3 
OGT1_HUMAN 10 
Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 PE=1 SV=1 SRSF3_HUMAN 10 
Integrator complex subunit 12 OS=Homo sapiens GN=INTS12 PE=1 SV=1 INT12_HUMAN 10 
Serine/threonine-protein phosphatase 1 regulatory subunit 10 OS=Homo sapiens 
GN=PPP1R10 PE=1 SV=1 
PP1RA_HUMAN 10 
Cell division cycle 5-like protein OS=Homo sapiens GN=CDC5L PE=1 SV=2 CDC5L_HUMAN 10 
CDKN2A-interacting protein OS=Homo sapiens GN=CDKN2AIP PE=1 SV=2 CARF_HUMAN 10 
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Transformer-2 protein homolog beta OS=Homo sapiens GN=TRA2B PE=1 SV=1 TRA2B_HUMAN 10 
Splicing factor 3B subunit 2 OS=Homo sapiens GN=SF3B2 PE=1 SV=2 SF3B2_HUMAN 10 
Nuclear fragile X mental retardation-interacting protein 2 OS=Homo sapiens GN=NUFIP2 
PE=1 SV=1 
NUFP2_HUMAN 9 
Tuftelin-interacting protein 11 OS=Homo sapiens GN=TFIP11 PE=1 SV=1 TFP11_HUMAN 9 
40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 RS8_HUMAN 9 
Splicing factor 3A subunit 1 OS=Homo sapiens GN=SF3A1 PE=1 SV=1 SF3A1_HUMAN 9 
Coiled-coil domain-containing protein 6 OS=Homo sapiens GN=CCDC6 PE=1 SV=2 CCDC6_HUMAN 9 
Condensin-2 complex subunit H2 OS=Homo sapiens GN=NCAPH2 PE=1 SV=1 CNDH2_HUMAN 9 
Round spermatid basic protein 1-like protein OS=Homo sapiens GN=RSBN1L PE=1 SV=2 RSBNL_HUMAN 9 
Zinc finger CCCH domain-containing protein 18 OS=Homo sapiens GN=ZC3H18 PE=1 SV=2 ZCH18_HUMAN 8 
Chromobox protein homolog 8 OS=Homo sapiens GN=CBX8 PE=1 SV=3 CBX8_HUMAN 8 
SAGA-associated factor 29 homolog OS=Homo sapiens GN=CCDC101 PE=1 SV=1 SGF29_HUMAN 8 
40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 RS3_HUMAN 8 
Serine/arginine-rich splicing factor 1 OS=Homo sapiens GN=SRSF1 PE=1 SV=2 SRSF1_HUMAN 8 
Nuclear cap-binding protein subunit 1 OS=Homo sapiens GN=NCBP1 PE=1 SV=1 NCBP1_HUMAN 8 
Ensconsin OS=Homo sapiens GN=MAP7 PE=1 SV=1 MAP7_HUMAN 8 
Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 PE=1 SV=1 SRSF7_HUMAN 8 
E3 ubiquitin-protein ligase RBBP6 OS=Homo sapiens GN=RBBP6 PE=1 SV=1 RBBP6_HUMAN 7 
Pre-mRNA-processing factor 19 OS=Homo sapiens GN=PRPF19 PE=1 SV=1 PRP19_HUMAN 7 
E3 ubiquitin-protein ligase UBR5 OS=Homo sapiens GN=UBR5 PE=1 SV=2 UBR5_HUMAN 7 
Mitogen-activated protein kinase kinase kinase 7 OS=Homo sapiens GN=MAP3K7 PE=1 
SV=1 
M3K7_HUMAN 7 
Serine/arginine-rich splicing factor 10 OS=Homo sapiens GN=SRSF10 PE=1 SV=1 SRS10_HUMAN 7 
DNA-directed RNA polymerase II subunit RPB2 OS=Homo sapiens GN=POLR2B PE=1 SV=1 RPB2_HUMAN 7 
WD repeat-containing protein 82 OS=Homo sapiens GN=WDR82 PE=1 SV=1 WDR82_HUMAN 7 
Polyadenylate-binding protein 2 OS=Homo sapiens GN=PABPN1 PE=1 SV=3 PABP2_HUMAN 7 
Integrator complex subunit 6 OS=Homo sapiens GN=INTS6 PE=1 SV=1 INT6_HUMAN 7 
Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 SV=2 LC7L2_HUMAN 7 
GC-rich sequence DNA-binding factor 1 OS=Homo sapiens GN=GCFC1 PE=1 SV=2 GCFC1_HUMAN 7 
Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC PE=1 
SV=4 
HNRPC_HUMAN 7 
ERC protein 2 OS=Homo sapiens GN=ERC2 PE=1 SV=3 ERC2_HUMAN 7 
Ataxin-1-like OS=Homo sapiens GN=ATXN1L PE=1 SV=1 ATX1L_HUMAN 7 
Condensin-2 complex subunit D3 OS=Homo sapiens GN=NCAPD3 PE=1 SV=2 CNDD3_HUMAN 7 
40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 RS7_HUMAN 7 
Crooked neck-like protein 1 OS=Homo sapiens GN=CRNKL1 PE=1 SV=4 CRNL1_HUMAN 7 
Zinc finger protein 644 OS=Homo sapiens GN=ZNF644 PE=1 SV=2 ZN644_HUMAN 7 
RNA-binding protein 7 OS=Homo sapiens GN=RBM7 PE=1 SV=1 RBM7_HUMAN 7 
A-kinase anchor protein 17A OS=Homo sapiens GN=AKAP17A PE=1 SV=2 AK17A_HUMAN 7 
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Deoxynucleotidyltransferase terminal-interacting protein 1 OS=Homo sapiens 
GN=DNTTIP1 PE=1 SV=2 
TDIF1_HUMAN 6 
Pre-mRNA-processing factor 6 OS=Homo sapiens GN=PRPF6 PE=1 SV=1 PRP6_HUMAN 6 
40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 RS18_HUMAN 6 
Exosome complex exonuclease RRP42 OS=Homo sapiens GN=EXOSC7 PE=1 SV=2 EXOS7_HUMAN 6 
Histone-binding protein RBBP7 OS=Homo sapiens GN=RBBP7 PE=1 SV=1 RBBP7_HUMAN 6 
UAP56-interacting factor OS=Homo sapiens GN=FYTTD1 PE=1 SV=3 UIF_HUMAN 6 
Heterogeneous nuclear ribonucleoprotein U-like protein 1 OS=Homo sapiens 
GN=HNRNPUL1 PE=1 SV=2 
HNRL1_HUMAN 6 
WD40 repeat-containing protein SMU1 OS=Homo sapiens GN=SMU1 PE=1 SV=2 SMU1_HUMAN 6 
Integrator complex subunit 9 OS=Homo sapiens GN=INTS9 PE=1 SV=2 INT9_HUMAN 6 
Serine/arginine-rich splicing factor 4 OS=Homo sapiens GN=SRSF4 PE=1 SV=2 SRSF4_HUMAN 6 
U2-associated protein SR140 OS=Homo sapiens GN=SR140 PE=1 SV=2 SR140_HUMAN 6 
La-related protein 7 OS=Homo sapiens GN=LARP7 PE=1 SV=1 LARP7_HUMAN 6 
Histone deacetylase complex subunit SAP18 OS=Homo sapiens GN=SAP18 PE=1 SV=1 SAP18_HUMAN 6 
Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 G3P_HUMAN 6 
Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens GN=HNRNPF PE=1 SV=3 HNRPF_HUMAN 6 
Ubiquitin-associated protein 2-like OS=Homo sapiens GN=UBAP2L PE=1 SV=2 UBP2L_HUMAN 6 
40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 RS2_HUMAN 6 
DNA-binding protein A OS=Homo sapiens GN=CSDA PE=1 SV=4 DBPA_HUMAN 6 
40S ribosomal protein S12 OS=Homo sapiens GN=RPS12 PE=1 SV=3 RS12_HUMAN 6 
60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 RL13_HUMAN 6 
40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 RS9_HUMAN 6 
40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 RS5_HUMAN 6 
40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 RS16_HUMAN 6 
40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 RS14_HUMAN 6 
Serine/arginine-rich splicing factor 9 OS=Homo sapiens GN=SRSF9 PE=1 SV=1 SRSF9_HUMAN 6 
Mitochondrial fission regulator 1 OS=Homo sapiens GN=MTFR1 PE=1 SV=2 MTFR1_HUMAN 5 
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 OS=Homo sapiens GN=TAB1 
PE=1 SV=1 
TAB1_HUMAN 5 
3'-5' exoribonuclease CSL4 homolog OS=Homo sapiens GN=EXOSC1 PE=1 SV=1 EXOS1_HUMAN 5 
RNA-binding protein 8A OS=Homo sapiens GN=RBM8A PE=1 SV=1 RBM8A_HUMAN 5 
SUN domain-containing protein 2 OS=Homo sapiens GN=SUN2 PE=1 SV=3 SUN2_HUMAN 5 
Cell division protein kinase 13 OS=Homo sapiens GN=CDK13 PE=1 SV=2 CDK13_HUMAN 5 
Structural maintenance of chromosomes protein 1A OS=Homo sapiens GN=SMC1A PE=1 
SV=2 
SMC1A_HUMAN 5 
Calcium homeostasis endoplasmic reticulum protein OS=Homo sapiens GN=CHERP PE=1 
SV=3 
CHERP_HUMAN 5 
E3 ubiquitin-protein ligase RING2 OS=Homo sapiens GN=RNF2 PE=1 SV=1 RING2_HUMAN 5 
Histone H2A.Z OS=Homo sapiens GN=H2AFZ PE=1 SV=2 H2AZ_HUMAN  5 
40S ribosomal protein S23 OS=Homo sapiens GN=RPS23 PE=1 SV=3 RS23_HUMAN 5 
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial OS=Homo sapiens 
GN=MCCC2 PE=1 SV=1 
MCCB_HUMAN 5 
 134 
E3 SUMO-protein ligase CBX4 OS=Homo sapiens GN=CBX4 PE=1 SV=3 CBX4_HUMAN 5 
Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 NPM_HUMAN 5 
Heat shock 70 kDa protein 6 OS=Homo sapiens GN=HSPA6 PE=1 SV=2 HSP76_HUMAN 4 
40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 RS11_HUMAN 4 
40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 RS6_HUMAN 4 
40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 RS25_HUMAN 4 
Serine/arginine-rich splicing factor 5 OS=Homo sapiens GN=SRSF5 PE=1 SV=1 SRSF5_HUMAN 4 
Transformer-2 protein homolog alpha OS=Homo sapiens GN=TRA2A PE=1 SV=1 TRA2A_HUMAN 4 
Transcription elongation factor B polypeptide 1 OS=Homo sapiens GN=TCEB1 PE=1 SV=1 ELOC_HUMAN 4 
Exosome complex exonuclease RRP43 OS=Homo sapiens GN=EXOSC8 PE=1 SV=1 EXOS8_HUMAN 4 
Uncharacterized protein C9orf82 OS=Homo sapiens GN=C9orf82 PE=1 SV=2 CI082_HUMAN 4 
Exosome complex exonuclease RRP46 OS=Homo sapiens GN=EXOSC5 PE=1 SV=1 EXOS5_HUMAN 4 
Probable ribosome biogenesis protein NEP1 OS=Homo sapiens GN=EMG1 PE=1 SV=4 NEP1_HUMAN 4 
Pre-mRNA-splicing factor SYF2 OS=Homo sapiens GN=SYF2 PE=1 SV=1 SYF2_HUMAN 4 
Putative tubulin beta-4q chain OS=Homo sapiens GN=TUBB4Q PE=5 SV=1 TBB4Q_HUMAN 4 
Exosome complex exonuclease MTR3 OS=Homo sapiens GN=EXOSC6 PE=1 SV=1 EXOS6_HUMAN 4 
Pleiotropic regulator 1 OS=Homo sapiens GN=PLRG1 PE=1 SV=1 PLRG1_HUMAN 4 
Luc7-like protein 3 OS=Homo sapiens GN=LUC7L3 PE=1 SV=2 LC7L3_HUMAN 4 
Nuclear cap-binding protein subunit 2 OS=Homo sapiens GN=NCBP2 PE=1 SV=1 NCBP2_HUMAN 4 
Integrator complex subunit 8 OS=Homo sapiens GN=INTS8 PE=1 SV=1 INT8_HUMAN 4 
Actin-like protein 6A OS=Homo sapiens GN=ACTL6A PE=1 SV=1 ACL6A_HUMAN 4 
Integrator complex subunit 7 OS=Homo sapiens GN=INTS7 PE=1 SV=1 INT7_HUMAN 4 
Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 ILF2_HUMAN 4 
Histone deacetylase 3 OS=Homo sapiens GN=HDAC3 PE=1 SV=2 HDAC3_HUMAN 4 
Dual specificity protein kinase CLK3 OS=Homo sapiens GN=CLK3 PE=1 SV=3 CLK3_HUMAN 3 
Treslin OS=Homo sapiens GN=TICRR PE=1 SV=2 TICRR_HUMAN 3 
Putative RNA-binding protein 15 OS=Homo sapiens GN=RBM15 PE=1 SV=2 RBM15_HUMAN 3 
Protein SON OS=Homo sapiens GN=SON PE=1 SV=4 SON_HUMAN 3 
Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 OS=Homo sapiens 
GN=DHX38 PE=1 SV=2 
PRP16_HUMAN 3 
Methyl-CpG-binding protein 2 OS=Homo sapiens GN=MECP2 PE=1 SV=1 MECP2_HUMAN 3 
Splicing factor U2AF 65 kDa subunit OS=Homo sapiens GN=U2AF2 PE=1 SV=4 U2AF2_HUMAN 3 
Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 SV=1 HNRPK_HUMAN 3 
40S ribosomal protein S17 OS=Homo sapiens GN=RPS17 PE=1 SV=2 RS17_HUMAN 3 
60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 RL12_HUMAN 3 
40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 RS19_HUMAN 3 
Small nuclear ribonucleoprotein Sm D1 OS=Homo sapiens GN=SNRPD1 PE=1 SV=1 SMD1_HUMAN 3 
RNA-binding protein EWS OS=Homo sapiens GN=EWSR1 PE=1 SV=1 EWS_HUMAN 3 
Akirin-2 OS=Homo sapiens GN=AKIRIN2 PE=1 SV=2 AKIR2_HUMAN 3 
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Protein DGCR6L OS=Homo sapiens GN=DGCR6L PE=1 SV=2 DGC6L_HUMAN 3 
60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 SV=2 RL27A_HUMAN 3 
40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 RS15A_HUMAN 3 
Exosome complex exonuclease RRP45 OS=Homo sapiens GN=EXOSC9 PE=1 SV=3 EXOS9_HUMAN 3 
Ribosomal L1 domain-containing protein 1 OS=Homo sapiens GN=RSL1D1 PE=1 SV=3 RL1D1_HUMAN 3 
Serine/Arginine-related protein 53 OS=Homo sapiens GN=RSRC1 PE=1 SV=1 RSRC1_HUMAN 3 
40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 RS13_HUMAN 3 
TOX high mobility group box family member 4 OS=Homo sapiens GN=TOX4 PE=1 SV=1 TOX4_HUMAN 3 
Exosome complex exonuclease RRP4 OS=Homo sapiens GN=EXOSC2 PE=1 SV=2 EXOS2_HUMAN 3 
Protein mago nashi homolog OS=Homo sapiens GN=MAGOH PE=1 SV=1 MGN_HUMAN  3 
DNA-directed RNA polymerase II subunit RPB3 OS=Homo sapiens GN=POLR2C PE=1 SV=2 RPB3_HUMAN 3 
DNA-directed RNA polymerases I, II, and III subunit RPABC1 OS=Homo sapiens 
GN=POLR2E PE=1 SV=4 
RPAB1_HUMAN 3 
Ribonuclease P protein subunit p30 OS=Homo sapiens GN=RPP30 PE=1 SV=1 RPP30_HUMAN 3 
SWI/SNF complex subunit SMARCC1 OS=Homo sapiens GN=SMARCC1 PE=1 SV=3 SMRC1_HUMAN 3 
ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 DDX3X_HUMAN 3 
Histone-lysine N-methyltransferase SETD2 OS=Homo sapiens GN=SETD2 PE=1 SV=3 SETD2_HUMAN 3 
Casein kinase II subunit alpha OS=Homo sapiens GN=CSNK2A1 PE=1 SV=1 CSK21_HUMAN 3 
MAP3K12-binding inhibitory protein 1 OS=Homo sapiens GN=MBIP PE=1 SV=2 MBIP1_HUMAN 3 
F-box-like/WD repeat-containing protein TBL1XR1 OS=Homo sapiens GN=TBL1XR1 PE=1 
SV=1 
TBL1R_HUMAN 3 
40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 RS20_HUMAN 3 
Dynein light chain 1, cytoplasmic OS=Homo sapiens GN=DYNLL1 PE=1 SV=1 DYL1_HUMAN 3 
Enhancer of rudimentary homolog OS=Homo sapiens GN=ERH PE=1 SV=1 ERH_HUMAN 3 
Pre-mRNA-splicing factor SPF27 OS=Homo sapiens GN=BCAS2 PE=1 SV=1 SPF27_HUMAN 3 
Histone H2B type F-S OS=Homo sapiens GN=H2BFS PE=1 SV=2 H2BFS_HUMAN 3 
UPF0468 protein C16orf80 OS=Homo sapiens GN=C16orf80 PE=1 SV=1 CP080_HUMAN 3 
U5 small nuclear ribonucleoprotein 40 kDa protein OS=Homo sapiens GN=SNRNP40 PE=1 
SV=1 
SNR40_HUMAN 3 
PHD finger-like domain-containing protein 5A OS=Homo sapiens GN=PHF5A PE=1 SV=1 PHF5A_HUMAN 3 
Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1 MEP50_HUMAN 3 
Polyadenylate-binding protein 3 OS=Homo sapiens GN=PABPC3 PE=1 SV=2 PABP3_HUMAN 3 
Bromodomain-containing protein 8 OS=Homo sapiens GN=BRD8 PE=1 SV=2 BRD8_HUMAN 3 
Protein CASP OS=Homo sapiens GN=CUX1 PE=1 SV=2 CASP_HUMAN 3 
Splicing factor 3B subunit 4 OS=Homo sapiens GN=SF3B4 PE=1 SV=1 SF3B4_HUMAN 3 
Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 SV=2 H13_HUMAN  2 
Probable ATP-dependent RNA helicase DDX41 OS=Homo sapiens GN=DDX41 PE=1 SV=2 DDX41_HUMAN 2 
60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 RL18_HUMAN 2 
Pre-mRNA-processing factor 17 OS=Homo sapiens GN=CDC40 PE=1 SV=1 PRP17_HUMAN 2 
Casein kinase II subunit beta OS=Homo sapiens GN=CSNK2B PE=1 SV=1 CSK2B_HUMAN 2 
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Phosphofurin acidic cluster sorting protein 1 OS=Homo sapiens GN=PACS1 PE=1 SV=2 PACS1_HUMAN 2 
Choline-phosphate cytidylyltransferase B OS=Homo sapiens GN=PCYT1B PE=1 SV=1 PCY1B_HUMAN 2 
Insulin-like growth factor 2 mRNA-binding protein 3 OS=Homo sapiens GN=IGF2BP3 PE=1 
SV=2 
IF2B3_HUMAN 2 
Cleavage and polyadenylation specificity factor subunit 1 OS=Homo sapiens GN=CPSF1 
PE=1 SV=2 
CPSF1_HUMAN 2 
Vacuolar protein sorting-associated protein 72 homolog OS=Homo sapiens GN=VPS72 
PE=1 SV=1 
VPS72_HUMAN 2 
Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 PE=1 SV=1 SMD3_HUMAN 2 
Serine/arginine-rich splicing factor 8 OS=Homo sapiens GN=SRSF8 PE=1 SV=1 SRSF8_HUMAN 2 
60S ribosomal protein L29 OS=Homo sapiens GN=RPL29 PE=1 SV=2 RL29_HUMAN 2 
F-box/SPRY domain-containing protein 1 OS=Homo sapiens GN=FBXO45 PE=1 SV=1 FBSP1_HUMAN 2 
60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 RL22_HUMAN 2 
40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 SV=1 RS10_HUMAN 2 
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit OS=Homo sapiens 
GN=PPP1CA PE=1 SV=1 
PP1A_HUMAN 2 
40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 RS26_HUMAN 2 
60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 SV=2 RL30_HUMAN 2 
60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 RL31_HUMAN 2 
Protein DGCR6 OS=Homo sapiens GN=DGCR6 PE=1 SV=3 DGCR6_HUMAN 2 
Reticulocalbin-1 OS=Homo sapiens GN=RCN1 PE=1 SV=1 RCN1_HUMAN 2 
DET1- and DDB1-associated protein 1 OS=Homo sapiens GN=DDA1 PE=1 SV=1 DDA1_HUMAN 2 
Pre-mRNA branch site protein p14 OS=Homo sapiens GN=SF3B14 PE=1 SV=1 PM14_HUMAN 2 
Putative RNA-binding protein Luc7-like 1 OS=Homo sapiens GN=LUC7L PE=1 SV=1 LUC7L_HUMAN 2 
RNA-binding protein 25 OS=Homo sapiens GN=RBM25 PE=1 SV=3 RBM25_HUMAN 2 
Cell division protein kinase 9 OS=Homo sapiens GN=CDK9 PE=1 SV=3 CDK9_HUMAN 2 
Pre-mRNA-splicing factor 38A OS=Homo sapiens GN=PRPF38A PE=1 SV=1 PR38A_HUMAN 2 
60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 RL9_HUMAN 2 
Protein LSM12 homolog OS=Homo sapiens GN=LSM12 PE=1 SV=2 LSM12_HUMAN 2 
Male-specific lethal 1 homolog OS=Homo sapiens GN=MSL1 PE=1 SV=2 MSL1_HUMAN 2 
Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 IF4A1_HUMAN 2 
60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 RL10A_HUMAN 2 
Nucleolar protein 9 OS=Homo sapiens GN=NOL9 PE=1 SV=1 NOL9_HUMAN 2 
Pre-mRNA 3'-end-processing factor FIP1 OS=Homo sapiens GN=FIP1L1 PE=1 SV=1 FIP1_HUMAN 2 
Glutamine and serine-rich protein 1 OS=Homo sapiens GN=QSER1 PE=1 SV=3 QSER1_HUMAN 2 
NF-kappa-B-repressing factor OS=Homo sapiens GN=NKRF PE=1 SV=2 NKRF_HUMAN 2 
Replication factor C subunit 1 OS=Homo sapiens GN=RFC1 PE=1 SV=4 RFC1_HUMAN 2 
60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 SV=2 RL18A_HUMAN 2 
RNA-binding protein with serine-rich domain 1 OS=Homo sapiens GN=RNPS1 PE=1 SV=1 RNPS1_HUMAN 2 
60S acidic ribosomal protein P1 OS=Homo sapiens GN=RPLP1 PE=1 SV=1 RLA1_HUMAN 2 
60S ribosomal protein L35a OS=Homo sapiens GN=RPL35A PE=1 SV=2 RL35A_HUMAN 2 
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RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1 FUS_HUMAN 2 
Serine/threonine-protein phosphatase PP1-gamma catalytic subunit OS=Homo sapiens 
GN=PPP1CC PE=1 SV=1 
PP1G_HUMAN 2 
40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 PE=1 SV=3 RS27_HUMAN 2 
60S ribosomal protein L21 OS=Homo sapiens GN=RPL21 PE=1 SV=2 RL21_HUMAN 2 
60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 SV=2 RL27_HUMAN 2 
S-phase kinase-associated protein 1 OS=Homo sapiens GN=SKP1 PE=1 SV=2 SKP1_HUMAN 2 
Large neutral amino acids transporter small subunit 1 OS=Homo sapiens GN=SLC7A5 
PE=1 SV=2 
LAT1_HUMAN 2 
Complement component 1 Q subcomponent-binding protein, mitochondrial OS=Homo 
sapiens GN=C1QBP PE=1 SV=1 
C1QBP_HUMAN 2 
60S acidic ribosomal protein P0-like OS=Homo sapiens GN=RPLP0P6 PE=5 SV=1 RLA0L_HUMAN  2 
F-box-like/WD repeat-containing protein TBL1Y OS=Homo sapiens GN=TBL1Y PE=2 SV=1 TBL1Y_HUMAN 2 
Zinc finger protein 576 OS=Homo sapiens GN=ZNF576 PE=1 SV=1 ZN576_HUMAN 2 
RNA-binding protein Raly OS=Homo sapiens GN=RALY PE=1 SV=1 RALY_HUMAN 2 
Poly(U)-binding-splicing factor PUF60 OS=Homo sapiens GN=PUF60 PE=1 SV=1 PUF60_HUMAN 2 
Exosome complex exonuclease RRP41 OS=Homo sapiens GN=EXOSC4 PE=1 SV=3 EXOS4_HUMAN 2 
L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 LDHB_HUMAN 2 
60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 RL8_HUMAN 2 
Polyadenylate-binding protein 1-like OS=Homo sapiens GN=PABPC1L PE=2 SV=1 PAP1L_HUMAN 2 
60S ribosomal protein L17 OS=Homo sapiens GN=RPL17 PE=1 SV=3 RL17_HUMAN 2 
26S protease regulatory subunit 4 OS=Homo sapiens GN=PSMC1 PE=1 SV=1 PRS4_HUMAN 2 
Integrator complex subunit 5 OS=Homo sapiens GN=INTS5 PE=1 SV=1 INT5_HUMAN 2 
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